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Abstract 
The autonomic nervous system innervates and influences every organ in the body 
through two major efferent pathways; the sympathetic and parasympathetic nervous 
systems. Autonomic dysfunction, especially orthostatic hypotension (OH) and olfactory 
dysfunction, are commonly present in a variety of neurological disorders, particularly, 
multiple system atrophy (MSA) and allied disorders, such as Parkinson’s disease (PD) and 
Pure Autonomic Failure (PAF) and can significantly impact quality of life and cause 
significant morbidity. Similarly, non-motor symptoms have been increasingly recognized in 
PD. The overlapping autonomic features of PD, PAF and MSA, e.g., OH, can sometimes 
make it difficult to differentiate a diagnosis between these conditions. The further evaluation 
of autonomic function, e.g., cardiovascular, olfactory and gastrointestinal function, in patients 
with primary chronic autonomic failure disorders could offer better diagnostic accuracy, 
improve the understanding of disease progression and inform the development of 
treatments.  
Cardiovascular autonomic function screening tests are commonly used to confirm a 
diagnosis of autonomic failure, e.g., orthostatic hypotension, but OH is not often reliable for 
distinguishing between PD and MSA. Novel indices of cardiovascular autonomic function in 
patients with chronic autonomic failure have therefore been evaluated as well as the severity 
of olfactory dysfunction and other non-motor (e.g., daily activities and depression) symptoms 
in MSA, PD and PAF. Results demonstrated that baroreflex sensitivity and blood pressure 
recovery time (BRPT) in response to the Valsalva Manoeuvre are useful for differentiating 
MSA from PD with autonomic failure (PD+AF). BPRT was also significantly prolonged in PD 
patients compared to healthy controls. In addition, an association of BPRT and disease 
duration in PD also suggests that this index may be useful for monitoring disease 
progression in PD. Other findings indicated that assessing olfactory function is also helpful 
for distinguishing between PD, MSA and PAF. A greater degree of depression and 
impairment of daily activities in MSA relative to PD and PAF were also evident.  
In order to further investigate the presenting symptoms and features of PAF, a time 
when diagnosis is often still unclear, and other disorders, such as MSA, can be suspected, 
the clinical characteristics and laboratory investigations, in a large cohort of PAF patients 
were examined. Results indicated that abnormal white matter lesions are prevalent in PAF. 
Furthermore, gastrointestinal symptoms were also evident in PAF and can also occur in 
other autonomic disorders, e.g., MSA. Using electrogastrography, impaired indexes of 
gastric motility were also evident in PAF.  
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Chapter 1 
1. Introduction 
The autonomic nervous system (ANS) innervates and influences every organ in the 
body. This complex system is mediated by two major efferent pathways, the sympathetic 
and parasympathetic nervous systems, which obtain afferent signals from different parts of 
the body, such as, neurons in the spinal cord and the cerebral autonomic centre; primarily 
the hypothalamus, midbrain and brainstem. The gastrointestinal tract is controlled by both 
the sympathetic and parasympathetic pathways and additionally the enteric nervous system 
(ENS). The ENS lies within two plexuses, Meissner’s and Auerbach’s plexuses, which 
mainly control the motility and secretion in the small and large intestines (Cersosimo & 
Benarroch, 2008).  
Since the ANS innervates organs throughout the body, dysfunction of the autonomic 
nervous system can present with a variety of symptoms according to the major system that 
is impaired, such as, cardiovascular, sudomotor, gastrointestinal, urinary or sexual function. 
Cardiovascular autonomic dysfunction can present with abnormal blood pressure (BP) 
regulation such as postural hypotension (or orthostatic hypotension; OH) and/or lability of BP 
and attendant symptoms of hypoperfusion of various organs and/or vascular beds. 
Orthostatic hypotension (OH) is a cardinal feature of cardiovascular autonomic dysfunction 
and can significantly impact quality of life and cause significant morbidity (Schrag et al., 
2000b; Rahman et al., 2008). OH is defined as a fall in systolic BP of >20 mm Hg or diastolic 
BP of >10 mmHg on standing or during head-up tilt (HUT) (Freeman et al., 2011) can lead to 
various problems, e.g., falls or injuries due to collapse or syncope (fainting). The associated 
symptoms of OH range from dizziness, light-headedness, visual disturbances, cognitive 
dysfunction, chest pain, neck pain (in “coat hanger” area) to non-specific symptoms, like 
fatigue or tiredness (Mathias, 2003).  
Autonomic dysfunction is commonly present in a variety of neurological disorders, 
particularly, Multiple System Atrophy (MSA) and allied disorders, such as Parkinson’s 
disease (PD), Pure Autonomic Failure (PAF), Dementia with Lewy bodies (DLB) and less 
commonly in autosomal dominant spinocerebellar ataxia (ADCA), fragile X-associated 
tremor/ataxia syndrome (FXTAS), Wilson’s disease, fatal familial insomnia and 
paraneoplastic syndromes. Autonomic dysfunction of the various organs/domains can 
commonly present in autonomic dysfunction disorders with overlapping features, often 
making it difficult to distinguish between different autonomic disorders. 
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Primary chronic autonomic failure disorders including MSA, PAF and Parkinson’s 
disease with autonomic failure (PD+AF), form the majority of patients with autonomic 
disorders. These disorders have quite distinctive pathophysiology but often present with 
similar features of autonomic dysfunction. 
Multiple System Atrophy (MSA) 
MSA is a sporadic, progressive adult-onset disorder, which is characterized by orthostatic 
hypotension (OH) or urinary disturbances, with erectile dysfunction in males, in addition to 
parkinsonism with a poor response to levodopa, or a cerebellar syndrome (Gilman et al., 
2008).  
Parkinson’s disease (PD) 
PD is characterized by extrapyramidal signs, including bradykinesia, tremor, rigidity and 
sometimes gait or postural disturbances (Hughes et al., 1992). Some PD patients, who 
develop autonomic failure, including OH, are typically diagnosed as PD+AF. 
Pure Autonomic Failure (PAF) 
PAF is an idiopathic, sporadic, neurodegenerative disorder characterized by autonomic 
failure without other neurological symptoms and signs (Kaufmann, 1996). 
Among these disorders, PD is by far the most common; the prevalence in the UK 
ranges from 105 to 168 per 100,000 (Schrag et al., 2000a; Hobson et al., 2005) and the 
incidence rises sharply with age, ranging from about 17 per 100,000 person-years between 
50-59 years to 93 per 100,000 person-years between 70-79 years (de Rijk et al., 1995; 
Bower et al., 1999). It is slightly more prevalent in males than females with an average age 
of onset of 60. PD patients have a higher life expectancy than other forms of parkinsonian 
disorders, such as MSA or DLB. In contrast to PD, MSA is less common with a prevalence 
ranging from 1.9-4.9 per 100,000 (Schrag et al., 1999; Chrysostome et al., 2004). Symptom 
onset typically starts in the mid-fifties but never before the age of 30. Patients with MSA 
have a relatively poor prognosis with a median survival of 6-9.5 years from symptom onset 
(Wenning et al., 1994a; Ben-Shlomo et al., 1997; Watanabe et al., 2002). There are two 
forms of MSA according to the prominent features; MSA with a parkinsonian subtype (MSA-
P) and MSA with a cerebellar subtype (MSA-C). Large epidemiology studies have shown 
that MSA-P is more common than MSA-C in European countries (Wenning et al., 2013). 
This is in contrast to a previous study in Japan, where MSA-C was reported to be more 
prevalent (Watanabe et al., 2002). PAF is much rarer and usually presents with orthostatic 
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hypotension (OH). There is no cerebellar or parkinsonian signs, unlike MSA and PD. The 
information on other clinical features is scarce and usually extracted from case series or 
research studies with limited amounts of patients. Abnormal sweating (both hyper and 
hypohidrosis) and bladder symptoms are also often reported in PAF. The exact prevalence 
and disease onset of PAF are unknown because of its rarity but the prognosis is better than 
MSA (Mabuchi et al., 2005). 
Extrapyramidal features are hallmark signs of PD and are quite common in other 
disorders, such as MSA. Non-motor symptoms have recently also been considered as 
important features in PD and some of the non-motor symptoms that have been reported 
include, constipation, urinary dysfunction, olfactory dysfunction, orthostatic hypotension, 
erectile dysfunction and abnormal sweating. These non-motor symptoms in PD can occur 
not only in the advanced stages but also in the early stages of PD (Khoo et al., 2013) or 
even in those without any medication (Mollenhauer et al., 2013). Among a range of non-
motor features, depression and autonomic dysfunction, including cardiovascular, 
gastrointestinal, urinary and thermoregulatory dysfunction, are considered to be key features 
which have an impact on patient’s quality of life (Gallagher et al., 2010). 
The overlapping features between parkinsonian syndromes and the complex features 
of MSA sometimes results in difficulties in differentiating the diagnosis between MSA and 
PD. Furthermore, a variety of presenting symptoms of MSA may lead the patient to see 
specialists in different areas of expertise prior to a neurologist, consequently delaying the 
correct diagnosis and management. The autonomic symptoms at the early stage of disease 
in a patient with Parkinsonism can provide vital evidence to help distinguish MSA from other 
parkinsonian disorders. For example, a more rapid progression of autonomic dysfunction is 
suggestive of MSA compared to those with PD (Lipp et al., 2009). Some MSA patients 
present with an isolated feature at the onset, such as orthostatic hypotension, urinary 
symptoms (including erectile dysfunction), stridor without parkinsonism or the combination of 
these symptoms. Consequently, autonomic dysfunction can predate the diagnosis of MSA 
for a while and patients can sometimes be misdiagnosed with another autonomic disorder, 
such as PAF, before the development of other hallmark MSA features.  
Orthostatic hypotension is one of the most common non-motor symptoms of PD 
which can occur at any stage of PD and has frequently been reported in previous studies 
(Chaudhuri et al., 2006b; Martinez-Martin et al., 2007). It is also one of the diagnostic criteria 
for MSA (Gilman et al., 2008). There are several causes of orthostatic hypotension in 
patients with parkinsonian features. It can be caused by the adverse side effects of anti-
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parkinsonian treatment, such as L-DOPA (with or without COMT inhibitors). Dopamine 
agonists and MAO-B inhibitors (Selegiline and Rasagiline) are among other common causes 
of OH. Other drugs which are used to treat other conditions, for example anti-hypertensive 
agents, vasodilator agents and diuretics, can also contribute to OH and intensify the severity 
of OH in patients with autonomic failure. The complication of metabolic disorders, particularly 
Diabetes Mellitus, can result in OH as part of autonomic neuropathy. Primary autonomic 
failure disorders, such as MSA or PD+AF, are therefore often considered after the various 
above causes are excluded.   
Cardiovascular autonomic screening tests are therefore used to confirm the 
diagnosis of autonomic failure but given that OH is common across a variety of 
autonomic/movement disorders and/or is a consequence of various medications, it may not 
ideally used as a single autonomic feature for distinguishing autonomic disorders, such as 
PD and MSA (Riley & Chelimsky, 2003). There are other autonomic function tests, for 
instance pressor tests (isometric exercise, mental arithmetic and cold pressor), 24 hour 
blood pressure (BP) and heart rate (HR) monitoring and other novel indices of quantitative 
cardiovascular autonomic function, such as, baroreflex sensitivity, blood pressure recovery 
time in response to a manoeuvre that reduces blood pressure and heart rate responses to 
alterations in blood pressure and respiration that have recently been developed and 
additionally been proposed to be useful in evaluating the autonomic function in chronic 
autonomic failure disorders (Vogel et al., 2005; Schrezenmaier et al., 2007). These indices 
are frequently abnormal in patients with autonomic failure relative to healthy controls 
(Schrezenmaier et al., 2007). The efficacy of using these indices of cardiovascular 
autonomic function for distinguishing different chronic autonomic disorders, as well as their 
relationship with disease duration, is still uncertain and has not been thoroughly investigated. 
Therefore, Aim #1 of this thesis is to examine cardiovascular autonomic function in 
primary chronic autonomic failure disorders using various parameters of 
cardiovascular autonomic function. These findings might reveal which cardiovascular 
autonomic indices could be useful markers for differentiating PD+AF, MSA and PAF.  
Impaired olfactory function is also a prominent non-motor feature in individuals with 
PD (Ansari & Johnson, 1975; Hawkes et al., 1997). Hyposmia is considered to be an early 
marker which predates motor symptoms in PD (Ponsen et al., 2004). Although impaired 
olfaction has been extensively studied and confirmed as a potential maker for PD, there are 
only a few studies investigating olfactory function in MSA and PAF (Silveira-Moriyama et al., 
2009b). In addition, results from previous studies were uncertain due to the relatively small 
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number of participants. In addition, it is still not clear whether there is a progression of 
impaired olfaction with disease duration and severity in PD and it is unknown if there are 
alterations in olfactory function with disease progression in MSA or PAF.  
In addition to classical motor features, patients with PD are commonly affected with 
non-motor symptoms. A previous study showed that non-motor features can present in up to 
88% of PD patients after 7-years of follow-up (Shulman et al., 2001). These non-motor 
aspects of parkinsonian and autonomic disorders often have profound effects on overall 
features of life, such as capacity for daily life activities, quality of life and psychological 
health, e.g., depression, which have typically been investigated in PD, MSA and PAF in 
isolation but have not been simultaneously compared between these disorders or related to 
other indices of autonomic function. Therefore, Aim #2 of this thesis will examine 
olfactory function, other non-motor aspects and quality of life in primary chronic 
autonomic failure disorders.  
PAF is characterized by autonomic failure without other neurological features. 
Cardiovascular autonomic dysfunction can present in PAF with a range of symptoms, such 
as dizziness, visual disturbances, lightheadedness, loss of consciousness, temporary 
cognitive impairment and neck muscle pain (“coat hanger” ache). These symptoms are 
caused by a reduction of organ perfusion which is well described in patients with orthostatic 
hypotension. There are several other clinical manifestations of PAF which suggest 
autonomic dysfunction, for example, urinary urgency and incontinence, dysphagia, 
constipation and erectile dysfunction. There are a number of reports demonstrating the 
presenting symptoms and clinical features of MSA but only a few studies that have 
specifically examined the presenting symptoms and clinical features of patients that have 
later obtained a confirmed diagnosis of PAF (Mathias et al., 1999). This is important to 
investigate because at the time of presentation, and just after, in a PAF patient, the 
diagnosis is often unclear, and other disorders, such as MSA, can be suspected. Therefore, 
Aim #3 of this thesis is to analyse the initial symptoms and clinical characteristics in 
patients with a confirmed PAF diagnosis. This aim will be achieved by evaluating 
autonomic symptoms, autonomic function test results and intracranial imaging to further 
characterise initial and presenting features in PAF and identify possible associated factors 
which will facilitate a better definition of the disease progression in this cohort.  
Previous pathological studies of PAF showed abnormal Lewy bodies in the 
intermediolateral grey columns of the thoracolumbar level of spinal cord, supporting that PAF 
is a form of Lewy body disease (Johnson et al., 1966; van Ingelghem et al., 1994; Hague et 
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al., 1997).  Cardiac MIBG uptake is markedly reduced in patients with PAF, which is 
consistent with PD, supporting a postganglionic sympathetic lesion in both disorders 
(Hirayama et al., 1995). Gastrointestinal symptoms can sometimes be prominent in PAF. 
Gastric electrical dysrhythmia using electrogastography (EGG) has been detected in PD (Lu 
et al., 2004), but not MSA patients (Suzuki et al., 2005). Although no pathological study of 
the involvement of Interstitial Cells of Cajal (ICC), a key centre of the stomach pacemaker, 
has been previously reported, there is evidence of alpha-synuclein deposition in Auerbach’s 
and Meissner’s plexuses, which are closely linked to the ICC, in patients with PD (Braak et 
al., 2006b). Given PD and PAF have a similar postganglionic sympathetic lesion, it may be 
that PAF patients have gastric dysrhythmia as a result of alpha-synuclein deposition in 
Auerbach’s and Meissner’s plexuses  To date, there have not been any studies investigating 
EGG activity in patients with PAF. Therefore, Aim #4 of this thesis will investigate 
gastric motility using Electrogastrography in primary chronic autonomic failure 
disorders with a particular focus on PAF.  
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Chapter 2 
2. Literature review 
2.1. Autonomic nervous system (ANS) function 
The term “autonomic nervous system” was first introduced by Langley in 1898. It 
referred to neurons in ganglia outside the brain and spinal cord which can function 
“independently and autonomously” without central nervous system control. It has now 
become clear that the ANS not only involves the peripheral control of visceral organs via the 
sympathetic, parasympathetic and enteric nervous systems and the sensorimotor nerves but 
the system is also regulated by the central autonomic network, which includes various key 
structures, such as the insular cortex, anterior cingulate cortex, amygdala, hypothalamus, 
periaqueductal gray, nucleus tractus solitarius, ventrolateral reticular formation of the 
medulla and the medullary raphe.  
 
Figure 2.1. Organisation of the Autonomic Nervous System. Reproduced from Jänig 
(1995). In: Schmidt and Thews, eds. Physiologie des menschen, 26th ed.Heidelberg: 
Springer-Verlag, 340–369. 
 The sympathetic and parasympathetic nervous systems share a similar characteristic 
with regard to their synaptic connection. Both systems consist of pre- and post-ganglionic 
neurons. Pre-ganglionic neurons start from their cell bodies in the spinal cord or brainstem 
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and send axons into the ganglia, where they synapse on the post-ganglionic neurons. The 
axons of post-ganglionic neurons then project to various tissues and organs in the body.  
 The obvious difference between the sympathetic and parasympathetic systems is the 
organisation within the ANS. The cell bodies of sympathetic pre-ganglionic neurons are 
located in the intermediolateral cell column of spinal cord from thoracic (T1 level) to lumbar 
(L3 level) regions. These neurons project axons to and synapse on post-ganglionic neurons 
either at the paravertebral or prevertebral sympathetic ganglia before innervating a range of 
organs, such as the eyes, salivary glands, as well as the adrenal medulla, intra-abdominal 
and pelvic organs and their blood vessels. More importantly, they also innervate and control 
the splanchnic circulation and blood vessels supplying muscle (Saper, 2002; Benarroch, 
2008), which are mostly responsible for short-term blood pressure regulation. The 
sympathetic nervous system also controls skin vasomotor and sudomotor function, which 
are critical for thermoregulatory function and metabolic control during stress (Cersosimo & 
Benarroch, 2012). 
In contrast, pre-ganglionic neurons of the parasympathetic system lie in the 
brainstem and sacral spinal cord (from levels S2 to S4). The cell bodies of the 
parasympathetic system are clustered as a number of autonomic nuclei in different areas 
within the midbrain, pons and medulla. The major autonomic nuclei in the brainstem include 
the dorsal motor nucleus of the vagus (DMV), the nucleus ambiguous (NAmb), salivary 
nuclei and the Edinger-Westphal nucleus. The DMV is crucial for gastrointestinal motility 
mediated by the enteric nervous system (Hopkins et al., 1996; Chang et al., 2003). The 
ventrolateral portion of the NAmb are essential for blood pressure and heart rate control via 
vagal output through the heart (Hopkins et al., 1996). A group of neurons in the ventrolateral 
medulla is particularly important since these neurons give rise to the majority of pre-
ganglionic innervation of the heart which are responsible for blood pressure and heart rate 
control (Spyer, 1994; Morrison, 2001; Dampney et al., 2003). The sacral parasympathetic 
output starts from the pre-ganglionic neurons at the sacral level of the spinal cord and 
project to various organs, including the rectum, bladder and sexual organs (de Groat, 2006). 
In contrast to post-ganglionic sympathetic neurons, the parasympathetic post-ganglionic 
neurons are mainly located close to the innervated organs. 
Gastrointestinal motility is uniquely different from other organs, as it is controlled by 
both the sympathetic and parasympathetic systems (extrinsic pathways), as well as by the 
enteric nervous system (intrinsic pathway). The enteric nervous system, containing the 
myenteric (Auerbach) and submucosal (Meissner) plexuses, is located throughout the gut 
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from the oesophagus to the anus.  
Because the ANS innervates every organ in the body, abnormalities of the system 
can present with a wide range of symptoms, such as those that are a result of abnormal 
blood pressure and heart rate control, abnormal sweating and temperature regulation, 
bladder and sexual dysfunction and gastrointestinal dysfunction.  
 
2.2 Neurotransmitters in the Autonomic Nervous System 
 Noradrenaline (NA) and acetylcholine (Ach) are the main neurotransmitters in the 
ANS. Ach is the primary neurotransmitter both in pre-ganglionic sympathetic, as well as in 
pre- and post-ganglionic parasympathetic neurons and the majority of ENS neurons, 
whereas NA is the primary neurotransmitter in post-ganglionic sympathetic neurons. Post-
ganglionic sympathetic neurons innervating sweat glands and muscle are exceptions, where 
Ach is utilized as a neurotransmitter. In addition, there are a number of other 
neurotransmitters which are increasingly reported in the ANS and coexist with Ach and NA. 
These neurotransmitters include neuropeptides (e.g., neuropeptide Y, substance P, 
vasoactive intestinal polypeptide, calcitonin gene-related peptide, adenosine triphosphate 
(ATP), nitric oxide (NO) and others (GABA, glutamate, dopamine and 5-HT) and play an 
important part in regulating the normal function of the ANS. For simplicity, this review will 
only cover key neurotransmitters in the ANS. 
Noradrenaline (NA) 
 NA is synthesized by converting tyrosine to L-dihydroxyphenylalanine (L-DOPA) via 
tyrosine hydroxylase, a rate limiting enzyme of catecholamine biosynthesis. L-DOPA is then 
converted to dopamine by DOPA decarboxylase. Noradrenaline and adrenaline are then 
synthesised via Dopamine-β-hydroxylase and phenylethnolamine N-methyltransferase, 
respectively. NA is co-released by exocytosis and then interacts with specific receptors, 
including, α1, α2 and β receptors, as well as their receptor subtypes. While the majority of α1 
receptors and its subtypes mediate vascular and visceral smooth muscle stimulation, the α2 
receptors are involved in inhibiting NA release and mediate smooth muscle contraction of 
blood vessels. The β receptors consist of β1, β2 and β3 receptor subtypes (Guimaraes & 
Moura, 2001). The β1 is responsible for sympathetic effects on heart rate, excitability and 
contractility, whereas the β2 causes smooth muscle relaxation. β3 receptor subtypes are in 
brown fat and its exact effect is still unclear. It has been found to be involved in 
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thermogenesis in animals. 
Acetylcholine (Ach) 
 The synthesis of Ach involves the acetyl coenzyme A, choline and choline acetyl 
transferase. It is released and interacts with two types of receptors, nicotinic and muscarinic. 
The nicotinic receptors are ionotropic ligand-gated channels, whereas the muscarinic types 
are G protein-coupled receptors. While the former are mainly found in autonomic ganglia, 
the latter are extensively located in autonomic innervated organs, autonomic ganglia and 
smooth muscle. Nicotinic receptors mediate fast responses from the pre-ganglionic neurons 
to the autonomic ganglion cells and ENS. The muscarinic receptors can broadly be divided 
into M1-like and M2-like receptors. M1-like receptors consist of M1, M3 and M5, of which nerve 
depolarization is induced by K+ channels inhibition and the release of Ca2+. M2-like 
receptors, including M2 and M4, are activated by the inhibition of adenylyl cyclise, K+ channel 
activation and the inhibition of Ca2+ release. M2 receptors inhibit the release of Ach in both 
cholinergic and sympathetic terminals. Examples of actions of this receptor include the 
reduction of excitability of the sinus node in the heart and counteracting the relaxation of 
muscle in the urinary bladder. 
Neuropeptides 
 Neuropeptides (substance P, CGRP, neuropeptide Y and VIP) are extensively 
present in the ANS, especially in peripheral pathways and the ENS. These act through the 
activation of G protein-coupled receptors and modulate synaptic transmission and trophic 
and vasomotor actions. In addition, they frequently coexist with other neurotransmitters and 
generally require stronger stimuli than those from other neurotransmitters to activate 
exocytosis.  Neuropeptides can generate multiple effects depending on the pattern of 
neuronal activity. Substance P is commonly found in the visceral organs and is involved in 
the control of smooth muscle contraction and endothelium nitric oxide-mediated 
vasodilatation. NPY, coexisting with NA in the sympathetic ganglia, mediate smooth muscle 
contraction and has inhibitory effects on NA release. VIP, which is located in the ENS, 
controls the relaxation of smooth muscle and also has a vasodilator effect within the 
intestines (Lundberg, 1996). 
Purines  
ATP and adenosine act via purinergic receptors, which are widespread in the 
sympathetic and parasympathetic nervous systems and the ENS. With regards to ATP, it 
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commonly co-releases with other neurotransmitters and interacts with two major receptor 
subtypes including P2x and P2y. P2x receptors are ligand-gated channels widely present in 
nociceptive neurons in visceral organs and autonomic ganglia. These receptors mediate the 
fast response of smooth muscle contraction and initiate sensory inputs to activate pain and 
physiological reflexes (Burnstock, 2006). The P2y receptors are G protein-coupled receptors 
involved in endothelium-mediated vasodilatation and control the release of neurotransmitters 
mediating slower responses. Adenosine also acts through G protein-coupled receptors that 
can be divided into 3 major subtypes; A1, A2 and A3. The main action of A1 is inhibiting the 
release of neurotransmitters including NA and Ach, whereas the A2 can cause 
vasodilatation. 
Nitric oxide (NO) 
 NO is formed from L-arginine and oxygen by nitric oxide synthetase and found in 
both pre- and post-ganglionic parasympathetic and some ENS neurons. It produces cyclic 
guanosine monophosphate (GMP) through the activation of cytoplasmic guanylate cyclase. 
This results in vasodilatation, penile erection and smooth muscle relaxation (Toda & 
Okamura, 2003).  
 
2.3 Cardiovascular Autonomic Function  
 Maintaining blood pressure within safe limits is critical in order to sustain appropriate 
organ perfusion, particularly in those above the heart, such as the brain. A postural change 
from supine to standing results in a shift of ~500-700 ml of blood from central compartments 
to the lower body (Mathias, 2002). A variety of complex systems including the neural system 
(via baroreflexes), the humoral system (renin-angiotensin and vasopressin systems), the 
capillary-fluid-shift system and the renal-body-fluid pressure control system (aldosterone, 
antidiuretic hormone) work closely together to sustain normal blood pressure during 
gravitational stress. The function of these systems will be briefly described. 
Neural Baroreflex Function 
 The baroreflex control system is responsible for the short-term blood pressure 
regulation (within seconds or minutes) via the regulation of total peripheral resistance (TPR; 
through vasoconstriction or vasodilation of vascular beds) and cardiac output (CO). The 
arterial and cardiopulmonary baroreceptors located in the carotid sinuses and aortic arch, 
and the heart and lungs are activated when there is a decrease or increase in BP and send 
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afferent signals to the cardiovascular control centre in the brainstem. An increase in BP 
results in increased vagal tone to the heart and decreased CO, as well as TPR, as a result. 
A reduction of BP causes the opposite effects, which increases sympathetic activity to the 
heart and inhibits vagal discharge, which results in a rise in TPR and CO in order to maintain 
BP. The latter phenomenon resembles the physiological changes during standing in 
humans.  
 The baroreflex system is divided into afferent and efferent pathways, the afferent 
pathway provides excitatory projections from the baroreceptors to the nucleus tractus solitarii 
(NTS) (Blessing, 2003). Efferent projection from the NTS plays an important role in 
sympathetic inhibition, which controls BP and HR by sending projections to the rostral 
ventrolateral medulla (RVLM) via interneurons in the caudal ventrolateral medulla (CVL). A 
group of neurons in the RVLM send a direct projection to pre-ganglionic neurons in the IML, 
which primarily generate vasoconstrictor effects in muscle, mesenteric and renal blood 
vessels. On the other hand, the NTS also sends output to a group of neurons in the 
ventrolateral portion of the nucleus ambiguous, which directly projects to cardiac ganglion 
neurons. This output is vital for controlling HR through the sinus node (Figure 2.2).  
 
Figure 2.2. Neural Baroreflex pathways and their role in BP regulation. Adapted from  
(Benarroch, 2008). 
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Humoral system (renin-angiotensin and vasopressin systems)  
 Renin-angiotensin-aldosterone (RAS) and vasopressin systems are two major 
humoral mechanisms, which are responsible for long-term (minutes to hours) BP control. 
These systems are minimally involved in the initial hemodynamic adjustments to alterations 
in BP if there is adequate blood volume in the circulation. By contrast, activation of these 
mechanisms is more prominent during hypovolemic states or prolonged orthostasis, such as 
orthostatic hypotension. 
Renin-angiotensin-aldosterone system (RAS) 
 Renin is synthesized in juxtaglomerular cells located in the renal arterioles and 
secreted into the circulation in response to a reduction of renal blood flow and an increase in 
sympathetic discharge. Renin hydrolyses angiotensinogen, a peptide in the liver, to form 
angiotensin I. Angiotensin I is then converted into angiotensin II (A2) by angiotensin-
converting-enzyme (ACE), mainly in the lungs and blood vessels. A2 is a strong vasopressor 
substance, which actively involves the vasoconstrictive function of renal arterioles and 
controls aldosterone secretion from the adrenal cortex. Aldosterone activates the Na+/K+ 
pump in the distal renal tubule, which is important for Na+ and water reabsorption as well as 
K+ excretion from urine. A2 is also involved in sympathetic activation, decreasing baroreflex 
sensitivity and closely interacts with neurohormonal and fluid-electrolyte changes.  
Antidiuretic hormone (ADH) or Vasopressin system 
 ADH is synthesized in the supraoptic and paraventricular nuclei of the hypothalamus 
and stored in the posterior pituitary gland. ADH is released in response to an increase in 
osmolarity and a reduction of fluid volume. The latter is controlled by feedback from the 
stretch volume receptors, which are located in the left atrium, inferior or superior vena cavae, 
pulmonary veins, carotid sinus and aortic arch. It has an important role in water reabsorption 
via cyclic AMP on the renal distal tubules and collecting ducts. In normal subjects, there is a 
rise in ADH during the upright posture.   
 
2.4 Classification of autonomic disorders 
 There are a number of ways to classify autonomic disorders. They can be divided by 
the onset and progression of disease (e.g. acute or chronic), regional involvement (e.g. 
localized or generalized), reversibility (fixed/chronic or intermittent) or the pathophysiological 
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mechanism (e.g. neurodegenerative, toxic or metabolic substances, autoimmune-mediated) 
or according to its onset and aetiology, for example, primary or secondary autonomic failure. 
Primary autonomic failure describes when the autonomic dysfunction occurs without a clear 
cause, while secondary autonomic failure is used when there are associated factors, disease 
or conditions that the autonomic dysfunction is secondary to, e.g., diabetes and amyloidosis. 
Autonomic failure can be a result of a lesion of central or peripheral origin. This thesis will 
focus on primary chronic autonomic failure. 
 
2.5 Primary chronic autonomic failure (CAF) 
 Primary chronic autonomic failure is a group of neurological disorders without 
identifiable causes (for the autonomic failure). This consists of multiple system atrophy 
(MSA), Pure autonomic failure (PAF), Parkinson’s disease with autonomic failure (PD+AF) 
and dementia with Lewy bodies (DLB). The focus of this thesis will be MSA, PD and PAF. 
MSA 
MSA is a sporadic adult-onset neurodegenerative disorder. It is characterized by 
orthostatic hypotension or urinary disturbances with erectile dysfunction in males, in addition 
to parkinsonian, cerebellar and pyramidal signs. Autonomic dysfunction is an essential 
diagnostic criterion for possible and probable MSA (Gilman et al., 2008). The overlapping 
features between parkinsonian syndromes and the complex features of MSA sometimes 
result in difficulties in a diagnosis of MSA. Some patients present with an isolated feature, 
such as orthostatic hypotension, urinary symptoms (including erectile dysfunction), stridor 
without parkinsonism or a combination of these symptoms at the onset. These features can 
predate the diagnosis of probable MSA for years. A variety of presenting symptoms of MSA 
may lead the patients to see specialists in different areas of expertise prior to a neurologist, 
which in turn delays the diagnosis and most appropriate management. Autonomic symptoms 
at the early stages of the disease in patients with parkinsonism provide vital evidence to 
distinguish MSA from other parkinsonian disorders. In addition, a more rapid progression of 
autonomic dysfunction is more likely in diagnosis of MSA than PD (Lipp et al., 2009).  
PD 
PD is the second most common neurodegenerative disorder characterized by 
extrapyramidal signs, including bradykinesia, tremor, rigidity and sometimes gait or postural 
disturbances. These signs are classified as motor features of PD and have generally been 
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used as a diagnostic criteria for the disorder (Hughes et al., 1992). Over the last decade, 
non-motor symptoms of PD have increasingly become of interest and studied. This is partly 
due to a neuropathological study by Braak et al (Braak et al., 2003) which described a 
categorisation of the progress of PD into 6 stages based on the areas of the brain that are 
affected. Although support for this hypothesis is equivocal, it proposes that PD could start 
from impairments in the gastrointestinal tract, abnormal olfaction and autonomic 
disturbances which correspond to abnormal Lewy body pathology in the enteric plexus, 
anterior olfactory nuclei and dorsal motor nucleus of the vagus nerve, respectively. The 
locus ceruleus, raphe and lateral tegmental nuclei are proposed to be affected in stage 2. In 
stage 3, the substantia nigra is affected and it is in this stage when the hallmark motor 
symptoms of PD develop in accordance with the large dopaminergic neuron loss (Schwarz 
et al., 2000; Marek et al., 2001). Lewy body pathology then affects other parts of the brain, 
including the basal forebrain and neocortex in stages 4-6. PD patients are typically 
diagnosed in these stages (stages 3-6) because of the prominent motor signs which 
correspond to at least 50% of substantia nigra cells loss (Fearnley & Lees, 1991). Based on 
this hypothesis, abnormal olfaction, impaired cardiovascular autonomic control and 
gastrointestinal disturbance may predate the motor symptoms and cognitive dysfunction in 
PD.  
PAF 
 PAF is a relatively rare neurodegenerative condition, characterized by orthostatic 
hypotension (OH) without other neurological features (Kaufmann, 1996). Although the 
prevalence of this disorder is unknown due to the limited number of patients, previous 
studies indicated that the prognosis of this condition is much better with a slow disease 
progression and patients generally live longer than other forms of primary chronic autonomic 
failure (Mabuchi et al., 2005). PAF has received more research attention recently. This is 
due to common features with patients with PD. Both patient groups have hyposmia, reduced 
cardiac MIBG reuptake and lewy body deposition both in the skin and central nervous 
system (Hirayama et al., 1995; Ikemura et al., 2008; Silveira-Moriyama et al., 2009b; 
Shishido et al., 2010). These features raise a question of whether or not PAF is a limited 
form of PD without motor features. Some even hypothesized that PAF may have a protective 
factor/substance that prevent patients from developing PD (Kaufmann & Goldstein, 2010).  
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2.5.1 Non-motor symptoms in Primary CAF 
2.5.1.1 Cardiovascular autonomic symptoms in Primary CAF 
Cardiovascular autonomic dysfunction results in a range of symptoms such as 
dizziness, visual disturbances, lightheadedness, loss of consciousness and temporary 
cognitive impairment and neck muscle pain (“coathanger” ache), which improve after lying 
down. These symptoms are caused by a reduction in organ perfusion and are well described 
in patients with orthostatic hypotension (OH) which is a well-known feature of cardiovascular 
autonomic dysfunction. It is defined by an orthostatic decrease of blood pressure within 3 
minutes of standing by at least 20 mmHg of systolic or 10 mmHg of diastolic blood pressure 
(Kaufmann, 1996). The prevalence of OH varies considerably depending on the study 
population. OH was reported in ~30% of the otherwise healthy population over 60 years of 
age (Cunha et al., 1991; Raiha et al., 1995) and this figure rises with increasing age (Lipsitz, 
1989; Masaki et al., 1998) . Nevertheless, many people may be asymptomatic even if they 
meet the criteria of OH (Forman & Lipsitz, 1997).   
Pathophysiology of OH  
To maintain arterial BP during standing and counteract the shift of blood to the lower 
part of the body, neural pathways, local reflexes and humoral systems are required to 
function appropriately. Cardiac output (CO; heart rate x stroke volume) and total peripheral 
resistance (TPR) are key determinants of arterial BP. A fall in BP alongside a reduction in 
CO (mediated by a decrease in stroke volume) during orthostatic stress will be compensated 
by increasing TPR via peripheral vasoconstriction, including constriction of the splanchnic, 
muscle, skin and renal vascular beds. Splanchnic vasoconstriction is particularly vital for 
maintaining BP during reductions in BP and subsequent sympathetic activation. The humoral 
system provides further stimulation for vasoconstriction as well as the balancing of body 
fluids. Both the RAS and Vasopressin systems play major roles in BP regulation. These 
mechanisms of BP control are usually somewhat impaired in patients with OH. Further 
details on the differences in clinical features and pathophysiological mechanisms of 
cardiovascular autonomic dysfunction according to specific primary CAF disorders will be 
discussed in the following section.  
MSA 
 Orthostatic hypotension (OH) is one of the key features in the diagnostic criteria of 
MSA. Apart from the lesion in the ANS, OH can be caused by other factors such as 
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dehydration, high ambient temperature and the influence of drugs (e.g., L-dopa). Given this 
reason, the OH cut-off point was changed to an orthostatic decrease of blood pressure 
within 3 minutes of standing by at least 30 mmHg of systolic or 15 mmHg of diastolic blood 
pressure in order to improve the diagnosis accuracy in the latest OH guidelines (Gilman et 
al., 2008). MSA pathology consists of widespread neuronal loss in the basal ganglia (Ozawa 
et al., 2004), cerebellum (Sakakibara et al., 2004b), brainstem (Benarroch & Schmeichel, 
2001), locus coeruleus (Wenning et al., 1994b), nucleus ambiguous (Benarroch et al., 2003), 
dorsal motor nucleus of vagus nerve (Benarroch et al., 2006b), ventrolateral medulla 
(Benarroch et al., 1998), hypothalamus (Benarroch et al., 2006a), as well as the 
intermediolateral (IML) column (Graham & Oppenheimer, 1969) and Onuf’s nucleus 
(Mannen et al., 1982) of the spinal cord. These neuronal losses accompany the glial 
cytoplasmic inclusions (GCIs) in neurons, particularly in the oligodendroglia.    
Although orthostatic symptoms are common among MSA patients (Mathias, 2006) 
syncope was reported in less than half of patients in comparison with PAF patients (Mathias 
et al., 1999) and the early development of autonomic dysfunction may also indicate a shorter 
survival in patients with MSA (Tada et al., 2007). Head-up tilt testing is routinely used for 
assessing OH (Figure 2.3) in autonomic laboratories. In the clinic this can also be performed 
by lying down and then sitting or standing. Tilt testing alongside plasma noradrenaline 
concentrations is often used as investigations in patients with MSA. Noradrenaline levels in 
MSA patients are typically within the normal range in the supine position and there is a slight 
increase in the upright position relative to normal controls (Mathias & Bannister, 1999). 
These findings are consistent with preserved post-ganglionic sympathetic function in MSA.  
Food ingestion can lower blood pressure in MSA (Figure 2.4) but not in healthy 
individuals which have normal compensatory cardiac and regional haemodynamic 
responses (Smith et al., 1998). A standard liquid meal of mixed composition can be used to 
determine post-prandial hypotension. BP before and after the liquid meal are measured in 
the supine and head-up tilt (or standing) positions in order to ascertain if food unmasks or 
exacerbates orthostatic hypotension (Mathias et al., 1991). Post-prandial hypotension is 
present in both MSA-P and MSA-C, but the severity in MSA-C is greater (Smith et al., 1998). 
Exercise-induced hypotension has also been reported in MSA (Smith & Mathias, 1995) as 
well as an exacerbating of OH after exercise (Smith et al., 1993). Exercise-induced 
hypotension in MSA-C was found to be greater than those with MSA-P (Smith & Mathias, 
1996).    
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Mechanisms of OH in MSA 
 The fundamental pathology which contributes to cardiovascular autonomic 
dysfunction, particularly OH, in MSA is the intermediolateral (IML) neuronal loss in the spinal 
cord of patients with MSA (Oppenheimer, 1980). Additionally, other neuropathology 
abnormalities were reported in a number of areas which are responsible for cardiovascular 
autonomic control. These include neuronal loss in the ventrolateral medulla (VLM), which 
consists of the rostral C1 neurons and non-C1 cells (Benarroch et al., 1998). The IML 
receives projections from these neurones and plays a crucial role in maintaining BP and 
regulating baroreflex function. A loss of neurons in the caudal ventrolateral medulla has also 
been reported in MSA (Benarroch et al., 2006a). As this area consists of noradrenaline-
producing A1 neurons which project to the neurons in supraoptic and paraventricular areas 
of the hypothalamus, noradrenaline-producing A1 neuronal loss results in impaired 
vasopressin secretion in response to hypotension. Neuronal loss in the ventrolateral portion 
of the Nucleus ambiguous was also described in MSA but not in PD (Benarroch, 2002). 
These neurons are linked to the impairment of vagal control of the heart which can be 
impaired in MSA. Clonidine stimulation has been proposed to be a useful investigation for 
distinguishing MSA from PD. While clonidine can stimulate a release of growth hormone in 
PD, this response is blunted in patient with MSA (Kimber et al., 1997) as a result of central 
neurotransmitter and alpha 2-adrenoceptor-hypothalamic abnormalities in MSA. 
PD 
Autonomic dysfunction has been increasingly recognized in Parkinson’s disease (PD) 
over the last decade. A number of autonomic nervous system disturbances, such as 
constipation, erectile dysfunction and orthostatic hypotension, have frequently been reported 
as common non-motor symptoms in PD patients (Tolosa et al., 2009). These autonomic 
disturbances significantly impact quality of life and cause significant morbidity. Among 
different autonomic abnormalities, cardiovascular autonomic dysfunction, such as orthostatic 
hypotension (OH), has been considered as one of the most important non-motor symptoms 
in PD. Dizziness is commonly reported as a frequent symptom of OH compared to other 
non-motor symptoms in PD. Although OH is commonly present in healthy individuals who 
are aged over 50 (van Dijk et al., 1993), the prevalence of OH seems to be higher in PD 
varying between 30 and 58% depending on the type of study, participants and methodology 
(Allcock et al., 2004; Goldstein, 2006). It could be due to the fact that many PD patients do 
not have symptoms even if they have OH (Mihci et al., 2006) and as a result it has not been 
recognized by clinicians (Senard et al., 1997). Moreover, various medications, particularly 
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dopaminergic therapy which is a mainstay of PD treatment, can also contribute to OH. It has 
now become clear that OH can be seen in any stage of PD but it is more prevalent in later 
stages. Since several studies reported OH in early stages of PD without medications, this 
supported that autonomic failure is a part of the disease progression (Bouhaddi et al., 2004). 
In addition, recent studies have also found cardiovascular dysautonomia even in untreated 
patients with early stages of PD (Oka et al., 2006). Given these findings, OH may not be 
used as a single autonomic feature for distinguishing PD and MSA (Lipp et al., 2009). 
Constipation, bladder symptoms and abnormal sweating can also occur in PD patients but 
with less severity compared to MSA (Lipp et al., 2009; Yamamoto et al., 2011).  
Mechanisms of OH in PD 
Proposed mechanisms of OH in PD include both pre- and post-ganglionic lesions, 
the former perhaps from autonomic lesions in the upper brainstem that affect blood pressure 
control during orthostasis through baroreflex dysfunction and the latter via cardiac 
denervation and/or impaired sympathetic mediated vascular responses (Asahina et al., 
2012). The alpha-synuclein related pathology in the intermediolateral column of the spinal 
cord, sympathetic ganglia and adrenal medulla (Braak et al., 2004; Bloch et al., 2006; Orimo 
et al., 2007; Dickson et al., 2009; Beach et al., 2010) and post-ganglionic cardiac 
denervation (Orimo et al., 2008) have been suggested as part of the pathogenesis of OH in 
PD. The autonomic centres in the brainstem that may also contribute to OH in PD, include 
the caudal raphe nuclei and the C1 group of the RVLM (Halliday et al., 1990a; Gai et al., 
1995; Jellinger, 2011). 
PAF  
OH and its related symptoms, such as lightheadedness or dizziness, is the most 
common presenting feature in PAF (Mathias et al., 1999). Although there are only a few 
case reports on the symptoms of PAF, sudomotor dysfunction was consistently reported in 
patients with PAF (Hague et al., 1997; Kaufmann et al., 2001). It can lead to the symptoms 
of heat intolerance or even fainting when patients stay in hot climates. Exercise and food can 
also worsen orthostatic symptoms in PAF. Bladder symptoms are also present in some PAF 
patients but these features are less severe than in MSA (Sakakibara et al., 2000). While 
respiratory symptoms such as stridor or sighing are common in MSA, these symptoms were 
not reported in patients with PAF (Mabuchi et al., 2005). There are only a few studies that 
have reported pathology in patients with PAF. Intracytoplasmic eosinophilic inclusions with 
Lewy bodies resembling those in PD patients were reported in the neurons in autonomic 
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ganglia and post-ganglionic  nerves (Kaufmann et al., 2001). Typical PAF patients have no 
parkinsonian features. Nevertheless, there was a report of Lewy body deposition in the 
substantia nigra, locus coeruleus, thoracolumbar and sacral spinal cord with limited neuronal 
loss (Hague et al., 1997). These findings raise the possibility by some that PAF may be a 
part of a “Lewy body disease” spectrum representing the peripheral form, alongside with PD 
and DLB (Kaufmann & Goldstein, 2010).  
Mechanisms of OH in PAF 
The pathogenesis of OH in PAF is thought to be mainly from post-ganglionic 
autonomic dysfunction. This hypothesis is supported by alpha-synuclein accumulation in 
cytoplasmic inclusions with accompanying neuronal loss in the IML column and sympathetic 
ganglia (Hague et al., 1997). Interestingly, these findings were also evident in the substantia 
nigra pars compacta, locus ceruleus and thoracolumbar/sacral spinal cord, which resemble 
findings in PD patients (Kaufmann et al., 2001). A recent study also reported a diminished 
reuptake of cardiac MIBG in patients with PAF resembling those with PD, which supports a 
post-ganglionic autonomic pathology (Kashihara et al., 2006). Vasopressin secretion 
appears intact during episodes of hypotension in patients with PAF (Kaufmann et al., 1992).  
While patients with PD and MSA can present with difficulty/abnormal movement or a 
wide range of non-motor symptoms, patients with PAF usually present with orthostatic 
hypotension. OH can sometimes make the diagnosis more difficult. For example, OH can be 
a presenting feature in PD, but also the hallmark of patients with MSA. This overlapping 
feature makes this more difficult to distinguish between these disorders. On the other hand, 
some patients with MSA can present with isolated OH without other features for several 
years before developing MSA features. Thus, it is recommended to follow-up these patients 
before diagnosing someone with PAF to ensure the correct diagnosis. As a consequence, 
this could also lead to the difficulty in diagnosis and uncertainty in predicting prognosis for 
the clinician, as these two disorders have a significant difference in life expectancy. 
 
2.5.1.2 Cardiovascular autonomic screening tests 
Cardiovascular autonomic function tests are essential for the diagnosis of cardiovascular 
autonomic dysfunction and/or autonomic failure and the purposes of these can be divided 
into 3 reasons; 1) to evaluate whether autonomic function is normal or abnormal. 2) If any 
abnormalities present, the severity of autonomic dysfunction would be assessed with an 
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emphasis on the site of lesion and the functional deficits and 3) to establish whether the 
autonomic dysfunction is a part of a primary or secondary autonomic disorder which would 
be useful to determine the extent of further investigations, prognosis and treatments 
(Mathias & Bannister, 2002). Autonomic screening tests have generally been used to 
evaluate the extent of cardiovascular autonomic dysfunction.  
OH/HUT 
OH is ideally assessed by head-up tilting in an autonomic laboratory because it can be used 
in patients who are less able to stand upright due to severe hypotension or neurological 
deficits. Furthermore, continuous measurement of heart rate (HR) and blood pressure (BP) 
by non-invasive techniques can be useful for early detection and safe monitoring when 
hemodynamics become unstable. Nonetheless, OH can also be performed by lying down 
and then sitting or standing in the clinic when an autonomic laboratory is not available.  
 
Figure 2.3. Blood pressure and heart rate before and during 60 degrees head up tilt 
(HUT) in (upper panel) a normal subject and (lower panel) a patient with MSA. In the 
normal subject, there is no fall in BP during HUT, unlike in a patient with autonomic 
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failure in whom BP falls promptly and remains low until return to horizontal (Adapted 
from Mathias 2006). 
 
MIBG 
Cardiac 123I-metaiodobenzylguanidine (MIBG) imaging has been helpful for making 
the diagnosis of chronic autonomic failure disorders. A number of previous studies 
demonstrated that cardiac MIBG uptake is markedly reduced in PAF and Parkinson’s 
disease, even in the early stage of disease (Spiegel et al., 2005), which results from post-
ganglionic  sympathetic dysfunction. The uptake is typically normal in MSA which can be 
explained by the pre-ganglionic lesion of MSA. Previous studies using MIBG to identify 
patients with PD from normal subjects showed that the sensitivity varies from 84.3-89.7% 
and specificity ranges from 89.5-94.6% when using MIBG to discriminate PD from MSA 
(Braune, 2001; Sawada et al., 2009). According to these results, cardiac MIBG may provide 
an additional benefit for separating PD and MSA when using it as a concomitant 
investigation. However the considerable overlap in the reduction of cardiac reuptake 
between PD, MSA, DLB and PSP indicated that MIBG cannot entirely discriminate PD from 
these disorders (Rascol & Schelosky, 2009). Moreover, the MIBG scan is a relatively 
invasive, costly and time-consuming technique. The correlation between a reduction of 
cardiac MIBG uptake and several clinical features of PD has been extensively studied. It is 
unclear whether the severity of PD and autonomic function are correlated with MIBG uptake 
in previous studies (Orimo et al., 1999; Nagayama et al., 2005; Matsui et al., 2006; Kim et 
al., 2008) but no correlation between rigidity or postural instability and MIBG uptake were 
found in advanced PD (Suzuki et al., 2007).  Furthermore, MIBG uptake does not correlate 
with the severity of motor dysfunction and orthostatic hypotension in PD (Matsui et al., 
2006). 
Pressor tests (Handgrip Isometric exercise, Mental arithmetic and Cold pressor test) 
Blood pressure (BP) and heart rate (HR) normally increase during sustained isometric 
exercise, mental arithmetic and cold pressor tests. These first 2 tests are indexes for 
sympathetic efferent function while the latter mainly measures adrenergic function (Low & 
Benarroch, 2008). Reduced responses are commonly seen in patients with cardiovascular 
sympathetic dysfunction. 
 
43 
 
24 hour-Ambulatory BP and heart rate monitoring (24 hr-ABPM) 
24 hour-ambulatory blood pressure monitoring (24 hr-ABPM) has traditionally been 
used as an investigation for arterial hypertension (Mancia, 1990) but is also routinely used in 
some autonomic laboratories for the assessment of cardiovascular autonomic dysfunction.  
Blood pressure (BP) in healthy individuals normally fluctuates with increased BP in the 
daytime while falling at night-time. This circadian rhythm is frequently found to be abnormal 
with a loss of nocturnal BP fall in MSA and PD patients compared to controls (Figure 2.4) 
(Schmidt et al., 2009a). Nevertheless, only a few studies have used 24 hr-ABPM to compare 
between parkinsonian disorders. In fact, there has been no study specifically investigating 
the difference between 24 hr-ABPM profiles in patients with MSA and PD with autonomic 
failure.  
 
Figure 2.4.  Blood Pressure (top panel; upper line systolic, lower line diastolic) and 
heart rate profiles (bottom panel) during 24 hr-ABPM of patients with a dipper (A)  
showing more than a 10% drop in BP at night time and (B) a reversed BP profile where 
BP increases at night time. Black bar indicates sleep. Adapted from (Stuebner et al., 
2013). 
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2.5.1.3 Novel quantitative cardiovascular autonomic function tests 
Cardiovascular autonomic screening tests have been used to confirm the diagnosis of 
autonomic failure but the use of OH as a marker of cardiovascular autonomic function may 
not be able to differentiate autonomic failure disorders (Riley & Chelimsky, 2003). Other 
indices of quantitative cardiovascular autonomic function, such as baroreflex sensitivity and 
blood pressure recovery time (BPRT), have recently been developed and additionally been 
proposed to be useful in evaluating autonomic function in chronic autonomic failure disorders 
(Vogel et al., 2005; Schrezenmaier et al., 2007). Beat-to-beat blood pressure and heart rate 
responses to the Valsalva manoeuvre (VM) depends on the integrity of the baroreflex 
pathways and has been proven to be useful for evaluating sympathetic and parasympathetic 
function. This has frequently been reported to be abnormal in patients with autonomic failure 
and have routinely been used as part of autonomic function tests. PRT derived from the VM 
was recently proved to be a valuable index of sympathetic function (Vogel et al., 2005). 
Since blood pressure is regulated by changing heart rate and total peripheral resistance, via 
baroreceptors, the measurement of baroreflex sensitivity (BRS) has been used as a 
quantitative index of cardiovascular autonomic function and can be assessed from the VM 
(Low & Benarroch, 2008) (Figure 2.5). These indices are frequently abnormal in patients with 
autonomic failure (Schrezenmaier et al., 2007).  
 
Figure 2.5. Baroreflex sensitivity (B) derived from the Valsalva manoeuvre (A). Blood 
pressure (BP; upper A) and heart rate (HR; lower A) during VM in a normal subject. 
Baroreflex sensitivity is obtained from the slope of the regression between R-R 
interval and systolic blood pressure (SBP) during phase II early of VM (B). Adapted 
from (Fu et al., 2007). 
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The Valsalva ratio (VR), derived from the VM by the ratio between the maximum and 
minimum heart rate during the manoeuvre are also helpful for evaluating parasympathetic 
function (Low et al., 1997) (Figure 2.6). The heart rate responses to deep breathing (sinus 
arrhythmia), which mainly assess cardiac parasympathetic function, are frequently abnormal 
in patients with autonomic failure (Gurevich et al., 2004; Deguchi et al., 2006). the efficacy of 
these tests for distinguishing between primary chronic autonomic failure disorders are still 
uncertain however (Riley & Chelimsky, 2003). 
 
Figure 2.6. Blood pressure (BP, upper panel) and heart rate (HR, lower panel) during a 
Valsalva Manoeuvre (VM) in a normal subject. The Valsalva Ratio is calculated by the 
ratio between maximum HR and minimum HR during and just after the VM. 
 
2.5.2 Other non-motor features in patients with Primary CAF  
2.5.2.1 The olfactory system and pathology in Primary CAF 
 The olfactory system consists of the olfactory epithelium, the olfactory bulb, the 
olfactory cortex and the orbitofrontal cortex. The olfactory signal starts from the activation of 
the bipolar olfactory sensory receptors, G-protein-coupled receptors which are located in the 
olfactory epithelium, by odorants. Adenylyl cyclise III subsequently synthesizes cyclic 
adenosine monophosphate (cAMP) (Kaupp, 2010), which causes depolarization by 
increasing intracellular calcium concentrations. The axons of olfactory sensory receptors 
enter through the cribriform plate and synapse with the dendrite of Mitral and Tufted cells 
within the glomerulus in the olfactory bulb. These cells project its axons to the anterior 
olfactory nucleus and different parts of the primary olfactory cortex, including, the olfactory 
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tubercle, piriform cortex and entorhinal cortex (Mouret et al., 2009). The primary olfactory 
cortex also connects to the amygdala, hippocampus and hypothalamus (Figure 2.7). 
 
Figure 2.7. Major olfactory structures, including the Olfactory epithelium (orange), 
Olfactory bulb (blue) and the Anterior olfactory nucleus (brown circle). The Olfactory 
bulb consists of 5 layers (from lower to upper): Glomerular layer, External plexiform 
layer, Mitral cell layer, Internal plexiform layer and the Ganule cell layer. Abbreviation: 
G, granule cell; M, Mitral cell; T, tufted cell. Adapted from (Duda, 2010). 
Despite frequent olfactory dysfunction in various neurodegenerative conditions, the 
olfactory pathology can vary. In PD, previous studies have consistently demonstrated 
abnormal olfactory pathology, including alpha-synuclein-related pathology, similar to that in 
the substantia nigra (Beach et al., 2009).  Lewy bodies and Lewy neurites have been 
reported in the olfactory bulbs, anterior olfactory nucleus and several areas in the primary 
olfactory cortex and occasionally in the neocortex (orbitofrontal/dorsolateral cortices and 
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insular cortex) (Harding et al., 2002; Braak et al., 2003; Silveira-Moriyama et al., 2009a). 
This alpha-synuclein-related pathology is regularly present in the olfactory bulb, particularly 
in the mitral and tufted cells and the granule and periglomerular cells along with olfactory 
neuronal loss (Pearce et al., 1995). The degree of neuronal loss in the anterior olfactory 
nucleus was negatively correlated with PD disease duration (Pearce et al., 1995). It is 
important to note that the severity of alpha-synuclein-related pathology seemed to correlate 
with the number of projections from the olfactory bulb (Sengoku et al., 2008). The distribution 
of alpha-synuclein-related pathology also progresses from the anterior olfactory nucleus 
centrally towards the olfactory primary cortex without the involvement of non-olfactory 
cortical structures (Braak et al., 2003). Interestingly, tau-pathalogy in the form of 
neurofibrillary tangles is also commonly present alongside alpha-synuclein pathology in the 
olfactory system in PD patients. This abnormal pathology was found in the olfactory bulb and 
the anterior olfactory nucleus with the associated olfactory neuron loss and is consistently 
reported not only in PD but also in those with Alzheimer’s disease (AD) and dementia with 
Lewy bodies (LBD) (Tsuboi et al., 2003; Mundinano et al., 2011). 
In contrast to PD, there are only few studies that have reported olfactory pathology in 
MSA. Glial cytoplasmic inclusions in oligodendrocytes were found in the olfactory bulb with 
olfactory neuronal loss in the anterior olfactory nucleus (Daniel & Hawkes, 1992; Kovacs et 
al., 2003). There has been no report of olfactory pathology in patients with PAF.   
Impaired olfaction is a common symptom among the general population. Complaints 
of abnormal taste can also sometimes be caused by smell loss because of the ability to 
appreciate the flavours of food depends upon olfaction (Deems et al., 1991). Upper 
respiratory tract infections, head injury and nasal/paranasal sinus were reported as frequent 
causes of impaired olfaction and account for almost two-thirds of patients with chronic 
anosmia/hyposmia (Deems et al., 1991). Age is the most important confounder for olfactory 
dysfunction. More than 60% aged over 80 have impaired olfaction (Murphy et al., 2002). This 
figure was even higher (more than three-quarters) in a study from a specialist clinic (Doty et 
al., 1984a). Gender is another factor which affects olfaction. Previous studies consistently 
showed that women usually performed smell tests better compared to men in the same age 
groups but there is no difference in the rate of deterioration with age (Doty et al., 1988; 
Hawkes et al., 1997). Olfactory tests are necessary because previous studies demonstrated 
that self-reporting of abnormal olfaction is often unreliable (Hawkes et al., 1997). 
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2.5.2.1.1 Assessment of olfactory function 
Smell function has been tested using various methods mainly divided into three main 
categories, including smell detection thresholds, smell discrimination and smell identification. 
Smell detection thresholds is the ability to recognize the perception of smell at the lowest 
concentration of an olfactory stimulus while smell discrimination is the ability to distinguish 
between different olfactory stimuli which are not dependent on the recognition of the smell. 
Smell identification is the most widely used method because it is more feasible and the 
easiest way to assess subjects both in clinical settings and research studies. Olfactory 
dysfunction is usually graded from normal to severe as normosmia, microsmia (which is 
often subdivided into mild, moderate and severe microsmia) and anosmia.  There have been 
several validated tools which can be used for smell testing. The University of Pennsylvania 
Smell Identification Test (UPSIT) is a 40-item scratch and sniff test which has been 
developed since 1984 in the US (Doty et al., 1984b). Each odour is contained in a 
microencapsulated paper strip and is released by scratching with a pencil. Patients select an 
answer which is the most likely from four choices. UPSIT has been most frequently used 
compared with other smell tests and normal values in different age distributions and genders 
are available. Given that culture greatly influences the result of smell tests, a 12-item Cross-
Cultural Smell Identification Test (CC-SIT), which is also known as the Brief Smell 
Identification Test (B-SIT), was later created from selected items from the UPSIT (Doty et al., 
1996). The B-SIT has also been validated with the UPSIT and has been adapted for use in 
other countries (Double et al., 2003). Sniffin’ Sticks is another smell test which was originally 
developed in Germany (Hummel et al., 1997).  
Sniffin’ Sticks were originally used for testing smell thresholds, smell discrimination 
and smell identification. The combination of the scores of the different methods in Sniffin’ 
Sticks are summarized as a TDI (Threshold, Discrimination, Identification) index which was 
validated and normative data are also available (Kobal et al., 2000). Since using TDI scores 
can be time-consuming, performing only part of this test, particularly smell identification 
testing, can provide useful information regarding a patient’s sense of smell. The smell 
identification part of the Sniffin’ Sticks test is performed by using scented felt tipped pens 
which have 16 different odours. Patients are asked to sniff the tip of pens at an interval of 30 
seconds each. Participants need to identify one of 4 choices by selecting the one which best 
describes the presented odour. Previous studies demonstrated that the 16-item smell 
identification test has been useful as a screening tool for detecting abnormal olfaction and 
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has been validated previously in several countries and is a good non-invasive instrument for 
distinguishing PD from control subjects (Muller et al., 2002). 
 
2.5.2.1.2 Olfactory function in Primary CAF  
Abnormal olfaction in PD has long been known since the first report in the 1970s 
(Ansari & Johnson, 1975). Nevertheless, it has become increasingly recognized among 
clinicians over the last decade. An increased recognition of this condition reflects the 
expansion of research relating to non-motor symptoms of PD in order to find a reliable 
biomarker for PD. Olfactory dysfunction in PD is prevalent ranging from 45-90% (Ansari & 
Johnson, 1975; Ward et al., 1983; Doty et al., 1988; Hawkes et al., 1997). The variation in 
studies might be explained by several factors, including, the dissimilarity of smell tests and 
methods used, age of participants, sample size, normative data and particularly cultural 
differences. It has also been suggested that olfactory dysfunction can predate motor 
symptoms of PD. This evidence came from the Honolulu Heart Program population-based 
prospective study (Ross et al., 2008). Olfactory function was assessed by B-SIT. 35 out of 
2,267 male participants aged between 71-95 years developed PD at the end of an 8 year-
follow-up period. The results showed that there was approximately a 5 times higher risk of 
developing PD within 4 years in participants who were in the lowest quartile of B-SIT scores 
compared to those in the highest quartile. This evidence was present even after adjustment 
for age and other potential confounders.  
Combining olfactory tests and functional imaging techniques were used for predicting 
PD by Ponsen et al., (2004). 361 asymptomatic relatives of PD patients were evaluated by 
smell tests (odor detection, discrimination and identification). 38 normosmic and 40 
hyposmic relatives were assessed by single-photon emission computed tomography 
(SPECT), using [123I] β-CIT for evaluating nigrostriatal dopaminergic function at baseline and 
after a 2 year follow-up. The results showed that 10% of hyposmic relatives subsequently 
developed clinical features of PD whilst none in the normosmic relatives had parkinsonian 
features (Ponsen et al., 2004). Previous studies have also showed that impaired olfaction 
was not associated with motor disability, tremor or cognitive function in PD however (Doty et 
al., 1988; Doty et al., 1989). Subsequent studies found that olfactory dysfunction was not 
correlated with dopaminergic medication (Doty et al., 1992) and there was no change during 
“on” and “off” states in PD patients with motor fluctuations (Quinn & Spraguer, 1986). It is still 
debatable whether there is a progression of impaired olfaction along with PD disease 
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duration and severity. Most studies suggest that there is no significant deterioration of smell 
deficit in PD patients with increasing disease duration (Doty et al., 1988; Double et al., 2003; 
Kim et al., 2007) while only a few studies showed that olfactory dysfunction was increased 
with the severity of disease (Tissingh et al., 2001). Interestingly, there was no correlation 
between striatal dopaminergic terminal loss in functional brain imaging and olfactory 
dysfunction (Siderowf et al., 2005; Goldstein et al., 2008).  
Olfactory dysfunction has also been reported in other neurodegenerative disorders 
but the severity is more prominent in PD, Alzheimer disease (AD) and Dementia with Lewy 
bodies compared to those with multiple system atrophy (MSA) and pure autonomic failure 
(PAF). It is important to note that Progressive supranuclear palsy (PSP), Cortico-basal 
degeneration and Vascular Parkinson’s disease are more likely to have relatively normal or 
only minimal impairment smell function (Hawkes, 2003), therefore smell tests are particularly 
useful for distinguishing PD from certain parkinsonian disorders. The sensitivity of smell tests 
for PD diagnosis were reasonably high; 80-90% among different methods and studies 
(Hawkes et al., 1999; Becker et al., 2002; Berg, 2006). Olfactory dysfunction has also 
recently been linked with other disorders such as REM sleep behaviour disorder (RBD) 
which is considered to a pre-motor symptom of PD (Postuma et al., 2006). To date, there 
have been only a few studies that have formally assessed sense of smell in a wide range of 
autonomic disorder patient groups such as MSA, PAF and PD (Silveira-Moriyama et al., 
2009b; Garland et al., 2011). Although an impaired olfaction in PD was consistently found in 
many studies, there are conflicting results in patients with MSA and PAF. While one study 
reported intact olfactory function in MSA (Garland et al., 2011), the other demonstrated 
mildly impaired olfaction in PAF (Silveira-Moriyama et al., 2009b). These contradictory 
results raise a possibility that there may be other factors contributing to olfactory dysfunction 
in these disorders. 
 
2.5.2.2 Gastrointestinal dysfunction  
2.5.2.2.1 Neural control of the gastrointestinal function 
Appropriate autonomic nervous system function is critical for effective gastrointestinal 
motility and secretion. The gastrointestinal tract is controlled by both intrinsic and extrinsic 
pathways. The intrinsic pathway is the enteric nervous system (ENS), consisting of the 
myenteric and submucosal plexus. The myenteric plexus is located in between the 
longitudinal and the circular smooth muscle layers, whereas the submucosal plexus is within 
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the submucosa. The extrinsic pathway consists of the pre-ganglionic sympathetic and 
parasympathetic output. The former sends output from the prevertebral ganglia 
(Szurszewski, 1981; Furness, 2006), whereas the latter mainly projects from two nuclei of 
the medulla, the dorsal motor nucleus of vagus nerve (DMV) and the nucleus ambiguous 
(Hopkins et al., 1996; Chang et al., 2003) and the sacral parasympathetic nucleus (Brading 
& Ramalingam, 2006).  
The pre-ganglionic sympathetic fibers arise from the thoracic level of spinal cord and 
synapse at the cell bodies of post-ganglionic neurons in three prevertebral ganglia, including 
celiac, superior and inferior mesenteric and hypogastric plexuses. Some of these 
sympathetic fibers are involved in vasoconstrictive function whereas others influence 
secretory function. Moreover, a number of sympathetic fibers innervate and terminate within 
the myenteric and submucosal plexuses. These projections inhibit gastrointestinal motility by 
controlling circular smooth muscle contraction.   
The extrinsic pathway projecting from neurons in the DMV predominantly control the 
smooth muscle contraction and relaxation of the oesophagus and stomach, which are 
important for swallowing and gastric emptying (Travagli et al., 2006). Striated muscle in the 
upper esophagus and pharynx receive projections from the nucleus ambiguous and work 
together with neurons in the NTS for the sequential motor pattern of swallowing and its 
coordination. While primary peristalsis is under the control of the DMV (extrinsic), which is 
influenced by the NTS, secondary peristalsis (intrinsic) is thought to involve local reflexes, 
which are interceded by the myenteric neurons.  
In the lower esophageal sphincter, there are both vagal excitatory and inhibitory 
pathways. These not only control tonic contractions during the resting state but also 
selectively activate esophageal sphincter relaxation. The NTS also has a major role in 
controlling gastric motility (Travagli et al., 2006). The vagal inhibitory pathway is responsible 
for stomach relaxation, which mainly occurs in the fundus (proximal). This is contradictory to 
the excitatory pathway, where it activates contraction of the corpus and the antrum (distal). 
The latter plays an important role in the gastric emptying process. While all extrinsic 
efferents utilize acetylcholine (Ach) as a primary neurotransmitter, the inhibitory pathway 
mainly uses nitric oxide (NO), vasoactive intestinal polypeptide (VIP) or adenosine 
triphosphate (ATP) (Chang et al., 2003). 
The extrinsic pathway also supplies the anorectal organs and pelvic floor. These 
structures receive output from the sacral parasympathetic nucleus in the spinal cord and 
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sympathetic and somatic nerves. The Onuf nucleus, located in the sacral spinal cord, sends 
somatic projections to the external anal sphincter and puborectalis muscle, whereas the 
internal anal sphincter receives tonic excitatory sympathetic input. These structures are vital 
for faecal continence (Brading & Ramalingam, 2006; Bharucha & Fletcher, 2007). Both the 
excitatory and inhibitory components of the parasympathetic output are key parts in 
controlling defecation. The excitatory pathway is for the colonic propulsive activity, whereas 
the inhibitory pathway elicits colonic relaxation. The relaxation of the puborectalis muscle, 
the internal anal sphincter and the external anal sphincter are required for defecation. 
Furthermore, the Onuf nucleus also receives direct inputs from several brainstem nuclei and 
projects to the external anal sphincter and pelvic floor for contributing to the control of 
defecation.  
The role of the extrinsic pathway is significantly less prominent in the small intestine 
and colon. Instead, gastrointestinal motility and secretion within these organs are mainly 
controlled by the intrinsic pathway within the ENS (Costa et al., 2000; Furness, 2000). While 
smooth muscle contraction of the intestines largely depends on the myenteric plexus, the 
submucosal plexus is primarily responsible for controlling mucosal blood flow and secretion.  
There are different types of neurons in the ENS, including intrinsic primary afferent neurons 
(IPANs), motor neurons, interneurons, the interstitial cells of Cajal, secretomotor, vasomotor 
neurons and intestinofugal neurons. The IPANs, located in submucosal and myenteric 
plexus, receive signals from local reflexes (e.g. changes in chemical substances in the 
intestinal lumen and/or mechanical stretch of the intestinal wall) and further synapse with 
motor neurons and interneurons. The interneurons are closely involved with excitatory and 
inhibitory motor neurons, which are responsible for normal peristaltic reflex. The majority of 
excitatory neurons in the ENS are mainly cholinergic neurons, whereas the inhibitory 
interneurons and motor neurons mainly express VIP, NO, substance P, neuropeptide Y or 
ATP, in various combinations. The interstitial cells of Cajal, the specialized pacemaker cells 
utilizing NO, generate gastric slow waves by itself which are responsible for relaying the 
signals between excitatory and inhibitory function of myenteric motor neurons to the smooth 
muscle cells (Huizinga et al., 2004; Ward & Sanders, 2006) and control smooth muscle 
membrane potentials (Hirst & Edwards, 2004). Intestinal blood flow and secretion are under 
control of the secretomotor and vasomotor neurons, which lie in the submucosal plexus. 
These neurons innervate both the gut epithelium and blood vessels and control the balance 
between blood flow and epithelial absorption within intestines. The intestinofugal neurons 
send signals from the gut to the prevertebral ganglia. These neurons are responsive to 
mechanical stimuli and are thought to be directly activated by the stretch of circular muscles, 
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which also contribute to the inhibitory reflex during active intestinal contractions (Miller & 
Szurszewski, 2002, 2003) (Figure 2.8). 
 
 
Figure 2.8. The innervation of the gastrointestinal tract. The outputs from CNS (Vagal and 
Pelvic pathways) mainly control esophageal, stomach and anorectal function.  The intrinsic 
pathway within the ENS is primarily responsible for gastrointestinal motility and blood flow 
and secretion in the small intestine and colon. Motor neurons and interneurons (blue circles) 
and sensory neurons (purple circles) control local reflexes. Intestinofugal neurons (red circles) 
project from the gastrointestinal tract to the CNS (yellow circles in spinal cord). Sympathetic 
prevertebral ganglia (green circles) work closely with the ENS by receiving inputs from the 
CNS and ENS. Sensory information projects to both the ENS via intrinsic primary afferent 
neurons (purple lines) and the CNS via extrinsic primary afferent neurons (also purple lines). 
Abbreviations: CNS, central nervous system; ENS, enteric nervous system. Adapted from 
(Furness, 2012).  
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2.5.2.2.2 Gastrointestinal function in Primary CAF 
Gastrointestinal (GI) symptoms can sometimes be prominent in PD, MSA and PAF 
patients. Some GI symptoms, in particular constipation, may predate the onset of typical 
motor symptoms in patients with PD. These features are in line with the pathological studies 
reporting the involvement of the enteric nervous system in PD (Wakabayashi & Takahashi, 
1997a; Braak et al., 2006a; Braak et al., 2006b), as well as the dorsal motor nucleus of the 
vagus (Halliday et al., 1990b; Gai et al., 1995), which are vital for maintaining appropriate GI 
function.   
A variety of GI features have been reported in PD, ranging from sialorrhea, 
dysphagia, delayed gastric emptying, small intestine motility dysfunction, colonic dysmotility 
and anorectal dysfunction. Previous studies showed that there was no increase of saliva in 
PD. In fact, saliva production is actually decreased and sialorrhea could be explained by the 
reduction of and inefficient swallowing in PD (Bagheri et al., 1999; Proulx et al., 2005).  
Oropharyngeal dysphagia is not uncommon among PD patients but unlike MSA it is usually 
asymptomatic and present in advanced stages. These findings came from both survey and 
objective studies. The results from large survey studies showed that the proportion of PD 
patients who reported difficulty of swallowing was between 30-82% (Kurihara et al., 1993; 
Leopold & Kagel, 1996; Clarke et al., 1998). Previous studies confirmed that at least more 
than 63% of PD patients show some abnormality in the modified barium swallow test (Fuh et 
al., 1997; Leopold & Kagel, 1997). Dysphagia was found in both oral and pharyngeal phases 
in PD patients even in asymptomatic patients (Robbins et al., 1986; Bushmann et al., 1989; 
Stroudley & Walsh, 1991; Nagaya et al., 1998). Esophageal dysphagia is also prevalent in 
patients with PD. This was demonstrated by abnormalities in studies using videofluoroscopy 
(Eadie & Tyrer, 1965; Gibberd et al., 1974), which were consistent with manometric 
esophageal studies (Bassotti et al., 1998; Castell et al., 2001). Dysphagia variably 
responded to dopaminergic treatment in PD patients, which indicates that dopaminergic cell 
loss might play a part in this symptom but is not entirely responsible for this problem (Hunter 
et al., 1997).  
Delayed gastric emptying has often been reported in PD patients. These patients 
may present with nausea, early satiety and abdominal distension. Impaired gastric motility 
was found to be longer even in untreated PD cases compared to controls (Hardoff et al., 
2001). A recent study reported different patterns of electrogastrography (EGG) between PD, 
multiple system atrophy and controls. This study found that PD patients had irregular gastric 
slow waves which suggested abnormalities of gastric pacemaker cells (Interstitial cells of 
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Cajal), whereas regular slow waves with low variability were found in MSA which may be 
explained by parasympathetic dysfunction. Small intestine dysmotility can be present in PD. 
This was confirmed by abnormal small intestine motor patterns in manometry (Bozeman et 
al., 1990). In colonic dysmotility, constipation is the most frequent lower GI symptom 
(Sakakibara et al., 2008) and has widely been reported ranging from 20-79% in PD (Siddiqui 
et al., 2002; Jost & Eckardt, 2003). Recent studies proposed that it resulted from delayed 
transport of the bowel with or without abnormal anorectal evacuation (Sakakibara et al., 
2008). A epidemiological study has also shown that there is approximately a 4 fold higher 
risk of PD in male participants who have bowel movements less than once a day compared 
to those with two or more times a day (Abbott et al., 2001). Therefore, constipation was 
suggested to be one of the potential markers for diagnosing PD before patients develop 
motor signs. With regards to this, colon transit time was also found to be longer in PD 
patients compared with age-matched controls (Sakakibara et al., 2003). Delayed colonic 
transit time was thought to be due to the degeneration of parasympathetic nuclei. It was 
unclear whether colon transit time correlated with the severity of disease but the severe 
constipation was found to be associated with the disease duration and severity of PD (Krogh 
et al., 2008). A number of colon abnormalities, including megacolon, intestinal pseudo 
obstruction and colonic obstruction have often been reported in PD (Kupsky et al., 1987; 
Shimada et al., 2006). Difficulty and incomplete evacuation are also common in PD(Edwards 
et al., 1991). Incoordination of external and internal anal sphincter contractions was 
considered to be the contributing factor of this symptom (Stocchi et al., 2000). Anorectal 
manometric abnormalities, including lower basal sphincter pressure, abnormal phasic 
contractions during voluntary contractions were observed in previous studies (Ashraf et al., 
1995; Normand et al., 1996; Stocchi et al., 2000). Pelvic floor dyssynergia and the lack of 
puborectalis relaxation might contribute to constipation (Mathers et al., 1988; Mathers et al., 
1989).  
A wide range of gastrointestinal (GI) symptoms are frequently reported in patients 
with MSA. These include, swallowing dysfunction, gastric dysfunction and anorectal 
dysfunction. Dysphagia is a common feature in MSA patients. It was a significant feature for 
differentiating atypical parkinsonian syndromes from PD if symptoms developed within 1 
year after the disease onset. The latency of dysphagia and dysarthria were correlated with 
shorter survival rate (Muller et al., 2001). Choking and coughing, particularly with liquid 
intake, were commonly reported in MSA (Mathias, 1996). Videofluoroscopy and manometry 
are valuable tools for investigating dysphagia in MSA. Swallowing dysfunction in MSA is 
frequently due to abnormalities in the oropharyngeal phase with a delay in bolus transport 
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from the oral cavity to the pharynx which is consistent with PD (Higo et al., 2003). 
Swallowing pressures were found to be lower compared to controls. Interestingly, a history 
of aspiration pneumonia was increased with the severity of disease (Higo et al., 2003) but 
not the duration of disease (Higo et al., 2005) and up to one-third of patients with MSA had 
confirmed aspiration by Videofluoroscopy even in patients who never reported swallowing 
problems (Smith, 1992). Gastrointestinal symptoms, such as abdominal pain, bloating and 
nausea/vomiting, are often reported in both PD and MSA which may sometimes be due to 
delayed gastric emptying. Comparing PD, MSA and healthy age-matched controls, there 
was a significant decreased gastric emptying time in MSA and PD compared to controls but 
there was no difference between these two disorders (Thomaides et al., 2005). Constipation 
is a well-known feature in MSA and may occur even during the early stages of disease 
(Mathias, 1996). Approximately one third of MSA patients reported the symptom of 
constipation in the EMSA-SG (The European MSA Study Group) registry (Stefanova et al., 
2009). This may be explained by the prolonged colonic transit time in line with the reduction 
of phasic rectal contraction and abdominal strain in patients with MSA (Sakakibara et al., 
2004a). The involvement of Onuf’s nucleus results in abnormalities of the anal sphincter 
EMG, which are in parallel with those obtained by urethral sphincter EMG (Yamamoto et al., 
2005). 
There are a number of previous studies that have reported gastrointestinal 
abnormalities in patients with PD. These investigations are more likely to be relatively 
invasive and require special gastrointestinal motility laboratory tests.  Electrogastrography 
(EGG) is an ambulatory technique that has been used for recording gastric myoelectrical 
activity (GMA) using 5-lead cutaneous electrodes placed on the abdomen. GMA was thought 
to originate from the Interstitial cells of Cajal (ICC), located on the major curvature of the 
stomach. ICC are considered as gastric pacemaker cells because they generate rhythmic 
depolarization with the same frequency as slow waves of gastric myoelectrical activity 
(Camborova et al., 2003). The frequency of gastric myoelectrical activity slow waves is 
approximately 3 cycles per minute in healthy subjects (Chang, 2005) and can be easily 
detected by cutaneous EGG. A number of studies have used EGG in various gastric 
disorders, for instance diabetic gastropathy (Koch, 2001), functional dyspepsia (van der 
Voort et al., 2003) and recently in Parkinson’s disease and Multiple system atrophy 
(Sakakibara et al., 2009). Gastric electrical dysrhythmia was detected in patients with PD (Lu 
et al., 2004) but not in MSA (Suzuki et al., 2005). Although no pathological study of the 
involvement of ICC has been previously reported, there was evidence of alpha-synuclein 
deposition in Auerbach’s and Meissner’s plexuses, which are closely linked to the ICC, in 
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patients with PD (Braak et al., 2006b). These abnormal gastric slow waves might reflect 
gastrointestinal involvement which is considered as a potential early marker of the pre-motor 
stage of PD and consistent with the neuropathological studies by Braak et al (Braak et al., 
2003).  Gastrointestinal symptoms, such as abdominal bloating, nausea/vomiting, are also 
common in patients with PAF. It is clear that PAF and PD share a number of characteristics, 
such as autonomic dysfunction, hyposmia, reduced cardiac MIBG reuptake and a presence 
of Lewy bodies, both in skin and the central nervous system (Hirayama et al., 1995; Ikemura 
et al., 2008; Silveira-Moriyama et al., 2009b; Shishido et al., 2010). However, EGG has not 
been used to investigate GI function in patients with PAF, thus it is unknown if PAF patients 
have gastric electrical dysrhythmia similar to PD patients. Similarly, MSA represents a pre-
ganglionic autonomic disorder whilst PAF has mostly post-ganglionic autonomic pathology 
(Hague et al., 1997). Comparing between these disorders using EGG would thus be an ideal 
model to evaluate autonomic disorders with different pathological lesions that present with 
similar clinical characteristics. 
 
2.5.3 Quality of life in patients with Primary CAF 
 Quality of life (QOL) is recognised as one of the most important health outcomes in 
clinical research. As the purpose of QOL assessment is to measure a patient’s perceptions 
of the effects of their illness on their life, the instruments (e.g. QOL questionnaires) are 
usually scored by patients, rather than clinicians, in order to more closely reflect the actual 
impact of the disease towards a patient’s daily life. This may or may not correlate with 
objective measures of the patient’s health status. There are different types of QOL 
questionnaires but they can broadly be divided into 2 types: generic and disease-specific 
QOL questionnaires. Examples of generic QOL questionnaires are the 36-item Short Form 
Health Survey (SF-36) and the EuroQoL (EQ-5D). The benefit of generic questionnaires is 
an ability to measure QOL and compare various medical conditions at the same time. On the 
other hand, this type of questionnaire has the limitation of an absence of disease-specific 
questions; this could potentially lead to an inability to detect an impact from general features 
of a generic questionnaire and/or the lack of specific features which are important for specific 
conditions. This can be overcome by using disease-specific QOL questionnaires, which 
contain questions relevant to the disease of the patient. For example, the disease specific 
QOL questionnaire for PD, contains items focussing on the impact of parkinsonian features 
on daily life while the QOL questionnaire for Rheumatoid Arthritis will more likely cover the 
impact of pain on the patient’s function. The limitation of disease-specific QOL 
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questionnaires is that data cannot be readily compared between different, albeit overlapping, 
disorders, e.g., PD vs. PAF. This section will cover only brief details on selected QOL 
questionnaires, which are included in this thesis, namely the SF-36, PDQ-39 and MSA-QoL. 
PDQ-39 
 The PDQ-39, a disease- specific QOL questionnaire for PD, covers 8 domains which 
impact a PD patient’s quality of life: mobility, activities of daily living (ADL), emotional 
wellbeing, stigma, social support, cognitive, communication and bodily discomfort, in 39 
questions. It also has a summary index score (PDQ-SI), which could be used to quantify an 
overall QOL score in PD (Peto et al., 1995). Several factors, such as motor symptoms 
(Gomez-Esteban et al., 2007), PD subtype (Hariz & Forsgren, 2011) and most importantly 
non-motor symptoms, have been reported to influence a PD patient’s quality of life using the 
PDQ-39 as an outcome measure. These non-motor symptoms, have ranged from 
depression (Schrag et al., 2000b), cognitive impairment (Marras et al., 2008), fatigue 
(Havlikova et al., 2008), sleep disorders (Forsaa et al., 2008) and pain (Rahman et al., 2008; 
Santos-Garcia & de la Fuente-Fernandez, 2013). These non-motor symptoms seem likely to 
have a greater impact on quality of life than motor symptoms (Martinez-Martin et al., 2011). 
MSA-QoL 
 A previous study using the SF-36 or EQ-5D consistently showed a significantly 
impaired QOL in patients with MSA compared to PD (Schrag et al., 2006).  As both generic 
questionnaires do not contain specific items for autonomic symptoms, which are very 
common among patients with MSA, the MSA-QOL has recently been developed for dealing 
with this issue (Schrag et al., 2007). It consists of 40-item questions divided into 3 domains: 
motor, non-motor and emotional/social domains. A recent study showed that MSA-QoL was 
severely impaired in patients with MSA and significantly worse after approximately 1-year of 
follow-up (Meissner et al., 2012).  
SF-36 
 The SF-36 is a self-reported generic QOL questionnaire which consists of 36 
items that define 8 category scales: physical functioning (PF), role limitation caused by 
physical problems (RP), bodily pain (BP), general health (GH), vitality (VIT), social 
functioning (SF), role limitation caused by emotional problems (RE) and mental health 
(MH). Scales range from 0 to 100 and a higher score indicates a better quality of life. The 
8 category scales are often aggregated in 2 summary scales: the physical component 
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summary scale (PCS) and the mental component summary scale (MCS) (Manocchia et 
al., 1998). It was designed to be used in a wide range of health conditions including PD, 
Multiple sclerosis (Riazi et al., 2003) and other medical conditions, such as chronic fatigue 
syndrome (Komaroff et al., 1996). The SF-36 has recently been challenged by disease-
specific questionnaires in some conditions, such as PD and MSA, due to its lack of 
specific questions for those conditions, such as cognitive dysfunction in PD and 
autonomic features in MSA. Nevertheless, the SF-36 still provides a generic measure and 
can be used to compare the quality of life across different disorders. 
Despite an increasing trend of QOL research, little work has been done on this 
measure in patients with chronic autonomic failure. There are a number of studies that have 
examined quality of life in patients with PD but only a few have assessed quality of life in 
patients with MSA and PAF. Validated questionnaires, such as the PDQ-39 and the PD-QoL, 
are widely used in PD research while little is known about quality of life in MSA and PAF. 
The MSA-QoL has been recently introduced and validated but this questionnaire has never 
been widely used in MSA research and there is no previous report on quality of life in 
patients with PAF. Some non-motor aspects of parkinsonian and autonomic disorders 
related to overall features of life, such as capacity for daily life activities, quality of life and 
depression have also been investigated in PD and MSA patients but have not been directly 
compared between these disorders or related to other indices of autonomic function.  
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Chapter 3 
3. General Methods 
3.1 Participant recruitment  
All participants and patients for prospective studies were recruited from the 
Autonomic and Movement Disorder clinics at the National Hospital for Neurology and 
Neurosurgery (NHNN) and the Autonomic and Neurovascular Medicine Unit (St Mary’s 
Hospital) in the UK. For retrospective studies, all records of patients referred to the 
Autonomic Units between 2001 and 2011 for testing with a diagnosis or clinical information 
containing the key words “parkinsonism”, “parkinson’s disease”, “pure autonomic failure”, 
“autonomic failure”, “multiple system atrophy”, “atypical Parkinson’s Disease” and 
“Parkinson-plus syndrome” were identified. All patients’ diagnoses had also been confirmed 
by autonomic and movement disorders specialists.  
 
3.2. Experimental group design 
Patients were divided into 3 groups: 
 
1. Parkinson’s disease  
Idiopathic PD patients were diagnosed by neurologists using the UK Parkinson’s 
Disease Society Brain Bank diagnostic criteria [UK-PDSBB] with an age at onset of more 
than 40 years and the presence of at least two of the three cardinal features of the disease 
(resting tremor, bradycardia or rigidity). PD severity ranged from mild to severe (Hoehn & 
Yahr stage I-IV). PD with autonomic failure (PD+AF) was defined as idiopathic PD with 
orthostatic hypotension (Orthostatic Systolic/Diastolic blood pressure falls > 20/10 mmHg). 
For all PD+AF patients, records were checked to ensure that after autonomic failure had 
been documented rapid clinical deterioration or emerging additional features of MSA did not 
occur.  
 
2. Multiple System Atrophy  
MSA patients were diagnosed using Gilman’s criteria (Gilman et al., 1999; Gilman et al., 
2008) for probable MSA. Only probable MSA patients were included in studies. These 
patients were clinically defined criteria of autonomic failure/urinary dysfunction with 
additional features of either poor response to levodopa medication or cerebellar dysfunction, 
defined as: 
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A: Autonomic and urinary features. 
Orthostatic fall in blood pressure (by 20 mmHg systolic or 10 mmHg diastolic) or urinary 
continence (persistent, voluntary partial or total bladder emptying, accompanied by erectile 
dysfunction in men) or both 
 
B: Parkinsonian features. 
Bradykinesia (slowness of voluntary movement with progressive reduction in speed and 
amplitude during repetitive actions) plus at least one of the following items: 
 
1. Rigidity 
2. Postural instability (not caused by primary visual, vestibular, cerebellar or proprioceptive 
dysfunction) 
3. Tremor (postural, resting or both) 
 
C: Cerebellar dysfunction. 
Gait ataxia (wide based stance with steps of irregular length and direction) plus at least one 
of the following items: 
1. Ataxic dysarthria 
2. Limb ataxia 
3. Sustained gaze-evoked nystagmus 
 
3. Pure Autonomic Failure  
PAF was diagnosed using the 1996 international consensus statement which consists of 
gradually progressive autonomic dysfunction with prominent orthostatic hypotension in the 
absence of cognitive, motor or sensory impairment (Neurology, 1996). 
 
Healthy Participants 
Healthy individuals were recruited if they did not fulfill any of the diagnostic criteria for PD, 
MSA and PAF and any other known cardiac, cardiovascular, neurological and metabolic 
disease. 
 
Exclusion criteria 
Participants were excluded if there was a chronic illnesses or the presence of conditions that 
potentially involved the autonomic nervous system. These included, congestive heart failure, 
recent (<6 months) myocardial infarction, severe anemia, diabetes mellitus, alcoholism, 
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malignant neoplasms, amyloidosis, hypothyroidism and history of the following diseases or 
treatments; sympathectomy, cerebrovascular disease and neurotoxins or neuroactive drug 
exposure. Individuals with a history of dementia or cognitive impairment and Schizophrenia, 
a history of severe head trauma leading to loss of consciousness or an active upper 
respiratory tract infection within 2 weeks prior to testing were also excluded. Patients were 
excluded if taking vasopressor, anti-hypertensive or other medications that could interfere 
with autonomic function. 
 
3.3. Study preparation 
 
All studies were performed in autonomic laboratories either at the National Hospital 
Neurology and Neurosurgery, Queen Square or at St Mary’s Hospital, London. Similar 
autonomic function assessment protocols were used at both Units with controlled ambient 
temperatures.  
 
Before each laboratory visit participants were asked to refrain from: 
1. heavy exercise for 24 hours  
2. alcohol ingestion for 12 hours  
3. caffeine intake for at least 12 hours  
4. eating for 1 hour  
5. Depending on the patient’s condition and medication, stop taking medication the 
night before each visit  
 
If participants were involved in any other study at the time that would affect the autonomic 
nervous system they were excluded. 
 
3.4. Cardiovascular autonomic function tests 
 
A battery of cardiovascular autonomic function tests were performed in the supine position 
unless otherwise stated and included: 
 
3.4.1 Head-up Tilt test  
Participants rested in the supine position on a horizontal tilt table, with their feet flat against 
the foot rest. At the end of 10-minute rest, straps were placed around the lower limbs and 
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torso and the tilt table was adjusted to 60° head-up (Figure 3.1). Head-up tilting was 
continued for 10 minutes or until participants developed symptoms of imminent syncope or 
the patient was no longer to tolerate the tilt. The participant was then returned to the 
horizontal position. Blood pressure (BP) and heart rate (HR) were recorded every 3 minutes 
during supine rest and during head-up tilting.  
 
 
Figure 3.1. Head-up tilt table and a participant performing a 10-minute HUT (left) and 
examples of a beat-to-beat blood pressure recording (Finometer) and a computer with 
the data acquisition software (Right). 
 
3.4.2 Noradrenaline plasma concentrations 
Blood samples were collected during supine and head-up tilt tests to assess catecholamine 
(noradrenaline) concentrations as a biochemical marker of sympathetic neural activity. The 
plasma level of noradrenaline (NA) was measured using high-performance liquid 
chromatography (Mathias et al., 1989).  
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3.4.3 Pressor tests 
 
Handgrip isometric exercise Test  
Participants were asked to perform a maximum voluntary handgrip contraction on 3-4 
occasions in order to establish a maximum value. Participants then rested in the supine 
position and were then asked to conduct a handgrip contraction at 33% of their maximum 
contraction for 3 minutes (Figure 3.2). BP and HR were measured at baseline and during the 
last 30 seconds of isometric exercise.   
 
Cold pressor Test 
An ice pack was applied to their hand/wrist for 90 seconds.  BP and HR were recorded prior 
to cold pack application and during the last 30 seconds of the cold stimulus (Figure 3.2). The 
ice pack was applied to the forearm of individuals with Raynaud's phenomenon.   
 
Figure 3.2. Manometer and a participant performing a handgrip contraction (left) and a 
participant with an ice pack on right hand and forearm during a cold pressor test 
(Right). 
 
Mental Arithmetic Test 
Participants were asked to serially subtract 7 or 17 from a suitable starting number (e.g. 400 
or 1000), speaking the answers aloud, for a period of 2 minutes.  BP and HR were recorded 
prior to and during the last 30 seconds of mental arithmetic. 
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3.4.4 Heart rate response to Deep breathing (HRDB) 
Participants were asked to breath at a rate of 6 breaths per minute for one minute.  
Participants were coached on how long each breath should take (Figure 3.3). The change in 
heart rate between inspiration and expiration was calculated. The heart rate response to 
deep breathing (or respiratory sinus arrhythmia; RSA) was derived from the average of the 
differences between the minimum and maximum heart rates of the 6 breaths.  
 
Figure 3.3. BP from Finometer (in yellow) and the average heart rate (in red). In the 
normal subject, heart rate fluctuates during deep breathing. 
 
3.4.5 Valsalva Manoeuvre 
Participants performed a forced expiration for 15 seconds against a fixed expiratory 
pressure of 40 mmHg for 10-15 seconds. A 2 ml syringe was used as a mouthpiece and 
was connected to a manometer (Figure 3.4). Participants inspired deeply, placed the tube 
in their mouth and sealed their lips before performing the expiration. The beat-to-beat BP 
responses during Valsalva manoeuvre were recorded (Figure 3.5). Three repetitions were 
performed with adequate time for hemodynamic recovery in between. 
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Figure 3.4. Manometer (left) and a participant blowing into the syringe connected to 
the Manometer for 15 seconds during the Valsalva Manoeuvre (Right). 
 
 
Figure 3.5. Blood pressure response during Valsalva Manoeuvre in a normal subject 
(upper panel) and a patient with autonomic failure (lower panel). Adapted from 
(Novak, 2011). 
 
3.4.6 Quantitative cardiovascular autonomic function indices 
Baroreflex sensitivity (BRS) and the blood pressure recovery time (BPRT) were 
derived from the Valsalva manoeuvre using on-line data acquisition software (Chart version 
7.1, ADInstruments, Oxford, UK). The BP response to the VM occurs in different phases 
including phase 2 early (phase II_E), phase 2 late (phase II_L) and phase 4 (phase IV) were 
determined as previously described (Vogel et al., 2005). BPRT was calculated as the time 
Blood pressure profile during a Valsalva 
Manoeuvre in a normal subject. The BP 
response can be divided into 4 phases; 
Phase 1, Phase 2 early and late, Phase 3 
and Phase 4  
Blood pressure profile during the 
Valsalva Manoeuvre in a patient with 
autonomic failure. Note the absence of 
BP recovery during phase 2 late and a 
Prolonged blood pressure recovery time 
(BPRT) in phase 4 
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interval starting from the lowest BP in phase 3 to the time with BP back to baseline (Vogel et 
al., 2005) (Figure 3.6). BRS was calculated from the slope of the linear regression between 
the length of the RR interval and preceding SBP during phase 2 of the VM (Goldstein et al., 
1982). The Valsalva ratio (VR) was measured by the maximum HR generated by the VM 
divided by the lowest HR occurring within 30 seconds of the peak heart rate.  
 
Figure 3.6. Representative Valsalva manoeuvre from a healthy individual. The amplitude of 
phase I is measured from baseline to peak of phase I. Phase II Early is measured from 
baseline to the trough of phase II. Phase II Late is determined from the end of phase II 
Early to the beginning of phase III. Phase III is measured from the end of phase II Late to 
the trough of phase III. Phase IV was determined as its height above baseline. 
 
3.4.7 Liquid Meal test 
After a baseline period of 15 min supine rest, participants consumed a 300 ml standard 
balanced liquid meal (66 g carbohydrate, 22 g fat and 18 g protein made up to 300 ml with 
full fat milk) through a straw whilst lying supine and then rested for ~45 min. A 10 min 60° 
HUT was performed before and 45 min after the liquid meal protocol. Blood pressure and 
heart rate were measured every 5 min before and after the meal.  
 
3.4.8 Instrumentation 
For all of the above experiments arterial blood pressure and heart rate were intermittently 
assessed using upper arm sphygmomanometry (GE Medical Systems, Tampa, FL, USA). 
Beat-to-beat heart rate and arterial blood pressure were assessed continuously using 5-lead 
chest electrode electrocardiography and digital photoplethysmography (Portapres® or 
Finometer®, TNO-TPD, Biomedical Instrumentation). The Finometer is a non-invasive 
technique to measure finger arterial blood pressure, using an inflatable finger cuff with a built 
in photoelectric plethysmograph. Each cuff has an infrared sensor running parallel to the 
digital artery and a pressure transducer, controlled by a valve, allowing rapid inflation and 
deflation of the cuff. The volume of the cuff is rapidly adjusted, under feedback control, to 
69 
 
keep the infrared signal amplitude constant. This in turn keeps the finger volume constant 
throughout the arterial pulse cycle. The signal output is displayed on screen, showing a real 
time continuous waveform, which is usually indistinguishable from that of a peripheral 
arterial, e.g., brachial, waveform. The Finometer technique has been validated by 
comparison with intra-arterial blood pressure during a range of manoeuvres, including 
orthostasis, and accurately reflects intra-brachial or radial blood pressure (Langewouters et 
al., 1998; Hirschl et al., 1999; van der Does et al., 2013). It is also reliable for tracking 
changes in arterial blood pressure (Langewouters et al., 1998; van der Does et al., 2013). 
Participants are asked to keep the finger movements to a minimum during testing and a 
height correction unit is applied to the device and/or the hand is positioned at heart level to 
avoid unwanted hydrostatic effects of any changes in the arm. Blood pressure and heart rate 
were recorded continuously online (Powerlab systems, ADInstruments, Australia). 
 
3.5 24 hour-Ambulatory BP and heart rate monitoring (24 hr-ABPM) 
Participants that conducted a 24 hr-ABPM with a custom autonomic protocol diary (see 
Appendix I) wore a standard upper arm blood pressure cuff (90207 Ambulatory Blood 
Pressure monitors, Spacelabs Healthcare, Hertford, U.K, Figure 3.7). 
 
Figure 3.7. 24 hr-ABPM (left) and a participant with the 24 hr-ABPM during monitoring 
(Right). 
 
3.6 Smell identification tests 
Olfactory function was assessed using the Sniffin’ Sticks (SS-16) Smell identification Test. 
Participants were asked to smell 16 different odored pens for up to 30 s (Figure 3.8) and 
then select 1 of 4 options that best describes the presented odour. Function was assessed 
as a score out of 16 (Hummel et al., 1997). 
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Figure 3.8. Sniffin’ Sticks (SS-16) smell test. 
 
3.7 Questionnaires  
Participants completed some or all of the following questionnaires:  
Motor Symptoms 
Unified Multiple System Atrophy Rating Scale (UMSARS) and Unified Parkinson’s Disease 
Rating Scale (UPDRS) are validated disease-specific scales that represent the diverse signs 
and symptoms of MSA and PD, respectively, such as daily living activities and mobility. The 
scales comprise the following components: Part I, historical, 12 items; Part II, motor 
examination, 14 items; Part III, autonomic examination; and Part IV, global disability scale 
(Wenning et al., 2004).  
Hoehn and Yahr Staging (HY) was used to rate the degree of functional ability in patients. 
The same investigator conducted these assessments in all patients. 
 
Non-motor Symptoms 
The Mini-Mental State Examination (MMSE) rating scale was used to rate all participants’ 
cognitive function. The MMSE score ranges from 0-30, with a lower score indicating greater 
impairment of cognitive function. Given that cognitive impairment is a confounder for the 
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validity of quality of life questionnaires, all patients with an MMSE score of less than 24 were 
not included in studies. 
 
The Hamilton Depression Rating Scale (HAM-D) was used to assess symptoms of 
depression and its severity in both patient and control groups. The scale consists of 17-item 
questions. The score ranges from 0-53 and the higher score correlates with more severe 
depression. A score between 0-7 is generally accepted as a normal range but a score of 20 
or higher suggests depression (Hamilton, 1960). 
 
The Schwab and England Activities of Daily Living Scale (SE) was used by the participants to 
rate how much their condition affects their functional capability. The SE score ranges from 
100 (Completely independent) to 0 (bedridden). 
 
Quality of life  
Patient population specific scales, as well as a generic scale in PAF, were used to assess 
Quality of Life. 
 
The 39 item Parkinson's Disease Questionnaire (PDQ-39) was used in PD patients. It was 
completed by patients and it covers 8 domains which impact a PD patient’s quality of life: 
mobility, activities of daily living (ADL), emotional wellbeing, stigma, social support, cognitive, 
communication and bodily discomfort in 39 questions. It has also a summary index score 
(PDQ-SI), which can be used to quantify an overall QOL score in PD. The higher score 
represents poorer quality of life. 
 
The MSA Health-Related Quality of Life Scale (MSA-QoL) was used in MSA patients. It was 
completed by patients and consists of 40-item questions and is divided into 3 domains: 
motor, non-motor and emotional/social domains. A higher score indicates poorer quality of 
life. 
 
The 36 item Short Form Health Survey (SF-36) was used in PAF patients due to the lack of a 
disease-specific QOL questionnaire for PAF. The SF-36 is a self-reported questionnaire that 
has been used to assess quality of life in various medical populations, and consists of 36 
items that define 8 category scales: physical functioning (PF), role limitation caused by 
physical problems (RP), bodily pain (BP), general health (GH), vitality (VIT), social 
functioning (SF), role limitation caused by emotional problems (RE), and mental health (MH). 
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The 8 category scales are often aggregated in 2 summary scales: the physical component 
summary scale (PCS) and the mental component summary scale (MCS) (Manocchia et al., 
1998). Scales range from 0 to 100 and a higher score indicates better quality of life. 
Healthy control participants only completed the Short Form Health Survey (SF-36), the Mini-
Mental State Examination (MMSE) and the Hamilton Depression Rating Scale (HAM-D). 
 
All questionnaires include in the studies are listed in the Appendix. 
 
3.8 Electrogastrography (EGG) 
For the liquid meal test, a four-channel cutaneous EGG recorder (Nipro EG; Nipro, Japan), 
which consists of four surface recording electrodes and one reference electrode, was used 
to record gastric myoelectrical activity (GMA). All electrodes were placed on abdominal skin 
as shown in Figure 3.9.  
 
 
Figure 3.9. EGG recording device with 4 surface electrodes (Red, Yellow, Brown and 
Blue) with one reference electrode (Green). Images courtesy of Dr Masato Asahina, 
Chiba University, Japan. 
 
GMA was recorded during the 15 minutes before and 45 minutes after the ingestion 
of the liquid meal and data were analysed using EGG software (EGS2 Ver 3.1 software, EG, 
Ram Co., Japan). Movement artefacts were excluded from the raw EGG data before 
obtaining EGG power spectra using Fast Fourier Transformation (FFT). The main outcome 
measurements were the dominant frequency (DF) of the GMA slow waves, which was 
defined as the frequency at which the overall power spectrum showed peak power in normal 
frequency ranges (NFR) and the instability coefficient of DF (ICDF), which is a marker of the 
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variability of the DF and is derived from the proportion of the standard deviation and the 
mean of the DF. 
 
3.9 Statistical Analyses 
Data are presented as mean (± 1 SD). Normally distributed data between patient 
groups were compared using ANOVA (3 or more groups) or by t-tests (2 groups). Non-
parametric tests, including Kruskal-Wallis and Mann-Whitney U tests, were used for non-
normally distributed data, where appropriate. Chi-square analyses were used for analysis of 
categorical variables. Repeated measures ANOVA was used for comparisons of data from 
more than two different time points. Receiver operating characteristic (ROC) analyses were 
used to determine the sensitivity and specificity for detecting and distinguishing the presence 
of disorders. Multiple logistic regression analysis was used to determine what factors (binary 
variables) were associated with outcome variables. The relationships between 
cardiovascular autonomic function indices and other factors, such as disease duration and 
disease severity (continuous variables), were assessed by correlation analysis (Pearson’s 
correlation for normally distributed data and Spearman’s correlation for non-normally 
distributed data) or multiple linear regression analysis. Statistical analyses were carried out 
using STATA 11.0 (STATA Corporation, College station, Texas, USA). All tests were 2-sided 
and a p value of <0.05 was considered significant. 
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Chapter 4 
4.1 Evaluation of cardiovascular autonomic function in chronic autonomic failure 
4.1.1 Quantitative cardiovascular autonomic function in patients with chronic 
autonomic failure (PD+AF, MSA and PAF) 
4.1.1.1 Introduction 
The overlapping features of cardiovascular autonomic dysfunction, particularly OH, in 
parkinsonian syndromes and MSA sometimes results in difficulties in differentiating the 
diagnosis between MSA and PD and suggests that OH may not be a suitable single 
autonomic feature for distinguishing PD and MSA (Lipp et al., 2009). Furthermore, some 
MSA patients present with an isolated feature at the onset, such as orthostatic hypotension, 
and consequently, autonomic dysfunction can predate the diagnosis of MSA for a while, or 
patients can sometimes be misdiagnosed with idiopathic PD before the development of other 
hallmark MSA features.  It is a critical and quite common question in clinical practice whether 
a patient presenting with parkinsonism and autonomic dysfunction has MSA or PD because 
of their vast difference in terms of disease prognosis, and as a result, is a vital differentiation 
to make judiciously with regards to instigating appropriate treatment strategies. 
Cardiac 123I-metaiodobenzylguanidine (MIBG) imaging has been proposed to be 
helpful for distinguishing between MSA and PD. Cardiac MIBG uptake was reported to be 
markedly reduced in Parkinson’s disease (Braune, 2001) which was consistent with a 
reduction of tyrosine hydroxylase immunoreactivity in myocardial sympathetic nerves (Amino 
et al., 2005). In contrast, cardiac uptake was mostly normal in MSA (Spiegel et al., 2005) 
Nevertheless, the reliability of this test has been reported as inconsistent in several studies 
and results have often showed no differences between these disorders (Orimo et al., 1999; 
Druschky et al., 2000; Kimpinski et al., 2012). In addition, the MIBG scan is a relatively 
invasive, costly and time-consuming technique. 
Cardiovascular autonomic screening tests are typically used to confirm the diagnosis 
of autonomic failure, including the use of head-up tilting for the assessment of OH. In order 
to overcome the limitation of the use of OH as index for differentiating autonomic disorders 
other indices of quantitative cardiovascular autonomic function, such as, baroreflex 
sensitivity (BRS) and blood pressure recovery time (BPRT) to perturbations in blood 
pressure have recently been developed and been proposed to be useful in evaluating 
autonomic function in chronic autonomic failure disorders (Vogel et al., 2005; Schrezenmaier 
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et al., 2007). BRS was previously reported to be abnormal in a few studies in PD+OH when 
compared with PD without OH (PD-OH) (Barbic et al., 2007) and MSA compared with 
MSA+OH (Goldstein et al., 2003b). More recently, BRS calculated from trigonometric 
spectral analysis was reported to be significantly lower in patients with MSA compared to PD 
(Friedrich et al., 2008). Beat-to-beat blood pressure and heart rate responses to the Valsalva 
manoeuvre (VM) are also useful for evaluating sympathetic and parasympathetic function, 
as well as baroreflex sensitivity (Vogel et al., 2005). The heart rate responses to deep 
breathing (sinus arrhythmia) can also be used to assess cardiac parasympathetic function 
and are frequently abnormal in patients with autonomic failure (Gurevich et al., 2004; 
Deguchi et al., 2006). Both BRS and BPRT have however never been specifically compared 
between MSA with autonomic failure and PD with autonomic failure. The relationship 
between these novel cardiovascular autonomic function indices and disease duration in MSA 
and PD+AF has also not been thoroughly examined either. The aim of this study was 
therefore to determine cardiovascular autonomic function in MSA and PD+AF using a 
standard orthostatic challenge test (Head-up Tilt test) and alternative indices of quantitative 
cardiovascular autonomic function, including baroreflex sensitivity (BRS), blood pressure 
recovery time (BPRT), Valsalva ratio (VR) and the heart rate responses to deep breathing 
(HRDB). 
 
4.1.1.2 Methods 
Subjects 
Patients with a confirmed diagnosis of Parkinson’s disease with autonomic failure 
(PD+AF), Probable Multiple System Atrophy (MSA) with orthostatic hypotension and Pure 
Autonomic Failure (PAF) and healthy controls were included (Chapter 3). All patients with 
MSA were confirmed to have autonomic failure in addition to other classical features such as 
severe urinary disturbances, sexual dysfunction, sudomotor dysfunction, sleep dysfunction 
(REM sleep behavioural disorders) and respiratory involvement (sigh or stridor). Patients 
were excluded if they were unable to perform the VM or had a flat top VM response. 
Clinical history  
History and relevant information of all patients and participants were retrospectively 
evaluated from medical records. These included age, gender, duration of disease (time from 
first symptom to date of testing), dopaminergic medications and presenting symptoms. 
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Presenting symptoms were divided into; cardiovascular autonomic symptoms (e.g. 
dizziness, lightheadness, visual disturbances, syncope and coat-hanger ache) (Mathias et 
al., 1999), bladder symptoms, parkinsonism and cerebellar symptoms.   
Cardiovascular autonomic screening tests (AFT) 
Cardiovascular autonomic function was assessed using Autonomic Unit protocols 
(Mathias et al., 2013a). This included all pressor tests, Valsalva manoeuvre (VM), deep 
breathing, Hyperventilation, 10-minute 60 degrees HUT as described in Chapter 3.  Beat-to-
beat blood pressure and heart rate were recorded continuously on-line using digital 
photoplethysmography and electrocardiography, respectively. These variables were also 
recorded intermittently using upper arm sphygmomanometry. Beat-to-beat blood pressure 
and heart rate data were used to analyse quantitative cardiovascular autonomic function 
indexes including BP responses to VM, blood pressure recovery time (BPRT), Valsalva ratio 
(VR) and HR responses to deep breathing (HRDB) off-line.   
Quantitative cardiovascular autonomic function indexes 
Phase 2 early (phase II_E), phase 2 late (phase II_L), phase 4 (phase IV), the 
Valsalva ratio (VR) and BPRT were determined from the VM as previously described (Vogel 
et al., 2005). BRS was calculated from the slope of the linear regression between the length 
of the RR interval and preceding SBP during phase 2 of the VM (Goldstein et al., 1982). The 
heart rate response during deep breathing (HRDB) was measured by the mean of the heart 
rate change (maximum-minimum) during 6 breath cycles. 
Statistical methods 
Data are presented as mean (± 1 SD) or median (inter-quartile range), where 
appropriate. Analysis of covariance (ANCOVA) was used for comparisons of 3 or more 
groups normally distributed data while the Kruskal-Wallis test was used if data were non-
normally distributed. If there was a significant difference, Mann-Whitney U tests were then 
used to compare between 2 groups for non-normally distributed data and unpaired t-tests for 
normally distributed data with Bonferroni corrections. Chi-square analyses were used for 
analysis of categorical variables. The relationships between quantitative autonomic 
measures and disease duration were assessed by regression analysis. Quantitative 
autonomic measures were set as the outcome variables while age, gender, disease duration 
and the use of dopaminergic medications were set as covariates. Statistical analyses were 
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carried out using STATA 11.0 (STATA Corporation, College station, Texas, USA). All tests 
were 2-sided and a p value of <0.05 was considered significant. 
 
4.1.1.3 Results 
74 patients (45 MSA, 18 PD+AF, 11 PAF) and 15 controls were included in the 
analyses (see Table 1). Patients with MSA were younger than the PD+AF patients (p<0.05). 
There was no difference in disease duration between disorders. Orthostatic symptoms were 
reported in 35 out of 45 (77.8%) MSA patients and in all PD+AF and PAF patients. Within 
the group of MSA patients, MSA-P was more common (26/45, 57.8%) compared to MSA-C. 
Age, disease duration and gender were not different between MSA sub-groups.  
 
Table 4.1. Patient demographic data  
Variable MSA PD+AF PAF Control 
Number 45 18 11 15 
% Male 56 67 91 47 
Age at testing               
Mean (SD), yrs 62 (8)* 70 (9)*
# 66 (7) 58 (8) 
Disease duration     
Median (range), yrs  5 (2-11) 5 (2-18) 6 (1-16) - 
% Dopaminergic 
treatment  47 89
# - - 
*p<0.05 vs. Control, #p<0.05 vs. MSA 
  
In PD+AF, 94% (17/18) had parkinsonian symptoms. In contrast, 40% (18/45) of 
MSA patients reported this as an initial symptom. Symptoms from cerebellar dysfunction 
were the second most common presenting symptom in MSA (29%, 13/45) followed by 
bladder symptoms (22%, 10/45) and orthostatic symptoms (9%, 4/45). OH presented in 
patients with MSA with a wide variation with respect to time ranging from 2-11 years after the 
onset of their first symptom. This figure was also similar in patients with PD+AF (2-18 years) 
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and PAF (1-16 years). Approximately 58% (26/45) of patients with MSA had OH within the 
first 5 years of reporting their first symptom. 
 
Table 4.2. Systolic and Diastolic blood pressure (SBP, DBP;mmHg) during supine and 
head-up tilt and orthostatic SBP changes in MSA, PD+AF, PAF and control groups.  
Variable MSA PD+AF PAF Control 
Supine SBP 135+21 134+24 134+21 124+18 
Supine DBP  81+12 74+13 80+10 66+9 
Tilt SBP 89+21* 91+24* 78+14* 128+16 
Tilt DBP 59+13* 58+18* 51+9* 74+9 
Orthostatic ∆SBP  -46+20* -44+18* -59+21*$ 4+11 
Values are mean+SD, * p<0.05 vs. Control $p<0.05 vs. PD+AF 
 
There was no difference in the group mean supine SBP among controls and each 
group of patients. The absolute SBP during tilt was significantly lower and the orthostatic 
SBP change was significantly greater in patients compared to controls (p<0.05). Systolic 
blood pressure during tilting in patients with MSA was not different when compared with 
PD+AF (p=0.39) and PAF patients (p=0.1). There was also no difference in the degree of 
orthostatic SBP change in MSA compared with PD+AF (p=0.61) and PAF (p=0.9). 
Orthostatic BP change was significantly larger in PAF compared to PD+AF (p=0.04) (Table 
4.2).  
The BP changes during phase 2 early and phase 2 late of the VM were significantly 
blunted in the patient groups when compared to healthy controls but there was no difference 
between disorders except in the BP change during Phase IV. The BP overshoot was 
significantly smaller in PAF compared with PD+AF (p=0.01) (Table 4.3).  
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Table 4.3. Systolic Blood pressure changes during the various phases of the Valsalva 
manoeuvre in MSA, PD+AF, PAF and control groups.  
Variable MSA PD+AF PAF Control 
Baseline SBP 136+29* 134+27* 131+29* 115+16 
∆SBP Phase II_E  57+29* 54+21* 47+18* 20+9 
∆SBP Phase II_L  2+4* 2+3* 3+4* 30+16 
∆SBP Phase IV  4+7* 8+7* 2+5*$ 45+16 
Values are mean+SD, SBP=Systolic BP, Phase II_E= Phase 2 early of VM,  Phase II_L= 
Phase 2 late of VM, Phase IV=Phase 4 of VM 
*p<0.05 vs. Control $p<0.05 vs. PD+AF 
 
Baroreflex sensitivity (BRS) was significantly lower in all patient groups compared to 
controls. Within the patient groups, BRS was significantly lower in MSA compared with 
PD+AF (p=0.024). PD+AF had a significantly higher BRS compared to patients with PAF 
(p=0.05). Blood pressure recovery time (BPRT) was significantly longer in all patient groups 
compared to controls but was significantly faster in patients with PD+AF patients relative to 
MSA (p<0.01) and PAF (p<0.01). After controlling for age, disease duration and gender, 
BRS remained significantly lower and BPRT was longer in patients with MSA compared to 
PD+AF (p=0.012 and p<0.01, respectively). BPRT in PAF was also significantly longer when 
compared with PD+AF after correcting for confounders. 
Table 4.4. Cardiovascular autonomic parameters during the Valsalva manoeuvre; 
Baroreflex sensitivity, Blood pressure recovery time (BPRT); in MSA, PD+AF, PAF and 
control groups.  
Variable MSA PD+AF PAF Control 
BRS, ms/mmHg 1.4+1.1* 2.1+1.2*# 1.6+2.3* 4.3+1.8 
BPRT, sec  26.6+16.3* 13.9+7.6*# 29.0+11.8*$ 0.8+0.5 
VR  1.2+0.1* 1.3+0.3* 1.2+0.2* 1.6+0.3 
HRDB (bpm) 6+5* 5+3* 4+2* 14+6 
Values are mean+SD, BRS= baroreflex sensitivity, BPRT=Blood pressure recovery time, 
VR=Valsalva Ratio,   HRDB = Heart rate response during Deep Breathing 
* p<0.05 vs. Control $p<0.05 vs. PD+AF #p<0.05 vs. MSA 
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HRDB in controls was significantly higher when compared with those in MSA, PD+AF 
and PAF (p<0.05) but there was no difference between patient groups (MSA vs. PD+AF, 
p=0.43 and PAF vs. PD+AF, p=0.27). Similarly, there was a significantly lower Valsalva 
Ratio (VR) in patients compared to controls (p<0.05) but no difference among patient groups 
(MSA vs. PD+AF, p=0.74 and PAF vs. PD+AF, p=0.7). There were no differences in age, 
disease duration, and orthostatic BP changes during HUT, BRS, BPRT, VR and HRDB 
between MSA-P and MSA-C sub-groups. 
Autonomic function parameters, including orthostatic SBP changes during HUT, 
BRS, VR and HRDB, were not correlated with disease duration in both MSA and PD+AF 
patients after adjusting for age and gender but there was a trend of association (P = 0.07) 
between BPRT and disease duration only in patients with PD+AF (see Table 4.5).  
 Table 4.5. Multiple regression analysis of the correlation between BPRT and disease 
duration adjusting for age and gender in PD+AF 
Variable Parameter estimate Standard error P-value 
Disease duration 0.78 0.40 0.07 
Age 0.03 0.19 0.87 
Gender 0.72 3.81 0.85 
 
4.1.1.4 Discussion 
The aim of this study was to compare novel cardiovascular autonomic function 
indices in MSA and PD with autonomic failure using a variety of cardiovascular autonomic 
function markers, including blood pressure changes during HUT, BRS, BPRT, VR, HRDB, 
and to examine whether any of these measures were correlated with disease duration. The 
main findings were that the MSA patients, relative to PD+AF, displayed no difference in 
orthostatic SBP changes but exhibited a longer blood pressure recovery time (BPRT) after 
the Valsalva Manoeuvre (VM) and a significantly lower BRS. Greater BP changes during 
HUT, lower BRS and prolonged BPRT in PAF compared with PD+AF indicate more severe 
adrenergic and cardiovagal dysfunction in PAF vs. PD+AF but these responses in PAF were 
comparable with MSA. 
Previous studies have reported equivocal results of cardiovascular autonomic 
function in differentiating between MSA and PD (Riley & Chelimsky, 2003; Reimann et al., 
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2010), which could be explained by differences in study populations (e.g. PD versus the 
combination of MSA with and without autonomic failure or PD without autonomic failure), 
data analyses (e.g. proportion of normal/abnormal tests vs. quantitative measures) and/or 
study protocols. Our study specifically compared PD with AF and MSA with AF using both 
standard autonomic testing (such as HUT, HRDB) and other potential autonomic measures, 
such as BRS and BPRT, which have never been directly compared between these groups 
and could be derived from a non-invasive procedure, the Valsalva manoeuvre, which is 
commonly used in standard autonomic test protocols. 
The similar orthostatic SBP responses, as well as Valsalva ratio (VR) and heart rate 
responses during deep breathing (HRDB) in patients with PD+AF and MSA are consistent 
with a previous study showing that these tests could not differentiate between MSA and PD 
(Riley & Chelimsky, 2003), however, baroreflex sensitivity (BRS) and BPRT were not 
evaluated in that study. Our findings show that both these measures were abnormal in MSA 
patients compared to PD+AF. Our findings confirmed that some autonomic function tests, 
such as BP response to HUT, HRDB and VR have limited effectiveness in detecting 
differences between MSA and PD (Riley & Chelimsky, 2003). In contrast, our study 
suggested that quantitative measures from the VM, BRS and BPRT, may provide a better 
diagnostic yield for this purpose compared to reporting only ‘normal’ or ‘abnormal’ grading of 
the VM, which has been used in a prior study and revealed no differences between MSA and 
PD (Schmidt et al., 2009b). 
A lower BRS in patients with MSA compared to those in PD+AF indicated a greater 
impairment of baroreflex dysfunction in MSA relative to PD+AF. BPRT is a useful measure 
of the adrenergic component, e.g. vasoconstrictor responsiveness, of baroreflex function 
(Vogel et al., 2005). Prolonged BPRT in MSA may indicate greater impairment of adrenergic 
function in MSA compared to PD+AF. A sub-group analysis of the parameters between MSA 
and PD+AF patients with orthostatic symptoms was also performed. The results did not 
show any difference from our main findings. In accordance with a previous study (Schmidt et 
al., 2008), we found no difference in any cardiovascular autonomic parameters between 
MSA-C and MSA-P.  
Although there were some overlap in BPRT and BRS values between MSA and 
PD+AF patients in our study, suggesting that these measures may not be able to be used for 
distinguishing PD+AF from MSA with autonomic failure, our results demonstrated that MSA 
generally had lower BRS and longer BPRT than PD+AF. Given that these are non-invasive 
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and relatively simple tests to perform, both measures should be included as part of 
autonomic investigations in suspected MSA/PD+AF workups. 
MSA patients were significantly younger and used less dopaminergic medications 
compared to PD+AF patients, These differences were not likely to have an impact on our 
results because both dopaminergic medications and increasing age were associated with 
reduced BRS (Oka et al., 2003) and prolonged BPRT (Huang et al., 2007). Thus, the lower 
BRS and longer BPRT in MSA relative to PD+AF could have been attenuated by the older 
age and greater use of dopaminergic medications in the PD group. In addition, differences in 
BPRT and BRS between MSA and PD+AF were still significant after adjusting for age, 
gender and disease duration. 
 Our findings cannot be used as epidemiological data showing the prevalence of 
autonomic dysfunction in MSA and PD because all patients were selected from autonomic 
laboratory investigations but it is important to note that cardiovascular autonomic symptoms 
were not present in more than 20% of MSA patients in our study even though they all met 
the criteria of Orthostatic Hypotension (OH). This symptomatic figure is close to a previous 
study (Ha et al., 2011) and confirmed that OH and orthostatic symptoms are not always 
correlated and patients who have any suggestive features of MSA should undergo 
autonomic function testing. The evidence of autonomic dysfunction would improve diagnostic 
accuracy and provide better information on disease prognosis, as well as treatment plans, in 
these patient groups. Our study has also revealed that the presentation of OH can occur in 
the later stages of the disease progression in MSA and OH is not necessarily a presenting 
feature in patients with MSA as OH occurred after 5 years of disease onset in more than 
40% of patients.  
Pathological studies have confirmed widespread neuronal loss in key areas within 
the central autonomic network including the periventricular nucleus (Benarroch et al., 
2006a), ventrolateral medulla (VLM) (Benarroch et al., 1998), dorsal motor nucleus of the 
vagus nerve (Benarroch et al., 2006b) and intermediolateral cell column (Kennedy & 
Duchen, 1985) with the presence of glial cytoplasmic inclusions (GCIs) in MSA patients 
suggesting a pre-ganglionic lesion in origin while autonomic dysfunction in PD has been 
proposed to be caused by the combination of pre- and post-ganglionic abnormalities. These 
include abnormal Lewy bodies pathology in the hypothalamus, lower brainstem autonomic 
nuclei, insular cortex, anterior cingulate, intermediolateral column and evidence of a reduced 
uptake of cardiac MIBG and Lewy body deposition in peripheral autonomic ganglia, 
respectively (Wakabayashi & Takahashi, 1997b). A lower BRS in MSA might be explained 
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by greater neuronal loss in the ventrolateral nucleus ambiguous (NAmb), compared with PD 
(Benarroch et al., 2003). The majority of neurons from this area consist of pre-ganglionic  
parasympathetic neurons projecting to the heart (Hopkins et al., 1996) which contribute to 
cardiovagal control and may be responsible for greater impairment of baroreflex function. 
Furthermore, a significant reduction of C1 catecholaminergic neurons in the rostral 
ventrolateral medulla have also been reported in MSA (Kato et al., 1995) and to a greater 
extent than in patients with PD+OH (Benarroch et al., 2000). This area involves the control 
of sympathetic vasomotor outflow and may explain the different degrees of prolonged BPRT 
in MSA and PD+AF. 
Pathological studies of PAF are quite limited because of the condition’s rarity. While 
the majority of pathological studies in PAF reported some abnormal lewy body deposition 
and neuronal loss in pre-ganglionic sympathetic areas (intermediolateral cell column of 
thoracic spinal cord) and severe involvement of post-ganglionic sympathetic lesions 
(sympathetic ganglia, stellate ganglion and celiac ganglion) (van Ingelghem et al., 1994; Arai 
et al., 2000), other case studies have also reported lewy body deposition in the substantia 
nigra and brainstem structures, which is similar to patients with PD (Hague et al., 1997). 
Nevertheless, greater BP changes during HUT, lower BRS and prolonged BPRT in PAF 
suggest more widespread impairment of both sympathetic and parasympathetic function in 
PAF compared with PD+AF. Comparing pathological involvement of the autonomic nervous 
system between PAF and PD+AF may provide further insight into whether there are 
differential neuronal losses to explain a greater autonomic dysfunction in PAF relative to 
PD+AF. 
There was no clear association between any cardiovascular autonomic parameters 
and disease duration in PD+AF, MSA and PAF patients. A trend of association between 
BPRT and disease duration in PD+AF patients was apparent. This may reflect the 
heterogeneous progression of autonomic dysfunction in MSA patients. Nonetheless, BPRT 
may be a potential measure to be used for follow-up in PD patients who have autonomic 
dysfunction/failure. There are only a few longitudinal studies of cardiovascular autonomic 
function in PD patients. The results showed a significant reduction of heart rate variability 
and greater orthostatic blood pressure change from baseline during standing after 2.5 years 
(Mesec et al., 1999). Another study found a significant worsening of autonomic symptoms, 
using the composite autonomic symptom scale (COMPASS), in MSA compared with PD 
after 12-months follow-up (Lipp et al., 2009). Further investigation of these findings in a 
greater number of patients with a longitudinal approach would provide a better 
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understanding of whether or not these tests could be used to follow-up patients in a clinical 
setting.  
In conclusion, despite a similar severity of OH between patient groups, a significantly 
prolonged BPRT and lower BRS were evident in MSA compared to PD+AF patients as well 
as in PAF compared to PD+AF, which may be explained by a greater impairment of 
autonomic function and more widespread autonomic failure in MSA and PAF. Our findings 
suggest that BPRT and BRS may be additional markers to help differentiate patients with 
MSA (who have orthostatic hypotension) from PD+AF, also between PAF and PD+AF.  
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4.1.2 Quantitative cardiovascular autonomic function in patients with Parkinson’s 
disease (PD) and healthy control individuals 
4.1.2.1 Introduction 
Cardiovascular autonomic dysfunction, such as orthostatic hypotension (OH), is 
increasingly recognised as a major non-motor feature in PD (Martinez-Martin et al., 2007). 
OH is commonly present in patients with PD and sometimes without orthostatic symptoms 
(Senard et al., 1997). It is often evident in later stages in PD, when patients become 
symptomatic or have apparent autonomic dysfunction. That said, cardiovascular autonomic 
dysfunction can occur in early stages of PD, even before the hallmark motor symptoms 
occur (Goldstein, 2006), which can range from mild autonomic dysfunction to autonomic 
failure (Ziemssen & Reichmann, 2010). A recent study demonstrated that abnormal reuptake 
from cardiac MIBG can be evident even in the early stage of PD (Hoehn and Yahr stage I) 
(Spiegel et al., 2005). Furthermore, a later study also reported an association between 
cardiovascular autonomic function test results; specifically, the blood pressure response in 
phase IV (e.g., the BP overshoot) during the Valsalva manoeuvre (VM), and the reduction of 
cardiac MIBG reuptake in de novo patients with PD (Oka et al., 2011). As abnormal reuptake 
of cardiac MIBG represents the post-ganglionic autonomic lesion in PD (Amino et al., 2005), 
cardiovascular autonomic dysfunction could be a potential non-invasive biomarker to aid 
diagnosis in early PD.  
More recently, other cardiovascular autonomic tests, such as spectral analysis of 
heart rate variability, baroreflex sensitivity (BRS), have been reported to be abnormal in PD 
patients (Kallio et al., 2000; Haapaniemi et al., 2001; Szili-Torok et al., 2001). These indices 
have been proposed to be useful for evaluating cardiovascular autonomic function in chronic 
autonomic failure disorders (Vogel et al., 2005; Schrezenmaier et al., 2007) but the efficacy 
of these tests remains uncertain in PD patients without cardiovascular autonomic symptoms 
and OH. There have been only few studies categorising patients with PD by the presence (or 
lack of) of OH and the assessment of quantitative CV autonomic function measures, 
including baroreflex sensitivity (BRS), blood pressure recovery time (BPRT), Valsalva ratio 
(VR) and the heart rate responses to deep breathing (HRDB).  
The aim of this study was to therefore investigate the usefulness of a variety of 
cardiovascular autonomic function indices, including BRS, BPRT, VR and HRDB in PD 
patients without both OH and orthostatic symptoms compared with age-matched healthy 
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controls. We also investigated the relationship between these CV indices with disease 
duration, age, gender and PD motor severity. 
 
4.1.2.2 Methods 
Subjects 
Patients with a confirmed diagnosis of Parkinson’s disease (PD) and healthy controls 
were included (Chapter 3). None of them met the criteria of OH. Patients were excluded if 
they were unable to perform the VM or had a flat top VM response. 
Clinical history  
History and relevant information of all patients and participants were recorded. These 
include age, gender, duration of disease (time from diagnosis to testing date), dopaminergic 
medications and presenting symptoms. Motor severity and depression in PD were evaluated 
by UPDRS and Hamilton rating (HAM-D) scales, respectively.  
Cardiovascular autonomic screening tests (AFT) 
Cardiovascular autonomic function was assessed using Autonomic Unit protocols 
(Mathias et al., 2013a). This included all pressor tests, Valsalva manoeuvre (VM), deep 
breathing, Hyperventilation, 10-minute 60 degrees HUT as described in Chapter 3.  Beat-to-
beat blood pressure and heart rate were recorded continuously on-line using digital 
photoplethysmography and electrocardiography, respectively. These variables were also 
recorded intermittently using upper arm sphygmomanometry. Beat-to-beat blood pressure 
and heart rate data were used to analyse quantitative cardiovascular autonomic function 
indexes including BP responses to VM, blood pressure recovery time (BPRT), Valsalva ratio 
(VR) and HR responses to deep breathing (HRDB) off-line.   
Quantitative cardiovascular autonomic function indexes 
Phase 2 early (phase II_E), phase 2 late (phase II_L), phase 4 (phase IV), the 
Valsalva ratio (VR) and BPRT were determined from the VM as previously described (Vogel 
et al., 2005). BRS was calculated from the slope of the linear regression between the length 
of the RR interval and preceding SBP during phase 2 of the VM (Goldstein et al., 1982). The 
heart rate response during deep breathing (HRDB) was measured by the mean of the heart 
rate change (maximum-minimum) during 6 breath cycles. 
89 
 
Statistical methods 
Data are presented as mean (± 1 SD). Mann-Whitney U tests were used to compare 
between the 2 groups for non-normally distributed data and unpaired t-tests for normally 
distributed data. Chi-square analyses were used for analysis of categorical variables. The 
relationships between quantitative autonomic measures including BRS, BPRT, VR and 
(HRDB) and disease duration were assessed by regression analysis. Quantitative autonomic 
measures were set as the outcome variables while other variables as covariates in 
univariate analysis. Multiple linear regression was performed to assess the relationship 
between autonomic measures and age, gender and disease severity in PD patients. 
Assumptions for the regression analyses were checked by the analyses of residuals. 
Statistical analyses were carried out using STATA 11.0 (STATA Corporation, College 
station, Texas, USA). All tests were 2-sided and a p value of <0.05 was considered 
significant. 
 
4.1.2.3 Results 
22 PD patients and 10 age-matched healthy controls were included in the analyses. 
Participants’ demographic data are presented in Table 4.6. PD patients had a mean UPDRS 
part III of 14.2+6.4 and Hoehn and Yahr (HY) staging ranged from 1-3 (I: II: III, 8:13:1). The 
mean age at PD onset was 56+7 years. The majority of patients presented with bradykinesia 
(11/22; 50%), followed by tremor (8/22; 36%) and gait unsteadiness (3/22; 14%). 
Table 4.6. Participant demographic data  
Variable PD (n=22) Control (n=10) 
% Male  68 40 
Age at Testing, yrs 63+8 58+9 
Disease duration, yrs  6+4 - 
HY stage 1.7+0.6 - 
 Values are mean+SD HY=Hoehn and Yahr  
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There was no difference in the group mean supine BP, Head-Up Tilt BP and 
orthostatic changes between controls and PD patients (p>0.05; see Table 4.7). None of the 
PD patients reported orthostatic symptoms during the 10-minute HUT.  
Table 4.7. Systolic and diastolic blood pressure (SBP, DBP; mmHg) and heart rate 
(HR; bpm) during supine and head-up tilt and orthostatic SBP changes in PD and 
control groups.  
Variable PD Control 
Supine SBP  130+17 129 +18 
Supine DBP 75+12 71+10 
Supine HR 66+12 64+9 
Tilt SBP  123+17 126+15 
Tilt DBP 75+11 77+9 
Tilt HR 74+12 73+9 
Orthostatic ∆SBP -7+7 -3+11 
Orthostatic ∆DBP -1+7 -6+7 
Orthostatic ∆HR 8+7 9+4 
Values are mean+SD 
Baseline SBP before VM was not different between patients with PD and controls (p=0.43) 
but the BP change during phase 2 early of the VM was significantly greater in the PD group 
(p=0.029) and the BP changes during phase 2 late (p=0.037) and phase 4 (p<0.01) were 
significantly lower in the PD group compared to controls (see Table 4.8).  
Table 4.8. Blood pressure changes (mmHg) during the various phases of the Valsalva 
manoeuvre in PD and control groups.  
Variable PD Control 
Baseline SBP 121+22  115+19  
∆SBP Phase II_E  36+23#  20+15  
∆SBP Phase II_L  16+10#  31+19  
∆SBP Phase IV  23+13$  46+19  
Values are mean+SD, SBP=Systolic BP, Phase II_E= Phase 2 early of VM,  Phase II_L= 
Phase 2 late of VM, Phase IV=Phase 4 of VM 
$p<0.01 vs. Control , #p<0.05 vs. Control  
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There was no difference in baroreflex sensitivity (BRS) in PD patients compared with 
controls (p=0.11). BPRT was significantly prolonged in PD compared with controls (p<0.01). 
There was no difference in VR and HRDB between patients and controls (p>0.05; see Table 
4.9).  
Table 4.9. Cardiovascular autonomic parameters during the Valsalva manoeuvre; 
Baroreflex sensitivity, Blood pressure recovery time, Valsalva ratio and Heart rate 
response during Deep breathing; in PD and control groups.  
Variable PD Control 
BRS, ms/mmHg 3.6+2.8  4.6+2.0  
BPRT, sec  3.0+3.3#  0.7+0.5  
VR  1.6+0.3  1.7+0.3  
HRDB (bpm) 11+5  15+6  
Values are mean+SD, BRS= baroreflex sensitivity, BPRT=Blood pressure recovery time, 
VR=Valsalva Ratio,   HRDB = Heart rate response during Deep Breathing 
# p<0.01 vs. Control  
 
Autonomic function parameters, including orthostatic BP changes during HUT, BRS, 
VR and HRDB were not correlated with disease duration in PD patients during the regression 
analysis. BPRT was associated with UPDRS motor score (p=0.02), age at testing (p=0.04), 
disease duration (p<0.01) and HY stage (p<0.01) in the univariate regression analysis. The 
HY stage was selected instead of UPDRS III to avoid colinearity. Multiple linear regression 
analysis showed that only disease duration was still significantly correlated with BPRT after 
adjusting for age, gender and HY scores (p=0.05; Table 4.10 and Figure 4.1).  
Table 4.10. Multiple regression analysis of the correlation between BPRT and disease 
duration (R2=0.44, p=0.05) 
Variable Parameter estimate Standard error P-value 
Disease duration 0.41 0.2 0.05 
Age 0.05 0.09 0.62 
HY 1.26 1.34 0.36 
Gender -0.84 1.34 0.54 
HY=Hoehn and Yahr 
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Figure 4.1. Scatterplot showing the correlation between blood pressure recovery time 
(BPRT; Y axis) and disease duration (X axis; R=0.60, p<0.01) in patients with PD. 
 
4.1.2.4 Discussion 
The main finding of this study was a significant prolonged blood pressure recovery 
time (BPRT) after the Valsalva Manoeuvre (VM) in PD patients without autonomic failure 
(orthostatic hypotension) compared to age-matched controls suggesting cardiovascular 
autonomic dysfunction may be present in PD patients even without OH. It was also 
demonstrated that there was a strong relationship between PD disease duration and BPRT 
even after taking age and motor dysfunction severity (HY stage) into account. 
 The mechanism of BP changes during the VM is complex but can provide useful 
information on the integrity of cardiovascular autonomic function. The BP and heart rate 
responses can broadly be divided into four phases during the VM. Phase I and III are 
mechanical phases, which are influenced by the performance of the manoeuvre.  The BP fall 
during phase II early is a result of an abrupt reduction of venous return, stroke volume and 
reduced cardiac output (CO) as a consequence BP continues to fall despite an increase in 
heart rate due to a withdrawal of cardiovagal influence. A fall of BP is arrested within 4 
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seconds after sympathetic discharge (Delius et al., 1972). Phase II early is then followed by 
a baroreflex mediated increase in total peripheral vascular resistance resulting from 
sympathetic discharge to muscle. Subsequently, BP transiently increases (1-2 seconds) 
during phase II late prior to phase III. During phase IV, there is a overshoot of BP at the end 
of the VM, as a result of the increased venous return (Wexler et al., 1968) and CO (Brooker 
et al., 1974) back to pre VM baseline while the systemic blood vessels remain 
vasoconstricted. 
Given that BP recovery during phase II late specifically represents a sympathetic-
mediated vasoconstrictor response (Vogel et al., 2005) and Phase IV is influenced by the 
combination of sympathetic vasoconstrictor function and cardiac sympathetic function 
(Sandroni et al., 1991), the significantly reduced BP changes (e.g., increases) in phase II 
late and phase IV, as well as the prolonged BPRT in the PD patients in the present study 
suggests that there may be subtle abnormalities in the sympathetic vasoconstrictor function 
in PD without classic autonomic failure and that BPRT can detect subtle sympathetic 
dysfunction before orthostatic hypotension becomes evident during HUT. Cardiac 
sympathetic dysfunction, as in abnormal cardiac MIBG uptake, is often reported in de novo 
PD patients (Oka et al., 2011). The findings of this study implicate that there may be post-
ganglionic sympathetic dysfunction in other vascular beds in addition to the heart even in the 
early stages of PD (Oka et al., 2006). 
Pathology in the central autonomic network has been proposed to be involved in 
cardiovascular autonomic dysfunction in PD. Indeed, the dorsal motor nucleus of the vagus 
nerve was found to be abnormal even in the early stages of PD and purportedly progresses 
to the olfactory nucleus, pontine tegmental nuclei and the locus coeruleus and ventrolateral 
area of the medulla (Braak et al., 2003). Since the ventrolateral medulla is part of the 
baroreflex pathway, it could be hypothesized that BRS could be abnormal in patients with 
PD. However, no significant difference in BRS in PD compared to controls was evident in 
this study. These findings are similar to previous reports (Barbic et al., 2007; Friedrich et al., 
2010), even though the BRS in those studies was derived from a different technique; 
spectral analysis. Nevertheless, there are some studies that have reporting an abnormal 
BRS in PD (Szili-Torok et al., 2001). These inconsistent results suggest that BRS is not 
universally abnormal in PD. The impairment of BRS occurs commonly in patients with 
PD+OH (Barbic et al., 2007)(see Chapter 4.1.1), whereas our results suggest that BRS is 
relatively normal in PD without OH compared with age-matched controls. These findings are 
in agreement with a proposed hypothesis that the occurrence of PD+AF depends on 3 
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different parts of the autonomic pathways, namely the arterial baroreflex, cardiac- and extra-
cardiac sympathetic function (demonstrated by a reduction of plasma noradrenaline) (Jain & 
Goldstein, 2012). 
Orthostatic BP changes were not different in patients with PD compared to age-
matched controls. This result indicates that these hemodynamic responses during HUT 
cannot be used as cardiovascular autonomic function markers to distinguish PD from the 
general population. Despite this finding from HUT, BPRT were still found to be significantly 
abnormal in PD. This finding suggests that changes in BPRT are not entirely reflected in 
HUT BP data. The mechanism of BPRT may be different from orthostatic BP responses to 
HUT. Although the BRPT reflects a combination of sympathetic vasoconstrictor and cardiac 
sympathetic function, the BP response to orthostatic challenge using HUT involves a much 
greater number of neural, hemodynamic and hormonal mechanisms in the BP response, any 
of which could compensate for any mechanism that might be impaired, e.g., the 
unremarkable BP changes during HUT may be a reflection of redundancy in other BP 
maintaining mechanisms in PD patients. In addition, the grading of orthostatic changes could 
be another factor that contributes to the difference between OH and BPRT findings. OH is 
quite a severe feature to detect, e.g., a decrease of 20 mm Hg SBP will represent a large 
deficit in CV autonomic function, whereas 5-10 mm Hg suggests a subtle defect.  
In the present study, there were also no differences in other cardiovascular 
autonomic parameters, including VR and HRDB. These findings are in line with previous 
studies (Gross et al., 1972; Mesec et al., 1999; Schmidt et al., 2009b). As these are 
measurements for cardiac parasympathetic function, these normal results may suggest 
either PD with no OH patients actually have an intact parasympathetic function or these 
parameters may not be sensitive enough to detect subtle abnormalities within this autonomic 
pathway. Nonetheless, there are a few studies that have reported an impairment of cardiac 
parasympathetic activity derived from heart rate variability in PD patients (Shibata et al., 
2009). A recent pathological study reported Lewy body deposition in the sinoatrial node 
ganglion (Okada et al., 2004), which may explain why only some patients with PD have 
impaired baroreflex function as part of their disease progression.   
The current study also described an association between BPRT and disease duration 
in PD patients after controlling for age and motor dysfunction severity (HY stage). Apart from 
BPRT, disease duration was not associated with any other cardiovascular autonomic 
function index. There have been only a few studies that have specifically examined the 
relationship between cardiovascular autonomic dysfunction and disease duration/severity in 
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PD. One study reported a greater degree of OH and a reduction of HRDB and VR in PD 
patients after a 3 year-follow up (Mesec et al., 1999), while other cross-sectional studies 
consistently found only an association between increasing severity of OH and disease 
duration and age (van Dijk et al., 1993; Linden et al., 1997; Wullner et al., 2007). These 
findings implicate that age and disease duration are likely to play an important part in the 
progression of cardiovascular autonomic dysfunction, particularly OH, in PD and the 
relationship between cardiovascular autonomic dysfunction and disease duration is complex 
and may not simply progress in a homogeneous pattern in individual patients with PD, 
similarly to what was evident in the present study. Larger longitudinal studies are needed to 
confirm whether BPRT is a useful marker to monitor CV autonomic dysfunction progression 
in PD patients.  
Comparing the BPRT and BRS results between PD (this chapter) and PD+AF 
patients (Chapter 4.1.1), there was no difference in BRS between these two groups (p=0.13) 
but there was a significantly prolonged BRPT in PD+AF compared to PD (p<0.01). Multiple 
linear regression analysis controlling for age and gender also demonstrated a significant 
association between BPRT and disease duration only with patients with PD but not in 
PD+AF. This finding suggests that BPRT progresses with disease duration in early PD and 
then plateaus when patients develop OH (e.g., PD+AF) in the later stages of disease. 
In conclusion, a significantly prolonged BPRT indicates early cardiovascular 
autonomic dysfunction in PD patients before potentially widespread autonomic failure may 
develop. Our findings suggest that BPRT is a useful marker in addition to the orthostatic 
challenge test and should be part of autonomic investigations even in PD without CV 
autonomic dysfunction symptoms.  
 
 
 
 
 
 
 
96 
 
4.1.3 Pressor tests in patients with chronic autonomic failure 
4.1.3.1 Introduction 
Pressor tests, that include isometric handgrip exercise (IE), cold pressor (CP) and 
mental arithmetic (MA) stressors, are routinely performed as part of standard autonomic 
function screening tests (AFT) (Mathias et al., 2013b). These tests are measures of 
sympathetic nerve function and are commonly impaired in patients with autonomic 
dysfunction/failure. 
The IE, MA and CP manoeuvres typically increase heart rate and stroke volume and 
thereby cardiac output, as well as total peripheral resistance in some manoeuvres, and 
blood pressure as a result of sympathetic activation (Ludbrook et al., 1975; Rowell & 
O'Leary, 1990; Nobrega et al., 1997). Although these 3 pressor tests produce relatively 
similar haemodynamic responses, each test involves different afferent pathways. Previous 
studies suggested that IE causes an increase in BP and HR (Lind et al., 1964) and this 
phenomenon was caused by the combination of central command and the peripheral 
activation of the exercise pressor reflex (Winchester et al., 2000). An increase in cardiac 
output is followed by an increase in peripheral vascular resistance (Mark et al., 1985). In 
contrast to IE, cardiovascular responses during MA are predominantly activated by central 
pathways. During MA, there is an increase in sympathetic outflow as a consequence of the 
activation of the central autonomic network, such as the right insular cortex and right anterior 
cingulate areas (Critchley et al., 2000). Furthermore, the cardiovascular responses are 
mainly a result of increased cardiac output without an increase in total peripheral resistance 
(Hjemdahl et al., 1984). The cold pressor test (CP), evoked by painful stimuli, transmits 
signals from temperature nociceptors and unmyelinated C-fibers and the A∂ fibers. 
Subsequently, these signals are integrated at the hypothalamus and vasomotor centres in 
the medulla causing an increase in sympathetic outflow and a rise in HR and BP (McLeod & 
Tuck, 1987).  
  Despite differences in the autonomic lesion between PD (pre- and post-ganglionic) 
and MSA (pre-ganglionic) patients with autonomic failure, these patients often share several 
autonomic abnormalities, such as sympathetic and parasympathetic dysfunction during 
autonomic function tests. Most studies have compared patients with PD and MSA regardless 
of the integrity of their cardiovascular autonomic function (e.g. PD or MSA patients with and 
without autonomic dysfunction/failure have been grouped together). There have been no 
studies specifically looking at the cardiovascular responses to pressor tests in PD with 
97 
 
autonomic failure (PD+AF) and MSA with autonomic failure (MSA+AF); 2 patient groups 
where the overlapping autonomic features are most evident and can cause the most 
difficulty in differentiating a correct diagnosis. 
The aim of this study was to therefore specifically assess the BP and HR responses 
to pressor tests in PD patients with (PD+AF) and without autonomic failure (PD) and MSA 
patients with autonomic failure, as well as comparing these groups with healthy controls in 
order to see whether there is any difference in responses between disorders. 
 
4.1.3.2 Methods 
Subjects 
Patients with a confirmed diagnosis of Parkinson’s disease with (PD+AF) and without 
autonomic failure (PD) and Probable Multiple System Atrophy (MSA) with orthostatic 
hypotension and healthy controls were included (Chapter 3).  
Test protocol 
The detailed protocols of all pressor tests are described in Chapter 3. Briefly, BP and 
HR were taken before and at the end of each pressor test. The tests included 1) cold pressor 
test performed by applying an ice pack to a participant’s wrist for 90 seconds. 2) Handgrip 
isometric exercise performed by voluntarily squeezing a partially inflated 
sphygmomanometer cuff and maintaining the contraction at 33% of maximum effort for 3 
minutes. 3) Mental arithmetic test performed by serial subtraction for 2 minutes. After each 
pressor test, BP and HR were allowed to return to baseline levels before performing the next 
pressor test. A 10-minute 60 degree head up tilting test (HUT) was also performed after the 
pressor tests. 
Statistical analyses  
Data are presented as mean (± 1 SD) and median (interquartile range; IQR) as 
appropriate. Independent t-tests or ANOVA were used to compare BP and heart rate 
responses between groups.  BP and heart rate responses before and after each pressor test 
as well as during supine and head-up tilting (HUT) were compared between groups using 
mixed models repeated measures ANOVA. If there was a significant main effect of time or 
group, post hoc analyses were performed using Bonferroni corrections for multiple 
comparisons. All data were analysed using commercial available software (STATA 11.0, 
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STATA Corporation, College station, Texas, USA). All tests were 2-sided and a p value of 
<0.05 was considered significant. 
4.1.3.3 Results 
Demographic data 
101 patients (48 MSA, 22 PD+AF, 31 PD) and 10 healthy controls were included in 
the analyses. Patients with MSA, PD+AF and PD were significantly older than controls 
(p<0.05) but the disease duration was not different among patient groups (p=0.11). 
Dopaminergic treatment was more commonly used in patients with PD and PD+AF 
compared to MSA (MSA vs. PD+AF; p<0.01 and MSA vs. PD; p<0.01). There was no 
difference in the number of patients on dopaminergic medication among PD and PD+AF 
(p=0.07; Table 4.11).    
Table 4.11. Patient demographic data  
Variable MSA PD+AF PD Control 
Number 48 22 31 10 
% Male 50 59 68 40 
Age at testing, yrs 62+8*£ 69+8* 63+9*£ 57+8 
Disease duration     
Median (IQR), yrs 5 (3-6) 6 (4-10) 7 (4-10) - 
% Dopaminergic 
treatment 42
£$ 82 97 - 
Values are mean+SD unless stated 
*p<0.05 vs. control,  $p<0.05 vs. PD, £p<0.05 vs. PD+AF 
 
Cardiovascular responses to HUT 
 Supine SBP and DBP were not significantly different between MSA, PD+AF, PD 
patients and controls but there was a higher baseline HR in MSA patients compared with the 
other groups. During head-up tilting (HUT), SBP was significantly lower in patients with MSA 
and PD+AF compared to PD (p<0.01) and controls (p<0.01). Correspondingly, the BP 
changes (e.g., the decrease in BP) during HUT were significantly greater in MSA and 
PD+AF compared to controls (MSA vs. controls; p<0.01 and PD+AF vs. control; p=0.01).    
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In PD, there was a significant SBP fall with HR rise during HUT (both p<0.01) but not DBP 
(p=0.43) compared to corresponding supine values. In contrast, only a significant HR was 
significantly increased on HUT compared to supine (p<0.01), but there were no differences 
in SBP and DBP in healthy controls (both p>0.05).   There was also no difference in the 
changes in BP and HR during HUT between PD and controls (both p>0.05). SBP and DBP 
during HUT were not different between MSA and PD+AF (p=0.35 and p=0.9, respectively) 
but HR was significantly higher in MSA during HUT (Table 4.12). 
Table 4.12. Blood pressure and HR during supine, head-up tilting and orthostatic 
changes in PD, PD+AF, MSA patients and controls.  
Variable MSA PD+AF PD Control 
Supine     
  Supine SBP 134+21 136+20 129+17 129+17 
  Supine DBP 80+12 75+11 73+11 71+7 
  Supine HR  78+10* 69+10# 66+11# 61+7 
  Tilt SBP 88+20*$ ϕ 93+23*$ϕ 122+18 ϕ 125+15 
  Tilt DBP 59+13**$ϕ 60+15**$ϕ 74+10 77+9 
  Tilt HR 87+12*ϕ 78+9#ϕ 74+11#ϕ 71+8 ϕ 
  Orthostatic ∆SBP  -46+20*$ -42+16*$ -7+6 -4+9 
  Orthostatic ∆DBP -21+12*$ -15+12*$ -1+7 5+5 
  Orthostatic ∆HR 10+8 8+6 8+6 10+3 
Values are mean+SD 
*p<0.05 vs. control, #p<0.05 vs. MSA, $p<0.05 vs. PD 
ϕp<0.05 vs. corresponding supine value 
 
Cardiovascular responses to pressor tests 
There was a higher baseline SBP, DBP in patients with MSA compared with PD 
(p<0.01) and controls (p=0.03). Baseline SBP and DBP were not different between MSA and 
PD+AF patients (p=0.25), as well as between PD and controls (p=0.82). During IE, SBP, 
DBP and HR significantly rose from baseline in PD+AF, PD and controls (p<0.05) but not in 
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MSA who only had a significant rise in HR (SBP pre- vs. post-IE; p=0.41, DBP pre- vs. post-
IE; p=0.06; HR pre- vs. post-IE; p<0.01).  
There were a significant increase in SBP and DBP during MA in PD+AF, PD and 
controls (p<0.05) but not in MSA patients (p>0.05). HR significantly increased during MA in 
PD+AF, PD, MSA patients and controls (p<0.01).   
During CP, BP and HR significantly rose from baseline in MSA and PD+AF (p<0.01), 
whereas there were an increase in SBP and DBP (both p<0.01) without a significant 
increase in heart rate (p=0.28) in controls. In PD, there was only an increase in SBP 
(p<0.01) without changes in DBP and HR (both p>0.05) during CP (Table 4.13).  
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Table 4.13. Blood pressure and HR responses to isometric exercise, mental arithmetic 
and cold pressor test in PD, PD+AF, MSA patients and controls  
Variable MSA PD+AF PD Control 
Isometric exercise (IE) 
Pre 
  
  
SBP 
DBP 
HR 
Post 
SBP 
DBP 
HR 
141+24* 
 80+13* 
73+10 
 
142+23 
82+12 ϕ 
79+10 ϕ  
134+17 
76+11 
62+9# 
 
143+18ϕ 
80+12 ϕ 
69+10# ϕ 
125+17# 
71+11# 
67+12 
 
147+19 ϕ 
81+12ϕ 
76+12 ϕ 
123+18 
69+10 
64+8 
 
155+8 ϕ 
85+9ϕ 
70+10 ϕ 
Mental arithmetic (MA) 
Pre 
SBP 
DBP 
HR 
Post 
SBP 
DBP 
HR 
 
 
139+23 
81+12 
73+9  
 
138+21 
79+11 
78+9*ϕ  
 
 
136+16 
76+11 
66+9  
 
143+19 ϕ 
79+11 ϕ 
70+10#  ϕ  
 
 
125+15# 
72+12# 
67+13 
 
139+17 ϕ 
77+12 ϕ  
74+13 ϕ  
 
 
127+17 
71+10 
62+8# 
 
140+20 ϕ  
79+9 ϕ  
68+6 ϕ  
Cold pressor test (CP) 
Pre 
SBP 
DBP 
HR 
Post 
SBP 
DBP 
HR 
 
 
142+24 
81+13 
74+9* 
 
150+25$ϕ  
85+13 ϕ  
77+10* ϕ  
 
 
138+23 
76+11 
66+8# 
 
148+23 ϕ  
79+13 ϕ  
68+8# ϕ  
 
 
127+17# 
72+11# 
67+12# 
 
137+17 ϕ  
79+11 
68+13# 
 
 
129+21 
71+8 
61+9 
 
148+26 ϕ  
82+7 ϕ  
63+9 
Values are mean+SD, *p<0.05 vs. control, #p<0.05 vs. MSA, $p<0.05 vs. PD  
ϕp<0.05 vs. corresponding baseline value  
 
With regards to BP changes from baseline during IE, MSA and PD+AF had 
significantly smaller BP changes when compared with PD and controls (Table 4.14). There 
was no difference in BP and HR changes between MSA and PD+AF (SBP; p=0.09, DBP; 
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p=0.32 and HR; p=0.29) and patients with PD had no difference in BP and HR changes to IE 
compared to healthy controls (SBP; p=0.19, DBP; p=0.13 and HR; p=0.5). HR changes were 
not different among groups (p>0.05). 
The SBP and DBP changes in MSA were significantly less than those in PD+AF, PD 
and controls during MA (MSA vs. controls; p<0.01, MSA vs. PD+AF; p=0.01 and MSA vs. 
PD; p<0.01). PD had a greater change during MA compared to PD+AF (p<0.01) but no 
difference when compared to controls (p=0.70). There was no difference in HR changes 
among groups during MA (p>0.05). SBP changes during CP were significantly lower in MSA, 
PD+AF and PD compared to control but there was no difference among patient groups 
(p>0.05; Figures 4.2-4.4). 
Table 4.14. Blood pressure and HR changes to isometric exercise, mental arithmetic 
and cold pressor test in PD, PD+AF, MSA patients and controls  
Variable MSA PD+AF PD Control 
Isometric exercise     
  ∆SBP 1+10**$$ 9+14**$$ 23+14  32+19 
  ∆DBP 2+7**$$  4+7**$ 10+12 16+9 
  ∆HR 
Mental arithmetic 
6+5 7+4 9+6 6+11 
  ∆SBP  -1+7**$$ 6+11##$$ 15+10 13+11 
  ∆DBP -2+6** 3+6## 5+6## 8+4  
  ∆HR 
Cold pressor 
4+5 4+4 7+6 6+5 
  ∆SBP  8+9** 9+8* 11+9* 20+11 
  ∆DBP 4+7 4+5 6+8 10+6 
   ∆HR 3+5 2+3 1+8 2+5 
Values are mean+SD, * p<0.05 vs. control, ** p<0.01 vs. control, # p<0.05 vs. MSA, ## 
p<0.01 vs. MSA, $p<0.05 vs. PD, $$p<0.01 vs. PD, £p<0.05 vs. PD+AF, ££p<0.01 vs. PD+AF 
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Figure 4.2. Blood pressure and HR changes to isometric exercise (IE) in MSA, PD+AF, 
PD patients and controls; *p<0.05 vs. control, $p<0.05 vs. PD 
 
Figure 4.3. Blood pressure and HR changes to mental arithmetic (MA) test in MSA, 
PD+AF, PD patients and controls; *p<0.05 vs. control, $p<0.05 vs. PD, #p<0.05 vs. MSA, 
£p<0.05 vs. PD+AF. 
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Figure 4.4. Blood pressure and HR changes to cold pressor (CP) test in MSA, PD+AF, 
PD patients and controls; *p<0.05 vs. control. 
 
4.1.3.4 Discussion 
The aim of this study was to compare the BP and HR responses to pressor stimuli in 
MSA and PD with and without autonomic failure and healthy controls using a variety of 
pressor tests alongside the cardiovascular responses to HUT. The main findings in this study 
were that despite similar degrees of orthostatic BP changes during HUT in MSA and PD+AF 
groups and in PD and control groups, there were differential BP and HR responses to 
pressor stimuli in different groups of patients. Patients with autonomic failure (MSA and 
PD+AF) had significantly smaller BP changes when compared with PD patients and healthy 
controls whilst performing isometric handgrip exercise (IE). BP responses to Cold pressor 
test (CP) were significantly less in all patient groups when compared with controls. BP 
responses were significantly attenuated in MSA and PD+AF when compared with PD 
patients and healthy controls during mental arithmetic test (MA) but were lower still in MSA 
vs. PD+AF.  
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There have been only few studies that have used pressor tests to investigate patients 
with chronic autonomic failure. Previous studies reported a reduced BP response to CP in 
MSA patients compared to controls (De Marinis et al., 2000; Kimber et al., 2000). Another 
study reported no difference in BP responses to MA between MSA and PAF. To our 
knowledge, BP and HR responses to pressor tests have not been directly compared in PD, 
PD+AF and MSA, who often share features of orthostatic hypotension. 
Similar BP responses in MSA and PD+AF to IE were evident in the current study. 
This may be explained by the complex pathways involved in IE as the responses are the 
summation of both central and peripheral (reflex) inputs. Pathological lesions anywhere 
within these two pathways can result in abnormal hemodynamic responses to IE. 
Comparable blood pressure rises during IE between MSA and PD+AF indicate that this test 
may not be suitable to differentiate between these conditions particularly when orthostatic 
hypotension is already present.  
BP responses to the cold pressor test were significantly attenuated in patients with 
MSA, PD+AF and PD compared with healthy controls. Given that none of our participants 
had problems with neuropathy and the noxious stimuli is mainly integrated in the vasomotor 
centers in the medulla (McLeod & Tuck, 1987), the abnormal BP and HR responses during 
the CP are more likely to be caused by the pathological involvement within this area which 
has been reported in patients with autonomic failure (Benarroch et al., 2005). The decrement 
in the BP response to CP in MSA compared to controls is consistent with previous studies 
(De Marinis et al., 2000; Kimber et al., 2000) as well as those in PD+AF and PD. Although 
there was no difference in BP responses between MSA, PD+AF and PD patients, an 
interesting result was that patients with PD had significantly blunted BP responses compared 
with healthy controls during CP. This finding may indicate that a subtle sympathetic 
abnormality is already present in patients with PD even if they do not have orthostatic 
hypotension, similar to the BPRT findings in the previous study. The similar responses 
between the MSA, PD+AF groups compared to PD indicate that, however, the CP test 
cannot reveal differences between varying levels of autonomic dysfunction/failure.  
Cardiovascular responses during MA are predominantly activated by central 
pathways. The blunted BP responses during MA in patients with MSA compared to PD+AF 
may reflect a greater involvement of central autonomic network dysfunction in MSA relative 
to PD+AF and PAF. Nevertheless, this hypothesis has not been previously confirmed and 
further research using MA in conjunction with functional MRI study in these patients may 
provide important insight in answering this question.  
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The results also showed that there was no difference in blood pressure and heart 
rate responses during orthostasis in patients with MSA compared to PD+AF. These findings 
are consistent with the majority of previous studies (Lipp et al., 2009). Although SBP was 
siginiciantly fall during HUT in PD, there was no statistical difference in SBP, DBP and HR 
responses in patients with PD and controls. Prior studies reported significant changes in BP 
in patients with PD compared to controls (Gross et al., 1972). This conflicting result may be 
explained by differences in PD disease stage and PD medications between studies. These 
factors were reported as contributing factors to cardiovascular autonomic dysfunction in 
patients with PD (van Dijk et al., 1993; Mesec et al., 1999). These inconsistent findings also 
indicate that orthostatic BP changes during HUT may not be a reliable test to differentiate 
PD from the age-matched healthy population. 
In conclusion, this study demonstrated that patients with PD+AF and MSA, who had 
similar degree of orthostatic hypotension during HUT, can have different BP responses 
during pressor tests, namely mental arithmetic testing. These differences may help 
distinguish between patients with PD and MSA who present with orthostatic hypotension. 
Moreover, the BP response to cold pressor test was also blunted in patients with PD even 
though there was no orthostatic hypotension. This finding would support the idea that 
sympathetic dysfunction is subtly present in PD patients even in those without orthostatic 
hypotension.  
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4.1.4 24 hour-ambulatory blood pressure and heart rate monitoring (24 hr-ABPM) in 
patients with chronic autonomic failure 
4.1.4.1 Introduction 
 24 hour-ambulatory blood pressure and heart rate monitoring (24 hr-ABPM) is widely 
used in patients with blood pressure problems, particularly in those with high blood pressure 
(hypertension). A number of studies have demonstrated the advantage of using this 
equipment to detect and follow-up patients with hypertension (Ohkubo et al., 2005; 
Rodriguez-Roca et al., 2006; Franklin et al., 2012). More recently, 24 hr-ABPM has also 
been utilized as a screening test for patients with orthostatic hypotension in conjunction with 
laboratory autonomic tests. Furthermore, 24 hr-ABPM offers information not only on the 
average daytime blood pressure (BP) but also circadian BP revealing key information on the 
daytime and night-time profiles. In normal subjects, BP is normally lower during night-time 
which has been described as the physiological or normal pattern of nocturnal blood pressure 
‘dipping’. This pattern can be absent or reversed (BP night-time>BP daytime) in patients with 
autonomic failure. These patients tend to have lower BP during the day (due to the repeated 
bouts of OH) and a loss of BP dipping or even a higher BP at night, also influenced by 
supine hypertension, a common occurrence in autonomic failure (Goldstein et al., 2003b). 
According to the latest guidelines from the European Society of Hypertension and the 
European Society of Cardiology for the management of hypertension, those who have a 
normal BP reduction at night (BP decrease >10%) are classified as dippers while those with 
a nocturnal fall of <10% BP are classified as non-dippers. Those patients with a BP increase 
during the night are grouped as reverse dippers, which are more likely to happen in chronic 
autonomic failure (O'Brien et al., 2013). 
 24 hr-ABPM is commonly reported as abnormal in patients with PD regardless of 
their underlying autonomic function (Schmidt et al., 2009a). The prevalence of non-dippers in 
PD ranges from 48 to 95% (Senard et al., 1992; Ejaz et al., 2006; Schmidt et al., 2009a).  
Abnormal nocturnal circadian falls in blood pressure occurred more often in PD+AF 
compared to PD suggesting that there is a link of abnormal BP circadian rhythms and 
orthostatic hypotension (Senard et al., 1992). More recently, 24 hr-ABPM was used among 
different forms of parkinsonian disorders, including Parkinson’s disease (PD), Multiple 
system atrophy (MSA) and Progressive supranuclear palsy (PSP). The results showed that a 
number of these patients had a significantly higher proportion of absent nocturnal BP dipping 
compared to age-matched controls. These findings support the use of this equipment for 
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screening autonomic function in these patients groups, where the autonomic laboratory is 
not available (Schmidt et al., 2009a).  
Nevertheless, 24 hr-ABPM has never been specifically compared in patients with PD 
with and without autonomic failure and MSA with autonomic failure. Furthermore, the 
efficacy of ABPM with an autonomic protocol diary in detecting OH, compared with head-up 
tilt-table testing in these patient groups, has also never been evaluated. The aim of this 
study was therefore to 1) examine 24 hr-ABPM in patients with chronic autonomic failure 
(MSA+AF, PD+AF and PD) and 2) determine the effectiveness of 24 hr-ABPM compared to 
standard orthostatic challenge testing (10 minute Head-up Tilt) in diagnosing orthostatic 
hypotension (OH) in these patients.  
 
4.1.4.2 Methods 
Participants 
Patients with a confirmed diagnosis of Parkinson’s disease with (PD+AF) and without 
autonomic failure (PD) and Probable Multiple System Atrophy (MSA) with orthostatic 
hypotension were included (Chapter 3). Patients were selected only if cardiovascular 
autonomic screening tests (AFT) and 24 hr-ABPM were performed during the same 
admission. In order to verify the efficacy of 24 hr-ABPM in detecting OH using an autonomic 
protocol, only patients who completed a diary as part of the test were included in the 
sensitivity analyses.  
Clinical history and evaluation of autonomic nervous system function 
Demographic data, such as age at testing, dopaminergic medications and disease 
duration were also noted. 
Cardiovascular autonomic screening tests (AFT) 
All patients underwent screening autonomic function tests (AFT) using the Autonomic 
Unit protocols (Mathias et al., 2013b) to ascertain whether or not patients had orthostatic 
hypotension (OH) and autonomic failure (AF).  
24 hour-Ambulatory Blood Pressure and Heart Rate Monitoring (24 hr-ABPM) 
All patients were fitted with the 24 hr-ABPM (model 90207, Spacelabs™ Medical, 
Redmond, Washington) after their AFT as part of their autonomic investigations. BP and HR 
109 
 
were recorded every 20 minutes during the day (0800-2300) and every 60 minutes during 
the night (2300-0800). The average BP and HR were calculated for daytime, night-time and 
the entire 24-hour period. Patients were asked to record their symptoms in the diary during 
the day (e.g. dizziness, light-headedness, blurred vision etc) as well as the position and 
activity (lying down, sitting, standing, walking, and exercising) at the same time. Patients 
were also asked to record additional BP readings in addition to the automated readings if 
they developed symptoms. Bedtime and wake-up time were also recorded in order to 
determine the period of sleep. Postural challenges were included in the diary for patients to 
complete during the 24 hr-ABPM monitoring. This included an orthostatic challenge using a 
5-minute standing test. Patients were asked to press a recording button after 5-minute of 
lying down and again after 5-minute standing 4 times throughout the 24 hours. Symptoms (if 
experienced by patients) were also noted in the diary. BP and HR variabilities were derived 
from the standard deviations of the means of the specific period of times (24-hr, daytime and 
night-time). 
Patients were classified into 3 groups: dipper (BP fall during night-time>10% 
compared to daytime), absent nocturnal BP fall or non-dipper (BP fall during night-time<10% 
compared to daytime) and reverse nocturnal BP (BP higher during night-time than daytime). 
Patients with an average daytime SBP >140 mmHg or DBP >90 were defined as daytime 
hypertensives and those with nighttime SBP >125 or DBP >75 as nighttime hypertensives 
according to international guidelines (Pickering et al., 2005).  
Statistical Analyses 
Data are presented as mean (± 1 SD) or median (inter-quartile range), where 
appropriate. Analysis of covariance (ANCOVA) was used for comparisons between the 3 
groups for normally distributed data while the Kruskal-Wallis test was used if data were non-
normally distributed. If there was a significant difference, Mann-Whitney U tests were then 
used to compare between 2 groups for non-normally distributed data and unpaired t-tests for 
normally distributed data with Bonferroni corrections. Chi-square analyses were used for 
analysis of categorical variables.  
SBP and DBP responses from the 24 hr-ABPM standing test with the greatest 
degree of BP reduction were compared with the BP and HR responses during HUT using a 
standard criteria of OH (SBP fall >20 mmHg or DBP fall >10 mmHg). Considering the BP 
responses during HUT as a gold standard test, sensitivity (Sn) of the 24 hr-ABPM to detect 
OH was defined as the proportion of patients who met the criteria of OH from a standing test 
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during 24 Hr monitoring and the proportion of patients who met the criteria of OH during 
laboratory HUT. Specificity (Sp) was defined as the proportion of patients who did not meet 
the criteria of OH in the standing test in 24 Hr monitoring and all patients who were correctly 
classified as no OH from HUT. ROC (Receiver operating characteristic) analysis was used to 
evaluate the sensitivity and specificity in detecting OH from 24 hr-ABPM and to calculate Sn 
and Sp using different BP cut-off points. In general, the optimal cut-off point would be both 
Sn and Sp that as close to 100% as possible. Nonetheless, it is less likely to happen as the 
Sn tend to vary inversely with Sp (Sn increases as Sp decreases, or vice versa). In this 
study, ROC curves were plotted Sn against 1-Sp and were used to determine the Sn and Sp 
of the 24 hr-ABPM in detecting a fall of 20-mmHg SBP and 10-mmHg DBP (according to a 
standard of OH diagnostic criteria). These were done alongside the calculation of the area 
under the curve (AUC). 
The AUC is an overall summary of the diagnostic performance of the test. The 
perfect discrimination for AUC is 1, which means the diagnostic test can perfectly 
differentiate between two conditions with both Sn and Sp equalling 100%. The AUC of 0.9 or 
higher represents an outstanding discrimination. A value of AUC of 0.8-0.9 shows an 
excellent discrimination; a value of 0.7-0.8, an acceptable discrimination. An AUC of 0.5 or 
less indicates that the diagnostic accuracy is questionable and not different from random 
chance.  The AUCs can be used to compare the diagnostic performance of the test; the 
higher value of the AUC shows better performance than the lower value. Statistical analyses 
were carried out using STATA 11.0 (STATA Corporation, College station, Texas, USA). All 
tests were 2-sided and a p value of <0.05 was considered significant. 
 
4.1.4.3 Results 
Demographic data 
74 patients (23 MSA, 18 PD+AF, 33 PD) were included in the analyses. Patients with 
PD+AF were significantly older than PD and MSA (both p<0.01) but there was no difference 
in age between MSA and PD (p=0.55). There was no difference in disease duration among 
groups (p=0.23). Dopaminergic treatment was more commonly used in patients with PD and 
PD+AF compared to those with MSA (MSA vs. PD+AF; p=0.01 and MSA vs. PD; p<0.01). 
There was no difference in the number of patients on dopaminergic medication among PD 
and PD+AF (p=0.53, Table 4.15).    
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Table 4.15. Patient demographic data  
Variable MSA PD+AF PD 
Number 23 18 33 
% Male 48 44 67 
Age at testing                 
Mean (SD), yrs 
62+9 72+7*$ 64+10 
Disease duration        
Median (IQR), yrs 
4 (3-6) 7 (4-10) 6 (2-10) 
% Dopaminergic treatment 39*# 78 85 
Values are mean+SD unless stated, * p<0.05 vs. PD, # p<0.05 vs. PD+AF, $p<0.05 vs. 
MSA 
 
Cardiovascular responses to HUT  
 Supine SBP and DBP were not significantly different between MSA, PD+AF, PD 
patients but there was a higher baseline HR in MSA patients. During head-up tilting (HUT), 
SBP was significantly lower in patients with MSA and PD+AF compared to PD (p<0.01). 
Correspondingly, BP changes during HUT were significantly higher in MSA and PD+AF 
when comparing with PD. There were no difference in SBP and DBP during HUT between 
MSA and PD+AF (p=0.35 and p=0.9, respectively) but HR was significantly higher in MSA 
during HUT (Table 4.16). During HUT, all patients with MSA and PD+AF fulfilled the criteria 
of OH, whereas none of the PD patients had OH during HUT.   
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Table 4.16. Blood pressure and HR during supine, head-up tilting and orthostatic 
changes in MSA, PD+AF and PD patients 
Variable MSA (n=17) PD+AF (n=11) PD (n=16) 
HUT    
  Supine SBP 137+18 140+21 130+14 
  Supine DBP 81+11 75+15 75+10 
  Supine HR 77+9 69+4$ 69+10$ 
  Tilt SBP 95+19* 101+24* 126+16 
  Tilt DBP  60+13* 63+17* 76+10 
  Tilt HR 85+13 77+6$ 76+11$ 
  Orthostatic ∆SBP  -42+17* -39+17* -5+8 
  Orthostatic ∆DBP -20+12* -12+10* 0+5 
  Orthostatic ∆HR 8+6 8+5 7+5 
Values are mean+SD unless stated, *p<0.05 vs. PD, $p<0.05 vs. MSA 
 
24 hour-Ambulatory BP Monitoring data 
 MSA patients had significantly lower daytime SBP and DBP compared to PD patients 
(both p<0.01), whereas there was no difference between PD+AF and PD patients (p=0.34), 
as well as between MSA and PD+AF (p=0.17). Daytime average HR was not different 
among patient groups (p=0.28). During nighttime, there was a significantly higher SBP in 
PD+AF patients compared to PD (p=0.01), but no difference between MSA and PD (p=0.17) 
or MSA and PD+AF (p=0.11). Nighttime HR in MSA was greater than PD (p=0.03) but there 
was no difference between PD and PD+AF (p=0.06). The average SBP, DBP and HR in the 
24-hour period were not different among groups (p>0.05). There were no differences in the 
number of patients with daytime and nighttime hypertension among groups (p>0.05).  
   The percentage nocturnal blood pressure falls in SBP and DBP were significantly 
lower in MSA compared to PD (both p<0.01) but there was no difference between MSA and 
PD+AF (SBP; p=0.71 and DBP; p=0.55). The percentage of nocturnal HR fall was not 
different among patient groups (p=0.06). Correspondingly, MSA and PD+AF had a higher 
proportion of patients with abnormal BP circadian rhythms (both absent and reversed BP 
circadian rhythms; non-dippers) than patients with PD (p<0.01 and p=0.04, respectively) but 
not between MSA and PD+AF (p=0.08). Patients with reversed BP circadian rhythms were 
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significantly more common in MSA and PD+AF compared to those with PD (both p<0.01) but 
not between MSA and PD+AF (p=0.14). There was also no difference in the number of 
patients with an absent BP circadian rhythm among groups (p>0.05). 
Table 4.17. 24 hr-ABPM profiles in MSA, PD and PD+AF 
Variable MSA (n=23) PD+AF (n=18) PD (n=33) 
Daytime 
- Mean SBP 
- Mean DBP 
- Mean HR 
 
116+12* 
71+7* 
81+9 
 
122+13 
73+12 
75+7 
 
127+12 
77+9 
79+10 
Patients with daytime 
hypertension, % (n) 4% (1/23) 6% (1/18) 18% (6/33) 
Nighttime 
- Mean SBP 
- Mean DBP 
- Mean HR 
 
119+12 
70+9 
72+11* 
 
127+16* 
72+13 
65+8 
 
115+12 
67+9 
66+8 
Patients with nighttime 
hypertension, % (n) 30% (7/23) 50% (9/18) 24% (8/33) 
24-hour values 
- Mean SBP  
- Mean DBP 
- Mean HR 
 
117+11 
71+6 
80+9 
 
123+13 
72+11 
73+7 
 
125+11 
76+9 
76+9 
Patients with abnormal BP 
circadian rhythm, % (n) 96% (22/23)* 78%(14/18)* 48% (16/33) 
Patients with absent BP 
circadian rhythm, % (n) 39% (9/23) 22%(4/18) 33% (11/33) 
Patients with reversed BP 
circadian rhythm, % (n) 57% (13/23)* 56%(10/18)* 15% (5/33) 
Nocturnal BP/HR Fall 
- Mean SBP (%) 
- Mean DBP (%) 
- Mean HR (%) 
 
2.8 +9.0* 
-1.6 +10.8* 
-11.1+9.9 
 
4.3 +14.7* 
-0.1 +20.7* 
-12.7+5.7 
 
-9.1 +8.9 
-12.9 +11.0 
-16.1+7.3 
Values are mean+SD unless stated, * p<0.05 vs. PD, # p<0.05 vs. PD+AF, $p<0.05 vs. MSA 
 
24-hr SBP variability was significantly higher in MSA and PD+AF patients compared 
to PD (both p<0.01) but there was no difference in 24-hr DBP variability between MSA and 
PD+AF (p=0.32). There was a significantly lower daytime DBP variability in PD+AF 
compared to PD.  MSA patients had significantly lower 24-hr HR variability compared to PD 
(p<0.01). SBP, DBP and HR variability during nighttime were not different among groups 
(p>0.05; Table 4.17).  
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Table 4.18. 24 hr-ABPM BP and HR variability in MSA, PD and PD+AF 
Variable MSA (n=23) PD+AF (n=18) PD (n=33) 
BP variability 
- SBP daytime 
- DBP daytime 
- HR daytime 
 
- SBP nighttime 
- DBP nighttime 
- HR nighttime 
 
- SBP 24-hr 
- DBP 24-hr 
- HR 24-hr 
 
15.6+5.2* 
10.0+2.9 
6.7+2.7* 
 
11.2+6.4 
7.9+3.6 
4.4+2.2 
 
15.5+4.5* 
10.2+2.3 
7.5+2.8* 
 
16.8+4.9* 
10.8+2.8* 
7.8+2.9 
 
12.8+5.3 
7.8+3.1 
5.5+2.7 
 
17.2+4.5 * 
11.2+2.7 
8.4+2.6 
 
11.6+4.4 
8.9+2.6 
9.3+3.2 
 
9.5+4.1 
7.3+3.0 
4.8+2.4 
 
13.1+4.6 
9.9+3.0 
10.2+2.9 
Values are mean+SD, * p<0.05 vs. PD, # p<0.05 vs. PD+AF, $p<0.05 vs. MSA 
SBP=Systolic Blood Pressure, DBP=Diastolic Blood Pressure; values in mmHg, Heart 
Rate=HR; value in bpm. 
NBPF=Nocturnal blood pressure fall 
 
24 hr-ABPM and patient-report diary  
Out of 74, 44 (59%) patients completed the diary during the 24 hr-ABPM monitoring. 
There was no difference in the number of patients who completed the diary among groups; 
17(74%) MSA, 11(61%) PD+AF and 16 (48%) PD patients. For the purpose of the sensitivity 
and specificity analyses of 24 hr-ABPM in detecting OH, patients were divided into those 
with and those without OH according to the BP responses during HUT. MSA and PD+AF 
patients were combined as a single group (OH+ group) and PD patients were a control 
group (OH-). The average supine SBP was significantly higher in patients with OH (OH+), 
but the mean DBP and HR were not different compared to patients without OH (OH-). During 
head-up tilting (HUT), Tilt SBP was significantly lower in OH+ compared to OH- (p<0.01). By 
definition, the degree of SBP and DBP changes during HUT were significantly higher in OH+ 
when comparing with OH- (p<0.01).  
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Cardiovascular responses to HUT and standing test using ABPM 
With 24 hr-ABPM, supine SBP, DBP and HR were not different between OH+ and 
OH- but the average SBP and DBP was significantly lower in OH+ during the standing test 
compared to OH-. The degree of orthostatic changes (both SBP and DBP) were also 
significantly different between OH+ and OH- (p<0.05) but not for HR (Table 4.18). 
Table 4.19. Blood pressure and HR during supine, head-up tilting and orthostatic 
changes in patients without OH (PD) compared with patients with OH (MSA and 
PD+AF) 
Variable 
Patients with OH 
(MSA and PD+AF) 
Patients without OH 
(PD) 
Number of patients 28 16 
HUT   
  Supine SBP  138+16£ 127+13 
  Supine DBP 79+11 74+9 
  Supine HR 73+8 70+7 
  Tilt SBP  100+19£ 125+17 
  Tilt DBP 63+13£ 75+8 
  Tilt HR 81+12 78+9 
  ∆SBP  -38+15£ -3+9 
  ∆DBP -16+11£ 1+5 
  ∆HR 8+6 8+4 
Standing test  
   Supine SBP 
   Supine DBP 
   Supine HR 
   Stand SBP 
   Stand DBP 
   Stand HR 
   ∆SBP  
   ∆DBP  
   ∆HR 
 
128+16 
75+13 
74+11 
99+14£ 
62+11£ 
84+12 
-29+19£ 
-13+13£ 
10+7 
 
128+18 
74+11 
74+10 
122+16 
78+12 
81+11 
-6+6 
4+6 
7+5 
Values are mean+SD, £ p<0.01 vs. patients without OH, ϕp<0.01 vs. corresponding Supine 
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ROC analysis for detecting OH comparing HUT and standing tests using ABPM with 
autonomic protocol diary. 
Using 24 hr-ABPM, the area under the curve (AUC) that distinguishes OH+ from OH- 
was 0.87 (95% CI, 0.75-0.99). A fall of 20 mmHg or more in SBP showed a sensitivity and 
specificity of 82% and 100% (AUC 0.91, 95% CI 0.84-0.98) in differentiating OH+ from OH-, 
respectively. A DBP fall of 10 mmHg or more had a 57% sensitivity and a 94% specificity to 
discriminate OH+ from OH- with an AUC of 0.75 (0.64-0.87; Table 4.19). A 20 mmHg 
systolic BP fall criteria had a significantly higher efficacy in detecting OH compared to a 10-
mmHg DBP fall using the 24 hr-ABPM with the autonomic protocol diary (p<0.01). 
Table 4.20. Sensitivity analysis for 24 hr-ABPM in detecting orthostatic hypotension 
(OH)  
 
 
Sensitivity (%) 
 
Specificity (%) 
 
AUC 
(95% CI) 
BP 
- SBP fall > 20 mmHg 
- DBP fall > 10 mmHg 
 
 
 
82 
57 
 
 
100 
94 
 
 
0.91 (0.84-0.98) 
0.75 (0.64-0.87) 
 
 
4.1.4.4 Discussion 
 
The aim of this study was to 1) examine 24 hr-ABPM in patients with chronic 
autonomic failure (MSA+AF, PD+AF and PD) and 2) determine the effectiveness of 24 hr- 
ABPM compared to standard orthostatic challenge testing (10 minute Head-up Tilt) in 
diagnosing orthostatic hypotension (OH) in these patients. The main findings in this study 
were that an abnormal circadian BP rhythm (either a blunted nocturnal fall of BP or a 
reversed nocturnal fall) occurred in about half of the patients with PD. This proportion was 
higher in PD+AF and in patients with MSA. In comparison to a recent study (Schmidt et al., 
2009a), the prevalence of an abnormal circadian BP rhythm in PD in the present study was 
similar whereas the prevalence of an abnormal circadian BP rhythm in MSA patients in the 
present study was higher (68% vs. 96%, respectively). These inconsistent MSA results may 
be explained by the fact that this study categorized patients with regards to a patient’s 
diagnosis and their autonomic function, whereas the previous study used only a diagnostic 
category (e.g., MSA patients without autonomic failure were included). Furthermore, a 
reversed nocturnal circadian BP pattern was more common in autonomic failure patients, 
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presenting in more than 50% of MSA and PD+AF patients compared to only 15% in PD 
patients. These findings suggest that even though a blunted nocturnal fall in 24-hr BP 
profiles can often be seen among PD patients without autonomic failure, a reversed 
nocturnal circadian BP pattern is much more common in patients with autonomic failure 
(PD+AF and MSA). Daytime SBP variability was also higher in patients with autonomic 
failure, which could be due to greater fluctuations in BP in MSA and PD+AF during daily 
activities compared to patients without autonomic failure, and supports the idea that this 
value could also be an additional useful measurement in 24 hr-ABPM in patients with 
suspected autonomic failure and/or orthostatic hypotension.  
The 24-hr BP profiles in patients with MSA and PD+AF were relatively similar as 
indicated by no differences in the number of patients with a blunted nocturnal BP fall, a 
reversed nocturnal circadian BP pattern and the daytime BP variability. These results 
suggest that 24 hr-ABPM patterns cannot be used to discriminate between MSA and 
PD+AF.  
Human circadian rhythms are controlled by the suprachiasmatic nucleus (SCN) in the 
hypothalamus (Hastings & Maywood, 2000). The SCN projects afferent input to the 
paraventricular nucleus (PVN), which plays an important role in controlling various 
autonomic functions, such as stress and metabolism (Ferguson et al., 2008). Both sleep and 
physical activity have a large influence on BP and HR circadian changes, including the 
normal physiological blood pressure fall during sleep (Fabbian et al., 2013). Although the 
cause of abnormal circadian BP rhythms in PD and MSA remains unclear, the involvement 
of SCN and PVN are likely to play an important contributing role (Buijs et al., 1998). The 
abnormal circadian BP rhythms in MSA is supported by prior pathological studies showing 
pathological changes within both the paraventricular nucleus (Benarroch et al., 2006a) and 
the suprachiasmatic nucleus (Ozawa et al., 1998) in MSA. In contrast to MSA, the neuronal 
loss and pathological involvement in these structures have never been reported in PD and 
PD+AF. Nevertheless, sleep dysfunction is common in both patients with PD and MSA. The 
major cause of this problem includes REM (Rapid Eye Movement) sleep behavior disorder 
(RBD), obstructive sleep apnea (OSA) and excessive daytime somnolence (EDS). These 
features may partly explain the reason why abnormal circadian BP profiles frequently occur 
in both disorders. Although abnormal circadian BP rhythms are common in PD, PD+AF and 
MSA, it is important to note that the number of patients with a reversed circadian BP profile 
at night was significantly higher in PD+AF and MSA compared to PD (without AF). This 
finding suggests that autonomic dysfunction plays an important contributing role in the 
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control of circadian BP rhythms. Supine hypertension is a common feature in patients with 
autonomic failure (Shannon et al., 1997) and is also associated with OH (e.g., the severity of 
autonomic failure) (Goldstein et al., 2003b). It is thus very likely that supine hypertension 
contributed to the reversed circadian BP pattern in MSA and PD+AF patients in the present 
study. The cause of supine hypertension in MSA has been suggested to result from an 
inappropriate residual sympathetic tone (Shannon et al., 2000). These findings also 
emphasizes that the reversed circadian BP pattern from 24 hr-ABPM is a shared 
phenomenon in both patients with autonomic failure from both pre- (MSA) and post-
ganglionic (PD) lesions, rather than a disease-specific feature. 
The present study also showed that using an autonomic protocol diary alongside 24 
hr-ABPM is useful for helping diagnose patients with OH. Using the standard criteria of OH, 
this technique provides a reasonably high sensitivity (82%) and specificity (100%) to 
distinguish OH+ from OH- patients with parkinsonism. Nevertheless, a 20-mmHg fall of SBP 
has a significantly better efficacy in detecting OH from 24 hr-ABPM when compared with a 
10-mmHg fall of DBP. To date, there has been no study that has used a diary with 24 hr- 
ABPM to investigate patients with OH. Given that these are non-invasive, relatively simple 
tests to perform without a requirement of an autonomic laboratory, this technique should be 
included as part of autonomic investigations in suspected OH workups. An adjunct diary to 
24 Hr BP monitoring can also provide additional information with regards to the effect of 
patient activities on BP and HR and their relation to symptoms. Such an approach would 
allow the clinician/scientist to make a connection between activities and BP/HR during 
events if symptoms develop (Stuebner et al., 2013).  24 hr-ABPM can also be used to 
monitor BP and HR in patients with OH/autonomic failure after starting anti-hypotensive 
medications. 
In conclusion, this study demonstrated that patients with PD+AF and MSA, who had 
a similar degree of orthostatic hypotension during HUT, generally have similar circadian BP 
and HR patterns as revealed by 24 hr-ABPM. As abnormal circadian rhythms are similarly 
present in both PD+AF and MSA, this suggests that the proportion of abnormal BP circadian 
patterns (both absent and reversed BP circadian rhythm) in 24 hr-ABPM depends on the 
autonomic function rather than the diagnosis. Moreover, this study also, for the first time 
demonstrated that 24 hr-ABPM can offer more information regarding OH in patients with 
autonomic failure if a patient-completed autonomic protocol diary containing postural 
challenges (standing) are used. This approach has reasonably high sensitivity and specificity 
in detecting OH.  
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5. Olfactory function, non-motor aspects and quality of life in primary chronic 
autonomic failure 
5.1 Olfactory function in primary chronic autonomic failure 
5.1.1 Introduction  
Abnormal sense of smell is a well-known and very common feature in patients with 
PD. The prevalence of olfactory impairment ranges from 80-100% depending on the study 
population (Doty et al., 1995; Hawkes et al., 1997). Smell identification is the most widely 
used method to assess olfaction because it is more feasible and the easiest way to assess 
subjects both in clinical and research settings. Sniffin’ Sticks is a smell identification test 
which was originally developed and has been widely used in Europe (Hummel et al., 1997). 
Previous studies demonstrated that the 16-item smell identification test has been useful as a 
screening tool for detecting abnormal olfaction in healthy subjects (Hummel et al., 1997) and 
is a good non-invasive instrument for distinguishing PD patients from control subjects 
(Ansari & Johnson, 1975; Muller et al., 2002).  
Post-ganglionic autonomic dysfunction is evident in PD as reductions of cardiac 
MIBG uptake are common, even in the early stages of PD (Spiegel et al., 2005). The 
frequent olfactory and cardiovascular autonomic dysfunction in PD are in accordance with 
the Braak and Braak hypothesis, which proposed the involvement of the dorsal motor 
nucleus of the vagus nerve and olfactory structures at the first stage of the pathological 
progression of PD (Braak et al., 2003). Few studies have reported the relationship between 
the degree of impaired olfaction and the decline in cardiac MIBG reuptake in PD patients 
however (Lee et al., 2006). Impaired sense of smell was reported to be more severe in PD 
with autonomic failure (PD+AF) compared to PD patients without autonomic dysfunction 
(Goldstein et al., 2010). These findings suggest that the impairment of olfactory dysfunction 
could occur in parallel to the cardiovascular autonomic dysfunction in PD but this has not 
been thoroughly investigated.   
In contrast to PD, little is known about olfactory function in MSA and PAF, 
neurodegenerative disorders that have overlapping features with PD. Previous studies 
suggested that patients with MSA may have a mild sense of smell impairment compared to 
PD while olfactory dysfunction seems to be impaired among patients with PAF (Silveira-
Moriyama et al., 2009b). Nevertheless, these smell studies in PAF and MSA were conducted 
with only a limited number of patients (MSA; n=14 and PAF; n=16) (Silveira-Moriyama et al., 
2009b). In addition, there was only one study that specifically investigated olfactory function 
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in patients with autonomic failure (Garland et al., 2011). The results showed that PAF had 
abnormal olfaction; whereas olfactory function in MSA was intact. The finding of intact 
olfactory function in MSA was inconsistent with some previous reports which found a mild 
degree of impaired olfaction in patients with MSA (Wenning et al., 1995; Silveira-Moriyama 
et al., 2009b). These different findings could be due to other differences in the MSA patients 
between studies, such as disease severity, disease duration or clinical presentation. This 
has not been documented previously and warrants further investigation of whether there are 
other factors that could explain these inconsistent findings in MSA patients. Furthermore, 
olfactory function and its associations with indices of autonomic function have also not been 
explored in PAF and MSA.  
It is still debatable whether there is a progression of impaired olfaction with disease 
duration and severity in PD and it is unknown if there are alterations in olfactory function with 
disease severity in MSA or PAF. The few previous studies that have been performed 
suggested that there was no significant deterioration of smell deficit in PD patients (Doty et 
al., 1988; Double et al., 2003; Kim et al., 2007) while only 1 study showed that olfactory 
dysfunction increased with the severity of PD (Tissingh et al., 2001). In support of the former 
findings, there was no correlation between striatal dopaminergic terminal loss in functional 
brain imaging and olfactory dysfunction in PD (Siderowf et al., 2005; Goldstein et al., 2008).  
The aim of this study was to therefore simultaneously investigate olfactory function 
and a range of other possible associated factors (such as age, disease duration, disease 
severity) in patients with MSA, PAF and PD. The sensitivity and specificity of olfactory 
function in differentiating between chronic autonomic disorders were also examined. 
 
5.1.2 Methods 
Participants 
Patients with a confirmed diagnosis of Parkinson’s disease with (PD+AF) and without 
autonomic failure (PD), Probable Multiple System Atrophy (MSA) with orthostatic 
hypotension and Pure Autonomic Failure (PAF) and healthy controls were included (Chapter 
3). Patients were tested on-medication. Patients and controls had no history of severe head 
injury (with loss of consciousness), dementia, nasal or sinus surgery or recent history of 
upper respiratory tract infection. All participants also were evaluated with the mini-mental 
status examination (MMSE) and had scores greater than 25 out of 30. Clinical history and 
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relevant information of all patients and participants were recorded. For example, age, gender 
and duration of disease (time from first symptom to testing date). 
Smell identification tests 
Olfactory function was assessed with the Smell identification Test using Sniffin’ 
Sticks (SS-16), which involves the smelling of 16 felt tip pens that are each scented with 
different smells. Patients were asked to sniff the tip of each pen for 30 seconds. The 
participant then identified 1 of 4 choices which best described the presented odour. Olfactory 
function was assessed as a score ranging from 0-16 (min-max). 
Clinical Features 
The Unified Multiple System Atrophy Rating Scale (UMSARS) was used to assess 
the severity of different clinical features in the MSA patients, including part 1 (activities of 
daily living-ADL), part 2 (Motor function) and part 4 (global disability scale). There are in total 
26 questions in part 1 and part 2, with each question containing a 5-point scale from 0 (no 
symptom) to 4 (severe). UMSARS part 3 included measuring BP and HR before and after a 
2-minute standing test. This section was not included in the UMSARS analysis in this study 
because of the overlap with cardiovascular autonomic function testing which was conducted 
(see chapters 4.1 and 4.2). UMSARS part 4 was used to measure the global disability scale 
ranging from 1 (completely independent) to 5 (totally dependent or bedridden).  
 
The Unified Parkinson’s Disease Rating Scale (UPDRS) was used to assess different 
symptoms and the ability to perform specific tasks in PD patients. The UPDRS score consists 
of 4 main parts: part I (Mentation, behavior and mood), part II (Activities of daily living-ADL), 
part III (Motor examination) and part IV (Complications of therapy). There are 44 questions in 
all 4 parts and each question contains a 5-point scale from 0 (no symptoms) to 4 (severe 
symptoms). 
 
Hoehn and Yahr Staging (HY) was used to rate the degree of functional ability in PD 
patients. The score ranges from 1 (mild) to 5 (severe). The same investigator conducted all 
of these assessments in all patients. 
 
Statistical Analyses 
Data are presented as mean (± 1 SD) or median (inter-quartile range), where 
appropriate. Analysis of covariance (ANCOVA) or the Kruskal-Wallis test was used to 
compare the 4 groups where appropriate. If there was a significant difference, Mann-Whitney 
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U tests were used to compare between 2 groups for non-normally distributed data and 
unpaired t-tests for normally distributed data with Bonferroni corrections.  
Chi-square analyses were used for analysis of categorical variables. The 
relationships between SS16 scores and other factors, including, age, disease duration, 
gender, UPDRS part III scores, were assessed by regression analysis. ROC (received 
operational curve) analysis was used to determine the sensitivity (Sn) and specificity (Sp) of 
different cut-off points for assessing the performance of a diagnostic test. In general, the 
optimal cut-off point would be both Sn and Sp that as close to 100% as possible. 
Nonetheless, it is less likely to happen as the Sn tend to vary inversely with Sp (Sn 
increases as Sp decreases, or vice versa). In this study, ROC curves plot Sn against 1-Sp 
and will evaluate the Sn and Sp of the SS-16 scores at different cut-off points in 
differentiating between disorders alongside the area under the curve data (AUCs). The AUC 
is an overall summary of the diagnostic performance of the test. The perfect discrimination 
for AUC is 1, which means the diagnostic test can perfectly differentiate between two 
conditions with both Sn and Sp equalling 100%. The AUC of 0.9 or higher represents an 
outstanding discrimination. A value of AUC of 0.8-0.9 shows an excellent discrimination; a 
value of 0.7-0.8, an acceptable discrimination. An AUC of 0.5 or less indicates that the 
diagnostic accuracy is questionable and not different from random chance. Statistical 
analyses were carried out using STATA 11.0 (STATA Corporation, College station, Texas, 
USA). All tests were 2-sided and a p value of <0.05 was considered significant. 
 
5.1.3 Results 
Demographics 
72 patients (32 PD, 19 MSA, 21 PAF) and 20 controls were included in the analyses 
(see Table 5.1). Patients with PD and PAF were significantly older than controls (p<0.01) but 
there was no difference between MSA and controls (p=0.09). Comparing between patient 
groups, PAF patients were significantly older than MSA and PD (both p<0.01). PAF had a 
significantly longer disease duration compared to MSA (p=0.022) but no difference when 
compared with PD patients (p=0.41) who had a similar duration to MSA (p=0.09). Hoehn & 
Yahr scores were significantly higher in patients with MSA compared to PD (p=<0.01).  
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Table 5.1. Participant demographic data. 
Variable PD (n=32) MSA(n=19) PAF(n=21) Control 
(n=20) 
p-value 
Age (yr) 65 + 8* # 61 + 7 71 + 7* 56 + 9 <0.01 
Gender (M/F) 22/10 9/10 11/10 6/14 0.06 
Disease 
duration 
(Median (IQR)), 
yrs 
7 (1-18) 4 (2-11) $ 7 (1-26) - 0.06 
% Never 
smoked 
29 19 21 31 0.11 
Hoehn & Yahr 1.7 + 0.6 3.3 + 0.9 - - <0.01 
Motor scores; 
(UPDRS part III 
and UMSARS II) 
14.4 + 6.4 22.8 + 7.0 - - - 
Values are mean+SD, if not specified, UPDRS=Unified Parkinson’s Disease Rating Scale, 
UMSARS=Unified Multiple System Atrophy Rating Scale 
*p<0.01 vs. Control, #p=0.05 vs. PAF, $p<0.05 vs. PAF 
 
Olfactory Function 
SS-16 scores were significantly lower in all patient groups compared to controls 
(p<0.01; mean SS-16 scores; MSA=13.2; PD=7.6; PAF=8.4 and Controls=14.1, 
respectively) and this difference was still significant after adjusting for age, gender and 
disease duration (p<0.01; Figure 5.1). MSA patients had higher SS-16 scores compared to 
PAF (p<0.01) and PD (p<0.01). These differences remained significant after controlling for 
age, gender and disease duration (p<0.01). There was no difference in SS-16 scores 
between PD and PAF (p=0.34). 
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In a sub-group analysis of MSA sub-types, there was no difference in age, disease 
duration, history of smoking or UMSARS scores between MSA-C (n=11) and MSA-P (n=8). 
There was no difference in SS-16 scores between sub-types of MSA (p=0.90). 
 
Figure 5.1. SS-16 scores in PD, MSA, PAF and controls 
In patients with PD there was no association between olfactory function and age or 
disease duration (both p>0.05). SS-16 scores were significantly correlated with gender 
(p<0.01), history of smoking (p=0.03) and motor severity as assessed by the UPDRS part III 
(p<0.01) in the univariate analysis. There was a significant negative correlation between SS-
16 scores and UPDRS part III in the multiple regression analysis after adjusting for gender 
and smoking history (R2=0.44, p<0.01; Figure 5.2 and Table 5.2). Although, the number of 
participants was limited, there was no difference in SS-16 scores in PD patients with and 
without autonomic failure. 
In MSA patients, SS-16 scores were only significantly associated with motor severity 
(UMSARS part II score) after controlling for age in the multiple regression analysis (R2=0.36, 
p=0.039; Table 5.3). In contrast, SS-16 scores were not associated with age, gender, 
disease duration and smoking in patients with PAF (p>0.05). 
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Table 5.2. Multiple regression analysis of the correlation between SS-16 and UPDRS 
motor (part III) scores adjusted for gender and smoking in PDs 
Variable Parameter estimate Standard error P-value 
UPDRS III score -0.24 0.07 <0.01 
Smoking 2.22 1.07 0.047 
Gender 0.33 1.23 0.79 
 
 
Figure 5.2. Scatterplot showing the correlation between SS-16 scores (Y axis) and 
UPDRS III scores (X axis; r=-0.51, p=<0.01) in patients with PD.  
Table 5.3. Multiple regression analysis of the correlation between SS-16 and UMSARS 
motor (part II) scores adjusted for age in MSA. 
Variable Parameter estimate Standard error P-value 
UMSARS II score -0.06 0.03 0.039 
Age 0.06 0.03 0.07 
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Using the SS-16 scores, the area under the curve (AUC) that distinguishes MSA from 
PD and PAF from PD were similar at 0.97 (95% CI, 0.93-1.00; Figure 5.3). An SS-16 score 
of 11 and lower showed a sensitivity and specificity of 97.4% and 81.3% (AUC 0.88, 95% CI 
0.79-0.97) in differentiating PD from MSA, respectively. An SS-16 score of 11 or less had a 
97.4% sensitivity and a 90.5% specificity to discriminate MSA from PAF with an AUC of 0.93 
(0.84-1.00; Figure 5.3, Table 5.4). 
 
 
Figure 5.3. ROC curves showing the relationship between sensitivity and specificity 
for SS-16 scores in PD vs. MSA (A; upper) and PAF vs. MSA (B; lower). 
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Table 5.4. Sensitivity analysis for different cut-off points in SS-16 scores for chronic 
autonomic disorders.  
  
Sensitivity (%) 
 
 
Specificity (%) 
 
 
AUC 
(95% CI) 
PD vs. MSA 
- SS-16 score < 11 
- SS-16 score < 12 
 
94.74 
84.21 
 
81.25 
96.88 
 
0.88 (0.79-0.97) 
0.91 (0.82-1.00) 
MSA vs. PAF 
- SS-16 score < 11 
- SS-16 score < 12 
 
94.74 
84.21 
 
90.48 
95.24 
 
0.93 (0.84-1.00) 
0.90 (0.80-0.99) 
 
 
5.1.4. Discussion 
 
The aim of this study was to therefore simultaneously investigate olfactory function 
and a range of other possible associated factors (such as age, disease duration, disease 
severity) in patients with MSA, PAF and PD. The sensitivity and specificity of olfactory 
function in differentiating between chronic autonomic disorders were also examined. The 
main findings were that olfactory function was impaired in PD, PAF and MSA patients 
compared to controls. Sense of smell in MSA patients was better than PD and PAF but there 
was no difference in the degree of impaired olfaction in PD and PAF patients. Furthermore, 
SS-16 scores were significantly correlated with motor dysfunction scores (UPDRS III score) 
in PD patients after controlling for gender and history of smoking, and with motor dysfunction 
scores (UMSARS II score) in MSA after controlling for age.  
In the present study, patients with MSA had mild olfactory impairment indicated by a 
lower score of SS-16 compared to healthy controls. A pathological study has reported glial 
cytoplasmic inclusions in the olfactory bulb in MSA (Kovacs et al., 2003) that could 
contribute to the mild impaired sense of smell in MSA. This finding was also in line with prior 
studies (Wenning et al., 1995; Abele et al., 2003; Silveira-Moriyama et al., 2009b). 
Nonetheless, a few studies have reported preserved olfactory function in patients with MSA 
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(Garland et al., 2011; Glass et al., 2012). These differences could be due to a small sample 
size in the latter studies (N=10, N=4, respectively). 
The results of the present study confirm previous findings that patients with PD have 
marked impairment of olfactory function similar to patients with PAF (Goldstein & Sewell, 
2009; Garland et al., 2011). Nevertheless, another prior study reported a milder deficit of 
olfactory function in PAF compared to PD (Silveira-Moriyama et al., 2009b). The reason for 
this difference in findings is unclear but may be partly explained by different etiologies 
between PAF patients in these studies. Many patients can initially present with symptoms 
similar to patients with PAF and eventually develop additional clinical features of other 
diagnoses, such as MSA or DLB after years of follow-up (Larner et al., 2000; Iodice et al., 
2012). Another possible explanation is the difference in age. Our patients with PAF were 
older than those in the previous study (Silveira-Moriyama et al., 2009b), which could 
potentially lower the scores of the olfactory identification test. However, age was taken into 
account in the final model of multiple regression analysis in the present study. 
Olfactory dysfunction in PD may result from Lewy body deposition in the olfactory 
bulb as proposed by Braak et al (Braak et al., 2003). There has been no report of olfactory 
bulb pathology in PAF and the cause(s) of olfactory dysfunction in PAF patients remains 
unclear. No previous study has ever examined the pathology of olfactory and related 
structures in patients with PAF. In the present study, age, gender, smoking and disease 
duration were not correlated with olfactory dysfunction in PAF. A recent paper reported intact 
olfactory function in patients with dopamine β-hydroxylase deficiency, a rare genetic disorder 
characterized by a lack of the Dopamine β-hydroxylase (DBH) enzyme which is required for 
converting dopamine into noradrenaline. An intact olfaction in these patients suggests an 
impaired sense of smell is not dependent on impairments in the noradrenaline pathway 
(Garland et al., 2011). As other neurotransmitters, such as Acetylcholine, Dopamine and 
Serotonin, are also involved in the pathogenesis of olfactory dysfunction (Doty, 2012), it 
might be that olfactory dysfunction in PAF could result from abnormalities in the kinetics of 
any of these neurotransmitters and/or central pathology. Future research is needed to 
explore this hypothesis, which may provide useful information regarding the causes of 
impaired olfaction, particularly in comparison with patients with PD. 
There is only one study reporting a more severe olfactory dysfunction in PD patients 
with OH, compared with PD patients without OH (Goldstein et al., 2010). Unfortunately, the 
difference in olfactory function between PD with and without AF in the present study could 
not be formally examined because of the limited number of PD patients with AF (n=4).  
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The significant relationship between olfactory dysfunction and motor dysfunction 
severity in PD patients in the present study is consistent with a previous study from Tissingh 
et al. (Tissingh et al., 2001). The results of the current study also found no correlation 
between disease duration and olfactory dysfunction in PD in accordance with a previous 
study (Hawkes et al., 1997). However, some previous studies found no association between 
olfactory dysfunction and motor severity in PD (Doty et al., 1988). A recent study suggested 
that olfactory dysfunction may progress over time in the early stages of PD and then possibly 
plateau thereafter (Berendse et al., 2011). Therefore, all these findings support the 
hypothesis that impaired olfaction is still a possible useful marker to determine disease 
progression in patients with early stage PD as it could progress in parallel to nigrostriatal 
degeneration, particularly at the beginning of motor symptoms.  
There has been no study examining the association between olfactory function and 
motor dysfunction function in MSA. This study is the first to reveal a correlation between 
UMSARS II (motor) scores and olfactory function in MSA patients. The relationship between 
SS-16 and UMSARS motor scores suggest that olfactory involvement is correlated with 
motor severity in MSA. The glial cytoplasmic inclusions in the olfactory bulb (Kovacs et al., 
2003) that have been reported in MSA may be a part of the disease progression and 
represent a widespread involvement which would have not occurred yet in early MSA 
patients. Given the limited number of MSA patients in the present study, a larger sample size 
would be needed to confirm this finding.  
With regards to the efficacy of the SS-16 in distinguishing between chronic 
autonomic failure disorders, the SS-16 had a high sensitivity and specificity in differentiating 
between PD and MSA. This was consistent with a recent study (Suzuki et al., 2011). This 
study is the first to report the efficacy of SS-16 in differentiating between MSA and PAF 
using ROC analysis. Cut-off values of 11 and 12 were used which provided reasonably high 
sensitivity and specificity. Moreover, the results of the area under the curve (AUC) analyses 
using the same cut-off points also suggested that this test has almost similar values in 
helping differentiating the diagnosis between PD and MSA as well as between MSA and 
PAF. Given the fact that MSA can initially present with isolated autonomic failure resembling 
PAF, impaired olfaction from SS-16 would support the diagnosis of PAF rather than MSA.  
In conclusion, this study confirmed the similar degree of olfactory dysfunction in 
patients with PD and PAF and a mild impaired sense of smell in MSA. Motor severity scores 
(UPDRS part III) were strongly associated with olfactory dysfunction in PD. In MSA, there 
was evidence to suggest an association between UMSARS (motor) part II and olfactory 
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dysfunction. The findings from the ROC analysis also indicated that the SS-16 could also be 
a useful investigation for differentiating between these chronic autonomic failure disorders.  
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5.2 Non-motor aspects and quality of life in primary chronic autonomic failure 
5.2.1 Introduction 
Non-motor symptoms in PD patients have recently received much more attention and 
are now recognized as important features of parkinsonian syndromes. These non-motor 
symptoms can vary widely between patients, for example olfactory dysfunction, sleep 
disturbances, neuropsychiatric features and autonomic dysfunction can occur to various 
extremes and with various prevalences between patients (Chaudhuri et al., 2006a). A variety 
of autonomic symptoms, such as orthostatic hypotension (OH), constipation, bladder and 
sexual dysfunction, were consistently reported as important non-motor symptoms in PD 
(Chaudhuri et al., 2006a). Depression was also reported as a common symptom in PD 
(Karlsen et al., 1999) and it is also considered to be part of disease progression in patients 
with PD and can predate motor symptoms in PD (Nilsson et al., 2001; O'Sullivan et al., 
2008). Importantly, non-motor features can have a significant impact on quality of life in 
patients with PD (Schrag et al., 2000b). A number of non-motor symptom questionnaires 
have recently been developed to be used as tools to interrogate these symptoms (Visser et 
al., 2004; Chaudhuri et al., 2007), but only a few specifically examine autonomic symptoms. 
The Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms (SCOPA-AUT) 
has been developed since 2004 in order to detect a range of autonomic symptoms in PD 
(Visser et al., 2004). It has been validated and is one of the questionnaires recommended by 
The Movement Disorders Society as a tool for screening autonomic symptoms in PD (Pavy-
Le Traon et al., 2011).  
Data from population-based epidemiological studies confirmed that non-motor 
symptoms are common in other chronic autonomic failure syndromes, such as MSA and 
PAF, in addition to PD, but they are generally milder compared in those with atypical 
parkinsonian disorders, such as MSA or PSP, relative to PD (Colosimo et al., 2010). 
Nevertheless, there have been only a few studies directly examining non-motor symptoms, 
including autonomic symptoms, and quality of life in patients with MSA (Meissner et al., 
2012) and also no previous report of this aspect in PAF patients. Other non-motor aspects of 
autonomic disorders, such as depression, have also been investigated in isolation in PD, 
MSA and PAF patients but have not been compared between these disorders in the same 
study or related to other indices of autonomic function. 
The purpose of this study was to therefore further examine the relationship between 
quality of life and non-motor aspects in primary chronic autonomic failure disorders by 
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correlating quality of life scores in MSA, PD and PAF patients with a variety of factors, 
including, age, gender, disease duration, motor symptoms (in MSA and PD) and depression. 
The relationship between autonomic symptoms in PD using the SCOPA-AUT instrument and 
these factors were also investigated.  
 
5.2.2 Methods 
Participants 
Patients with a confirmed diagnosis of Parkinson’s disease with (PD+AF) and without 
autonomic failure (PD), Probable Multiple System Atrophy (MSA) with orthostatic 
hypotension and Pure Autonomic Failure (PAF) and healthy controls were included (Chapter 
3). Patients were tested on-medication. History and relevant information of all patients and 
participants were recorded. These included, age, gender and duration of disease (time from 
motor dysfunction/first symptom onset to testing date). 
Protocol 
A range of assessments of motor and non-motor symptoms were conducted as 
follows:  
Motor Function and Clinical Features 
 
The Unified Multiple System Atrophy Rating Scale (UMSARS) was used to assess the 
severity of different clinical features of MSA patients, including part 1 (activity daily living-
ADL), part 2 (Motor function) and part 4 (global disability scale). There are a total of 26 
questions in part 1 and part 2, with each question containing a 5-point scale from 0 (no 
symptoms) to 4 (severe symptoms). UMSARS part 3 was for measuring BP and HR before 
and after a 2-minute standing test. UMSARS part 4 was used to measure the global disability 
scale ranging from 1 (completely independent) to 5 (totally dependent or bedridden). This 
section was not included in the UMSARS analysis in this study because of the overlap with 
cardiovascular autonomic function testing which was conducted (see chapters 4.1 and 4.2). 
 
The Unified Parkinson’s Disease Rating Scale (UPDRS) was used to assess different 
symptoms and the ability to perform specific tasks in PD patients. The UPDRS consists of 4 
main parts: part I (Mentation, behavior and mood), part II (Activities of daily living-ADL), part 
III (Motor examination) and part IV (Complications of therapy). There are a total of 44 
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questions in all 4 parts, with each question containing a 5-point scale from 0 (no symptoms) 
to 4 (severe symptoms). 
 
Hoehn and Yahr Staging (HY) was used to rate the degree of functional ability in MSA and 
PD patients. The score ranges from 1 (mild) to 5 (severe). The same investigator conducted 
all these assessments in all patients. 
 
Non-motor Questionnaires 
 
The Hamilton Depression Rating Scale (HAM-D) was used to assess symptoms of 
depression and its severity in all groups. The scale consists of 17-item questions. A score 
between 0-7 is generally accepted as a normal range but a score of 20 or higher suggests 
depression.  
 
The Schwab and England Activities of Daily Living Scale (SE) was used by all patient groups 
to rate how much their condition affects their functional capability. The SE score ranges from 
100 (Completely independent) to 0 (bedridden). 
 
The SCOPA-AUT was used by all patient groups to rate their symptoms on different domains 
of autonomic function, including, cardiovascular, gastrointestinal (GI), urinary (GU), 
thermoregulatory, pupillomotor and sexual symptoms. The SCOPA-AUT ranges from 0 (no 
symptoms) to 100 (severe symptoms) in each domain. 
 
The Mini-Mental State Examination (MMSE) rating scale was used to rate all participants’ 
cognitive function. The MMSE score ranges from 0-30, with a lower score indicating greater 
impairment of cognitive function. Given that cognitive impairment is a confounder for the 
validity of quality of life questionnaires, all patients with an MMSE score of less than 24 were 
not included in the study. 
 
The same investigator conducted all these assessments in all patients. 
 
Quality of life  
 
Patient population specific scales were used to assess Quality of Life. 
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The 39 item Parkinson's Disease Questionnaire (PDQ-39) was used in PD patients, the MSA 
Health-Related Quality of Life (MSA-QoL) Scale in MSA patients and the 36 item Short Form 
Health Survey (SF-36) in PAF patients (see Chapter 3 for further details).  
 
Healthy control participants completed the Short Form Health Survey (SF-36), the Mini-
Mental State Examination (MMSE) and the Hamilton Depression Rating Scale (HAM-D). 
 
The same investigator conducted all these assessments in all patients. 
 
Statistical Analyses 
Data are presented as mean (± 1 SD) or median (IQR), where appropriate. Analysis 
of covariance (ANCOVA) was used for comparing 3 or 4 groups for normally distributed 
data, while the Kruskal-Wallis test was used if data were non-normally distributed. If there 
was a significant difference, Mann-Whitney U tests were then used to compare between 2 
groups for non-normally distributed data and unpaired t-tests for normally distributed data 
with Bonferroni corrections. Chi-square analyses were used for analysis of categorical 
variables. The relationships between PDQ-39 scores and other variables, including age, 
disease duration, gender, UPDRS part III scores, were assessed by Pearson’s correlation 
coefficients or Spearman’s Rank Correlations, where appropriate. Similar methods were also 
used to determine the relationship between MSA-QoL and other potential associated factors 
and the PAF SF-36 data and other potential associated factors. Statistical analyses were 
carried out using STATA 11.0 (STATA Corporation, College station, Texas, USA). All tests 
were 2-sided and a p value of <0.05 was considered significant. 
 
5.2.3 Results 
Demographics 
75 patients (32 PD, 23 MSA and 20 PAF) and 20 controls were included in the 
analyses. Patients with MSA were younger than PAF and PD patients (p<0.05) but there 
was no difference in age between MSA and controls (p=0.31). Patients with MSA had a 
shorter disease duration compared to PAF (p=0.01) and PD (p=0.05) but there was no 
difference between PD and PAF (p=0.36). Hoehn & Yahr (HY) scores were significantly 
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lower in PD when compared with MSA patients (p<0.01). Age, disease duration and gender 
were not different between MSA sub-groups (Table 5.5). 
Table 5.5. Participant demographic data 
 
Variable 
 
PD (n=32) 
 
MSA(n=23) 
 
PAF(n=21) 
 
Control (n=20) 
 
p-value 
Age, yrs 65 + 8 60 + 7#$ 70 + 7 56 + 9 <0.01 
Gender (M/F) 23/9 12/11 14/6 6/14 0.03 
Disease 
duration 
Median (IQR), 
yrs 
7 (4-10) 4 (3-7)#$ 8 (6-15) - 0.04 
Hoehn & Yahr 1.7+0.6 3.3 + 0.9# - - - 
Motor scores; 
UPDRS part III 
or UMSARS II 
14.4 + 6.3 22.8 + 7.4 - - - 
HAM-D  6.4 + 2.9* 11.4 + 5.5*#$ 7.4 + 3.2* 0.5 + 0.7 <0.01 
SE 86 + 12 57 + 27#$ 85 + 6 - <0.01 
*p<0.05 vs. Controls, #p<0.05 vs. PD, $p<0.05 vs. PAF  
Values are mean+SD unless stated, UPDRS=Unified Parkinson’s Disease Rating Scale, UMSARS=Unified 
Multiple System Atrophy Rating Scale, SE=Schwab and England Activities of Daily Living Scale, HAM-
D=Hamilton Depression Rating Scale 
 
Depression and Activities of Daily Living Scale 
Patients with chronic autonomic failure had significant higher depression scores 
compared to healthy controls (p<0.01). MSA patients had a significantly higher HAM-D score 
compared to those with PAF and PD (both p<0.01). The depression score in PAF was not 
different from PD (p=0.28). Schwab and England Activities of Daily Living Scale scores (SE) 
were significantly lower in patients MSA compared to PD and PAF (both p<0.01) but there 
was no difference between PD and PAF (p=0.15, Table 5.5).  
Parkinson's Disease Questionnaire (PDQ-39) and the Scale for Outcomes in Parkinson’s 
disease for Autonomic Symptoms (SCOPA-AUT)  
On the PDQ-39 the highest scores were reported in bodily discomfort domain, followed 
by the cognitive and mobility domains. On the other hand, social support and stigma were 
the two domains with the lowest scores. With regards to the SCOPA-AUT, sexual 
dysfunction and bladder symptoms were scored highest. Other data of the PDQ-39 and 
SCOPA-AUT, including sub-scores, are presented in Table 5.6. 
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Table 5.6. PDQ-39 and SCOPA-AUT, including subscores, responses in patients with 
PD 
Item Scores Mean + SD 
PDQ-39 
- PDQ-Summary Index (PDQ-SI) 
- Mobility 
- Activities of daily living (ADL) 
- Emotional wellbeing 
- Stigma 
- Social support 
- Cognitive 
- Communication 
- Bodily discomfort 
 
28.2 + 17.4 
30.1 + 26.2 
28.0 + 23.7 
26.6 + 20.7 
17.0 + 17.0 
16.5 + 23.3 
36.9 + 27.2 
29.6 + 21.0 
38.5 + 25.7 
SCOPA-AUT 
- Total 
- Gastrointestinal 
- Genitourinary 
- Cardiovascular 
- Thermoregulatory 
- Pupil 
- Sexual 
 
20.9 + 12.9 
21.1 + 12.4 
27.4 + 17.5 
8.7 + 10.0 
17.8 + 19.2 
17.4 + 26.3 
35.1 + 36.4 
Values are mean+SD 
 
Correlation Analyses of Quality of life and non-motor symptom scales in PD  
There was a strong significant correlation between the PDQ Summary Index score 
(PDQ-SI) and UPDRS part I and part II scores (r=0.61 and r=0.62, respectively, both 
p<0.01). HAM-D and SE scores were also significantly correlated with PDQ-SI (r=0.58 and 
r=-0.49, respectively, p<0.01). There was a trend of correlation between PDQ-SI and 
disease duration (r=0.34, p=0.08) and between PDQ-SI and Total SCOPA-AUT (r=0.36, 
p=0.08). In contrast, Total SCOPA-AUT was significantly correlated with disease duration 
(r=0.66, p<0.01), UPDRS part II (r=0.52, p<0.05), HAM-D scores (r=0.51, p<0.05) and 
gender (r=0.46, p<0.05; Table 5.7).  
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Table 5.7. Spearman’s Rank correlations between PDQ-39 Summary Index (PDQ-SI), 
SCOPA-AUT and age, gender, disease duration, UPDRS and HY scores, HAM-D and 
SE in patients with PD. 
 PDQ-SI SCOPA-AUT 
Age 0.17 0.26 
Gender -0.04   0.46* 
Disease duration 0.34    0.66** 
Hoehn and Yahr (HY) 0.28                    -0.04 
UPDRS  
- part I (Mood and behavior) 
- part II (ADL) 
- part III (Motor) 
 
   0.61** 
   0.62** 
0.33* 
 
0.21 
  0.52* 
0.26 
Other non-motor features 
   HAM-D 
   SE  
   SCOPA-AUT 
 
   0.58** 
   -0.49** 
0.37 
 
  0.51* 
                   -0.31 
- 
SE=Schwab and England Activities of Daily Living Scale, HAM-D=Hamilton Depression Rating Scale, 
UPDRS=Unified Parkinson’s Disease Rating Scale 
**p<0.01, *p<0.05  
 
Quality of life and UMSARS scores and Correlation Analyses in MSA  
Quality of life (QOL) and UMSARS scores in MSA are presented in Table 5.8. There 
was a strong correlation between MSA-QoL total score and Activities of daily living scale 
(SE) scores (r=-0.71, p<0.01), UMSARS part I (ADL) (r=0.66, p<0.01) and part IV (Disability) 
(r=0.63, p=0.017) scores. No correlation was evident between MSA-QoL and age, disease 
duration and UMSARS part II (motor) scores (Table 5.9). 
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Table 5.8. MSA-QoL and UMSARS scores, including subscores, in patients with MSA 
Item Scores Mean + SD 
UMSARS  
- part I (ADL) 
- part II (Motor) 
- part IV (Disability) 
 
23.8 + 8.3 
22.8 + 7.4 
2.7 + 1.2 
MSA-QoL  
- Motor 
- Nonmotor 
- Emotional/social 
- Total 
 
46.0 + 23.1 
35.0 + 19.0 
45.5 + 20.2 
42.2 + 17.8 
Values are mean+SD 
 
Table 5.9. Spearman’s Rank Correlations between MSA-QoL scores and age, gender, 
disease duration, UMSARS scores, HAM-D and SE in patients with MSA 
 Spearman’s Rho p-value 
Age -0.049 0.87 
Gender 0.47 0.09 
Disease duration 0.45 0.10 
Hoehn and Yahr (HY) 0.19 0.51 
UMSARS  
- part I (ADL) 
- part II (Motor) 
- part IV (Disability) 
 
0.66 
0.28 
0.63 
 
<0.01 
0.35 
0.02 
Other features 
   HAM-D 
   SE  
 
0.42 
-0.71 
 
0.16 
<0.01 
SE=Schwab and England Activities of Daily Living Scale, HAM-D=Hamilton Depression Rating Scale, 
UMSARS=Unified Multiple System Atrophy Rating Scale 
 
Quality of life and non-autonomic symptom scales in PAF 
 There were significantly lower SF-36 subscores in PAF patients relative to healthy 
controls, including physical function, role limitation physical, bodily pain, general health 
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perceptions, vitality, social functioning, role limitation emotional as well the physical health 
summary scores (p<0.01; Table 5.10). Mental health subscores and the mental health 
summary scores were not different between groups (p=0.13 and p=0.1, respectively). 
Table 5.10. SF-36 domain sub-scores and summary measure scores in patients with 
PAF and controls  
 PAF (n=20) Control (n=20) p-value 
SF-36 sub-score dimensions 
- Physical Functioning (PF) 
- Role Limitation Physical (RP) 
- Bodily Pain (BP) 
- General Health Perceptions (GH) 
- Energy/Vitality (VT) 
- Social Functioning (SF) 
- Role Limitation Emotional (RE) 
- Mental Health (MH) 
 
38+27 
16+37 
55+31 
40+23 
34+22 
55+29 
62+44 
66+23 
 
91+20 
92+29 
85+22 
82+12 
69+16 
94+13 
100+0 
81+7 
 
<0.01 
<0.01 
0.01 
<0.01 
<0.01 
<0.01 
<0.01 
0.13 
SF-36 Summary Measures 
- Physical Health 
- Mental Health 
 
30+9 
47+12 
 
53+10 
55+4 
 
<0.01 
0.10 
Values are mean+SD 
 
Correlation Analyses of Quality of life and non-autonomic symptoms in PAF  
SF-36 Physical Health summary measure scores (PH-SM) were moderately 
correlated with SE scores (r=0.48, p=0.032) and gender (r=-0.45, p=0.04) but not with age or 
disease duration (Table 5.11).  
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Table 5.11. Spearman’s Rank Correlations between SF-36 Physical Health summary 
measures and age, gender and disease duration, HAM-D and SE in patients with PAF 
 Spearman’s rho p-value 
Age 0.11 0.64 
Gender -0.45 0.04 
Disease duration -0.05 0.82 
Other features 
   HAM-D 
   SE  
 
-0.26 
0.48 
 
0.27 
0.03 
SE=Schwab and England Activities of Daily Living Scale, HAM-D=Hamilton Depression Rating Scale 
 
5.2.4 Discussion 
The purpose of this study was to further examine the relationship between quality of life 
and non-motor aspects in primary chronic autonomic failure disorders by correlating quality 
of life scores in MSA, PD and PAF patients with a variety of factors, including, age, gender, 
disease duration, motor symptoms (in MSA and PD) and depression. The relationship 
between autonomic symptoms in PD using the SCOPA-AUT instrument and these factors 
were also investigated. The main findings of this study were that the difference in the 
severity of depression in a group of patients with chronic autonomic failure; MSA patients 
had higher HAM-D scores than both PAF and PD patients but these scores were 
comparable between PAF and PD. The measurement of Activity daily living (ADL) using the 
SE scale also indicated that ADL were significantly limited in MSA compared to other 
disorders, whereas no difference was found between PD and PAF.  
Other main findings were the differences in correlations between quality of life and 
non-motor symptoms in different chronic autonomic failure patients. In PD, PDQ-SI were 
correlated with depression, UPDRS part I (mood and behavior) and part II (ADL) (all p<0.01) 
but less strong correlations were evident with disease duration, UPDRS part III (motor) and 
SCOPA-AUT (both p=0.08). These findings suggest that non-motor features have more 
influence on quality of life in patients with PD, compared to motor components. These 
findings are supported by a number of previous studies showing consistent evidence of the 
impact of various non-motor symptoms/features on quality of life in patients with PD (Schrag 
et al., 2000b; Martinez-Martin et al., 2009; Havlikova et al., 2011; Martinez-Martin et al., 
2011; Santos-Garcia & de la Fuente-Fernandez, 2013; Song et al., 2013). 
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A correlation analysis between demographic factors and autonomic symptom scores 
using SCOPA-AUT in PD was also performed. SCOPA-AUT is a patient-completed 
questionnaire that measures different domain of autonomic symptoms including 
cardiovascular autonomic, gastrointestinal (GI) function, genitourinary (GU) function, 
sudomotor function and sexual function. In the present study, there was a strong relationship 
between the SCOPA-AUT total score and disease duration in PD. There were also some 
evidence showing that a higher SCOPA-AUT total score (e.g., greater autonomic symptoms) 
correlated with female gender and higher motor and depression scores. These correlations 
including, disease duration, greater motor and depressive symptoms are in accordance with 
a prior study (Verbaan et al., 2007), except female gender that has never been previously 
reported. This may be partly explained by a low number of female PD (N=9) patients in the 
present study’s cohort.  
Depression was common among patients with PD (Karlsen et al., 1999)and MSA. 
Previous studies showed that the prevalence of depression in MSA is in the range 40-60% in 
large cohorts of patients (Benrud-Larson et al., 2005; Tison et al., 2006). The findings of the 
present study suggested that MSA had a higher severity of depression than patients with 
PD, which was consistent with a prior study (Tison et al., 2006). Greater depression in MSA 
may be explained by a higher degree of symptom severity, such as autonomic dysfunction 
and motor severity, in MSA compared to PD. Even though MSA had the highest score of 
depression among patient groups, there was no correlation between the MSAQoL and HAM-
D scores suggesting that the relationship between quality of life and depression in MSA may 
be non-linear, e.g., it may increase exponentially early or later in the course of the disease. 
In fact, MSAQoL scores were positively correlated with UMSARS part I (ADL), UMSARS part 
IV (Global disability scale) and negatively correlated with SE scores. As the UMSARS part I 
mainly consists of different activities in daily living, it is more likely to have an impact on the 
global disability scale (UMSARS part IV) as well as SE, e.g., some co-linearity may be 
evident in these indices. In addition, this study also firstly demonstrates a significantly higher 
HAM-D score in patients with PAF compared to healthy controls, which is comparable to PD. 
Unlike PD, there has been no report of pathological brain lesions that could explain the 
symptoms of depression in patients with PAF. This higher score of HAM-D in PAF compared 
to controls could reflect the disease-related factors which are caused by the autonomic 
dysfunction. 
Schwab and England Activities of Daily Living Scale scores (SE) were significantly 
lower in patients MSA compared to PD and PAF. Given that SE reflects how much the 
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disease limits patients’ daily functional capability, the lower score in MSA in this study clearly 
demonstrated a greater impact in this domain, compared to PD and PAF.  The findings of 
the present study also imply that the severity of motor dysfunction in MSA may not 
exclusively contribute toward an MSA patient’s quality of life as there was no association 
between UMSARS part II (motor) and MSAQoL. Supportive treatments, particularly those 
which are relevant to MSA patients’ ADL (e.g. management of swallowing and speech, 
walking aids, treatment for orthostatic symptoms etc.), may provide a better quality of life in 
MSA patients even in those with a greater motor severity. 
The present study reported for the first time that a quality of life measure was lower in 
patients with PAF, who have only autonomic problems without motor symptoms, compared 
to age-matched healthy controls. PAF patients had lower SF-36 sub-scores in almost every 
domain except for the mental health domain. The latter finding is slightly in contrast to the 
higher depression scores in PAF compared to controls. Possible explanations for this 
discrepancy could relate to the clear differences in the design of the 2 instruments and that 
the mental health domain of the SF-36 may assess various aspects of mental health as 
opposed to depression specifically on the HAM-D. Furthermore, there are some questions in 
the HAM-D which contain generic symptoms, such as fatigue, tiredness as well as anxiety-
related symptoms (sweating, bladder symptoms etc), which can be caused by autonomic 
dysfunction and are prominent in PAF patients. These findings also perhaps highlight a need 
for a disease-specific QOL questionnaire for PAF.  
There were no association between SF-36 scores and age, disease duration and 
HAM-D scores in PAF but Schwab and England Activities of Daily Living Scale (SE) scores 
and female gender were found to be correlated with the SF-36 Physical Health summary 
measures (PH-SM; an overall index of the physical health related sub-score domains) in 
PAF. The association between SE and SF-36 scores in PAF could be due to the fact that 
orthostatic hypotension has a huge impact on patients’ activities and mobility, which in turn 
affects their quality of life by limiting their physical capabilities. The association between 
lower PH-SM scores and female gender may need further investigation because of the small 
sample size of female PAF patients (N=6). Interestingly, although statistical comparisons 
were not possible, the PAF patients in the present study had lower scores compared to PD 
patients from a previous study in every SF-36 domain except Role limitation Emotional (RE) 
(Riazi et al., 2003). These observations suggest that autonomic dysfunction can significantly 
affect quality of life in patients with PAF, and perhaps more so than in PD.  
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In conclusion, this study indicates that there are different severities of depression and 
ADL scores among patients with chronic autonomic failure. MSA patients had more severe 
depression and lower ADL scores than those in PD and PAF. In contrast, PD and PAF seem 
to have a similar degree of depression, as well as ADL dysfunction, but both are more 
evident than in healthy controls. Depression, UPDRS part I and II correlated with quality of 
life in PD rather than UPDRS part III (motor severity), whereas autonomic symptoms, 
indicated by the SCOPA-AUT scores, clearly correlated with disease duration in PD, further 
supporting the contribution of non-motor symptoms to quality of life in PD. Despite higher 
depression scores in MSA, quality of life was strongly correlated with ADL scores, as 
reflected by the correlations with UMSARS part I, part IV and SE scores. Finally, quality of 
life in patients with PAF was clearly impaired compared with healthy controls. 
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6. Initial symptoms and clinical characteristics in Pure Autonomic Failure 
6.1 Introduction 
Pure autonomic failure (PAF) is an idiopathic, sporadic, relatively rare 
neurodegenerative disorder characterized by post-ganglionic autonomic failure without other 
neurological symptoms and signs (Kaufmann, 1996). PAF has a substantially better 
prognosis than other primary chronic autonomic failure disorders, such as Multiple System 
Atrophy (Mabuchi et al., 2005). The clinical features of PAF, however, have not been well 
defined and often overlap with other autonomic failure disorders such as MSA and PD, thus 
sometimes making a judicious diagnosis difficult. Supine and nocturnal hypertension is 
commonly observed in PAF alongside with orthostatic hypotension (Shannon et al., 1997). 
There is only one report that details symptoms exclusively associated with orthostatic 
hypotension in PAF (Mathias et al., 1999). There is minimal research that has examined the 
presenting symptoms and features of patients that have later obtained a confirmed diagnosis 
of PAF. Assessing the presenting symptoms of confirmed PAF patients is important as it will 
provide an objective analysis of features at a time when the diagnosis is often still unclear, 
and other disorders, such as MSA, can be suspected, and thus may generate key 
information that may help improve the accuracy and speed of diagnosis in PAF and other 
chronic autonomic failure disorders 
The prognosis of PAF is generally much longer than other chronic autonomic failure 
disorders, e.g., MSA. The chronic effects of the features of PAF, especially the 
cardiovascular autonomic dysfunction, have not been thoroughly investigated however. 
Patients with PAF who have supine hypertension, like patients with essential hypertension, 
have been reported to develop ventricular hypertrophy (Vagaonescu et al., 2000). The long-
term vascular damage in different vascular territories (e.g., renal, retinal, peripheral and 
cerebral vasculature) must also be considered, but have as yet been fully investigated. For 
example, the frequent episodes of orthostatic hypotension may cause ischemic damage in 
several organs, particularly cerebral ischemia, but this has not been adequately researched.     
The aim of this study is to therefore further examine the clinical characteristics of 
PAF by assessing the frequency of initial and presenting autonomic symptoms in confirmed 
PAF patients, as well as examine the intracranial imaging results and evaluate what factors 
(if any) are associated with ischemic small vessel lesions in cerebral white matter (WML) in 
this group of patients.  
147 
 
6.2 Methods 
Patients 
Medical records of 70 confirmed PAF patients who had been diagnosed between 
1998 and 2009 were retrospectively reviewed. PAF patients were diagnosed using existing 
international consensus criteria (Kaufmann, 1996). Patients who had been diagnosed with or 
had suspected autoimmune related autonomic failure, such as autoimmune autonomic 
ganglinopathy (AAG) or paraneoplastic syndromes were excluded. All patients had been 
tested and had confirmed cardiovascular autonomic failure and had been followed up for at 
least 3 years without other emerging neurological features, such as cerebellar dysfunction or 
parkinsonism.  
Initial symptoms, clinical history, presenting symptoms and signs  
History and relevant information of all patients were retrospectively evaluated from 
medical records. Factors investigated included, age, gender, initial symptoms, clinical 
history, presenting symptoms and signs, duration of disease (time from first symptom to the 
autonomic testing date), current pressor medications (Fludrocortisone, Midodrine, 
Ephedrine) and number of medications were recorded,  
Symptoms were divided into initial symptoms (the first symptom reported by patients) 
and presenting symptoms (all reported symptoms described by patients in their first visit to 
hospital/consultation). The initial symptoms were classified as cardiovascular autonomic 
symptoms (e.g. dizziness, lightheadness, visual disturbances, syncope, fatigue, chest pain 
and coat-hanger ache), erectile dysfunction, bladder symptoms, gastrointestinal (GI) 
symptoms (constipation and diarrhoea) and abnormal sweating in line with a previous study 
(Mathias et al., 1999). The same classification was used for the presenting symptoms but 
bladder symptoms were subdivided into urinary frequency, urgency and frequent nocturia. 
Evaluation of autonomic nervous system function 
Results of cardiovascular autonomic function (supine and head up tilting and 24 hr 
ambulatory monitoring), plasma noradrenaline concentrations assessments and brain MRI 
reports were reviewed. Patients were asked to stop anti-hypotensive medications 12 hours 
prior to their cardiovascular autonomic function tests. 
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Cardiovascular autonomic screening tests (AFT) 
AFT was performed using Autonomic Unit protocols (Mathias et al., 2013a). These 
included pressor tests, Valsalva manoeuvre (VM), deep breathing, Hyperventilation, 10-
minute 60 degrees HUT and standing tests as described in Chapter 3.  Blood pressure was 
recorded continuously online using photoplethysmography and intermittently offline using 
upper arm automated sphygmomanometry. Continuous beat-to-beat cardiac activity was 
recorded continuously online with ECG monitoring.  
24 hour-Ambulatory Blood Pressure and Heart Rate Monitoring (24 hr-ABPM) 
All patients were fitted with a 24 hr-ABPM monitor (model 90207, Spacelabs™ 
Medical, Redmond, Washington) after their AFT as part of their autonomic investigations. BP 
and HR were recorded every 20 minutes during the day (0800-2300) and every 60 minutes 
during the night (2300-0800). The average BP and HR were calculated for daytime, night-
time and the entire 24-hour period. Patients were classified into 3 groups: dipper (BP fall 
during night-time>10% compared to daytime), absent nocturnal BP fall or non-dipper (BP fall 
during night-time<10% compared to daytime) and reverse nocturnal BP profile (BP during 
night-time higher than daytime). Patients with an average daytime SBP >140 mmHg or DBP 
>90 were defined as daytime hypertensives and those with nighttime SBP >125 or DBP >75 
as nighttime hypertensives according to international guidelines (Pickering et al., 2005).  
Plasma noradrenaline (NA) concentrations 
Blood samples were collected during supine and head-up tilt tests to assess 
catecholamine (noradrenaline) concentrations as a biochemical marker of sympathetic neural 
activity. The plasma level of noradrenaline (NA) was measured using high-performance liquid 
chromatography with an electrochemical detector.  
 
Brain MRI  
 Brain MRI was conducted using a 1.5 or 3-tesla MRI scans following a standard MRI 
protocol which includes an axial T1-weighted, T2-weighted and Fluid-attenuated inversion 
recovery (FLAIR) images as well as midsagittal T1 in all patients. 
Statistical analyses 
Normally distributed data were presented as mean (± 1 SD), whereas median (inter-
quartile range) were used for non-normally distributed data. Frequency of initial and 
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presenting symptoms were reported in percentages. Statistical analyses were performed 
using non-parametric tests; Chi-square analyses and Fisher exact tests were used for 
analysis of categorical variables and Mann-Whitney U tests for quantitative data.  
In order to estimate the risk of cerebral white matter lesions (WML), patients were 
classified into 2 groups according to their brain MRI results; PAF with WML and without 
WML. Variables were compared between these two sub-groups with univariate analysis. 
Potential confounders, including age, disease duration, supine hypertension and nocturnal 
BP dipping and other factors with significant differences from the univariate analysis were 
then included in the multiple variable logistic regression analysis in order to determine what 
factors are associated with an increased risk of cerebral WML. 
Relationships between quantitative cardiovascular autonomic function, including 
plasma supine NA and orthostatic NA changes, and clinical features, as well as relationships 
between supine hypertension (SHT) and other factors were assessed using multiple linear 
regression analysis. Statistical analyses were carried out using STATA 11.0 (STATA 
Corporation, College station, Texas, USA). All tests were 2-sided and a p value of <0.05 was 
considered significant. 
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6.3 Results 
A total of 70 records of PAF patients were identified. PAF was more common in 
males (44 males vs. 26 females) and the age of diagnosis was between 54 and 83 years old. 
Disease duration ranged from 3-28 years. Other details including anti-hypotensive 
medications are presented in Table 6.1. 
Table 6.1. Demographic data of Pure Autonomic Failure patients 
 Total Male Female 
Number (N) 70 44 26 
Age (yrs) 69 + 7 69 + 7 70 + 8 
Disease duration           
median (IQR), yrs 
12 (7-16) 14 (7-17) 12 (7-16) 
Pressor drugs (%) 
  Fludrocortisone 
  Midodrine 
  Ephedrine 
 
55 
30 
17 
 
34 
17 
9 
 
21 
13 
8 
Number of pressor drugs (%) 
- 0  
- 1  
- 2 
- 3 
 
11 
33 
46 
10 
 
13 
39 
41 
7 
 
8 
23 
54 
15 
 
Initial symptoms  
Most patients had multiple initial symptoms. Out of the 70 patients, the incidence of 
pre-syncopal symptoms as the initial symptom, including faintness (lightheadedness, 
dizziness) and visual disturbances (blurring, greying-out, enhanced brightness, darkening, 
tunnel vision), was the highest (61.4%). Syncope (loss of consciousness, blackouts or 
fainting) was present in 11/70 (16.9%) of patients. Erectile dysfunction was a common first 
symptom in males (44%). Decreased sweating was described in 7 (10%) patients while 
urinary symptoms were reported as an initial symptom in 5 (7.1%) patients. In addition, 
fatigue induced by standing or walking was an initial symptom in approximately 4% (see 
Figure 6.1). With regards to gender, there were no difference between males and females in 
the majority of initial symptoms, including syncope, anhidrosis, bladder and GI symptoms, 
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coat-hanger ache and chest pain (p>0.05). Interestingly, presyncopal symptoms were 
reported more in females compared to males (p=0.01), and patients who reported fatigue 
symptoms are all female. 
 
 
Figure 6.1. Initial symptoms in 70 PAF patients.  *p<0.05 male vs. female.  
Presenting symptoms at clinic 
The most common presenting symptoms at clinic were pre-syncope and syncope 
(100% and 77.1%, respectively). Erectile dysfunction was prevalent, presenting in 31/44 
(70%) of male patients. Hypohidrosis and hyperhidrosis were present in 43/70 (61.4%) and 
5/70 (7.1%) patients, respectively. Pain in the suboccipital/paracervical and shoulder region 
(“coat-hanger” ache), which was typically relieved after lying flat, was reported in 54% of 
patients. Constipation and urinary frequency were less common, presenting in less than half 
of the patients. Non-specific symptoms like fatigue occurred in 20/70 (28.6%) of patients 
while chest pain was reported in 14/70 (20%) patients (see Figure 6.2). With regards to 
gender, there was no difference in almost all presenting symptoms between male and 
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female PAF patients. The exception was coat-hanger ache, which was more common in 
females compared to males (p<0.05).    
 
Figure 6.2. Presenting symptoms at clinic reported by PAF patients. *p<0.05 male 
vs. female. 
 
Laboratory Examinations 
 Orthostatic hypotension was found in all PAF patients on head-up tilting. Supine 
hypertension (SBP>150 and/or DBP>90 mmHg) was evident in 51 out of 70 patients (73%). 
There were no difference in SBP, DBP and HR during supine and HUT, as well as the 
number of patients with supine hypertension (SHT), between male and female patients (all 
p>0.05). 
24 hour-ambulatory blood pressure monitoring (24 hr-ABPM) was performed in 62 
patients. A reversed circadian blood pressure rhythm was present in 40 patients (65%), 
whereas 14 patients (22%) had an absent nocturnal BP fall. Only 8 patients (13%) had a 
normal BP fall during nighttime. In addition, there were 13 patients (21%) with daytime 
hypertension and 41 patients (66%) with nighttime hypertension. There were no difference in 
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daytime or nighttime SBP, DBP and HR, as well as the number of patients with abnormal BP 
circadian rhythms, between male and female patients (all p>0.05). 
Plasma noradrenaline (NA) concentrations were measured in 52 patients. A low 
concentration (<200 pg/ml) was found in 48 patients (92%) with a minimal rise in plasma NA 
on head-up tilting (increase of 11.4 + 20.4 pg/ml, see Table 6.2). There were no differences 
in plasma NA during supine, HUT, as well as the HUT change between male and female 
patients (all p>0.05). 
Table 6.2. Cardiovascular autonomic function and biochemical results from 70 Pure 
Autonomic Failure patients. 
Cardiovascular autonomic function  
Tilt Table Test 
(N=70) 
 
-Supine 
-Head-Up Tilting 
 
SBP (mmHg) 
166 + 30 
84 + 27* 
 
DBP (mmHg) 
90 + 14 
54 + 15* 
 
HR (bpm) 
69 + 11 
75 + 11* 
24 hr-ABPM (N=62) 
-Daytime 
- Nighttime 
 
134 + 22 
141 + 23 
 
80 + 13 
84 + 14 
 
74 + 9 
70 + 10 
Biochemical analyses  
Plasma Noradrenaline (N=52) (NA) (pg/ml) 
-Supine NA 
-HUT NA 
-∆ NA change 
129.8 + 58.0  
141.2 + 68.0 
11.4 + 20.4 
SBP; Systolic Blood Pressure, DBP; Diastolic Blood pressure, HR; Heart Rate, NA; 
Noradrenaline 
*p<0.05 vs. corresponding supine value 
 
MRI findings 
Brain MRI studies were performed in 52 patients. There were radiographic ischemic 
changes, particularly deep white matter hyperintensity areas on T2 and FLAIR (see Figure 
7.3), in 45 patients (86.5%). There was no difference in the number of patients with 
abnormal white matter lesions between male and female (p>0.05). 
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Comparison of PAF patients with and without cerebral WML lesions  
Patients with cerebral WML were significantly older than those without WML 
(p<0.01). There were no differences in gender and disease duration between sub-groups 
(see Table 6.3). With regards to autonomic function, there was no difference in supine and 
HUT BP and HR responses between PAF patients with and without WML (all p>0.05). Mean 
daytime and nighttime BP and HR were not different between sub-groups (p>0.05). Supine 
hypertension was also not different between sub-groups (p>0.05). Supine and tilt plasma 
NA, as well as the orthostatic changes in plasma NA, were not different between the PAF 
with and without WML sub-groups. With regards to medication, there was no difference in 
the different types and the number of anti-hypotensive medications between the sub-groups 
(see Table 6.4). 
 
 
 
 
Figure 6.3. An example of a Brain MRI in a patient with PAF (74 years old, male) 
demonstrating ischemic small vessel lesions in cerebral white matter in the 
area circled.   
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Table 6.3. Comparison of PAF patients with and without ischemic small vessel lesions 
in cerebral white matter (WML). 
 
PAF with WML  
(n=45) 
PAF without WML 
(n=7) 
P-value 
Gender, n (%) 
- Female 
- Male 
 
17 (38) 
28 (62) 
 
1 (14) 
6 (86) 
 
0.4 
 
Age, yrs, mean + SD 70 + 8 62 + 4 <0.01 
Disease duration            
median (IQR), yrs 
 
12 (7-16) 
 
12 (8-15) 
 
0.66 
BP responses, mmHg 
- Supine SBP 
- Supine DBP 
- Supine HR 
- HUT SBP 
- HUT DBP 
- HUT HR 
 
168 + 30 
90 + 14 
68 + 12 
84 + 28 
55 + 15 
76 + 12 
 
168 + 35 
87 + 11 
70 + 11 
80 + 22 
50 + 10 
72 + 12 
 
0.96 
0.59 
0.86 
0.85 
0.34 
0.29 
Supine Hypertension, n (%) 33 (73%) 5 (71%) 0.92 
24 hr-ABPM, mmHg 
- Daytime SBP 
- Daytime DBP 
- Daytime HR 
- Nighttime SBP 
- Nighttime DBP 
- Nighttime HR 
 
133 + 23 
80 + 13 
73 + 9 
142 + 21 
83 + 13 
70 + 10 
 
132 + 20 
82 + 14 
71 + 8 
146 + 32 
90 + 17 
71 + 11 
 
0.98 
0.79 
0.63 
0.94 
0.35 
0.63 
24 hr-ABPM profile 
Non-dipper, n (%)  
 
29 (73%) 
 
5 (57%) 
 
0.41 
Plasma Noradrenaline (NA), pg/dl 
Supine 
HUT 
∆ NA change 
 
137.4 + 59.8 
151.5 + 71.3 
12.9 + 20.3 
 
105.1 + 35.8 
115.1 + 36.1 
10.0 + 9.8 
 
0.12 
0.18 
0.82 
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Table 6.4. Drug comparison of PAF patients with and without ischemic small vessel 
lesions in cerebral white matter (WML).  
 PAF with WML (n=45) PAF without WML(n=7) P-value 
Anti-hypotensive Medications* 
-Fludrocortisone 
-Midodrine 
-Ephedrine 
 
36 (80%) 
20 (44%) 
10 (22%) 
 
5 (71%) 
5 (71%) 
2 (29%) 
 
0.61 
0.18 
0.71 
Number of anti-hypotensive 
medications 
-no drug 
-1 drugs 
-2 drugs 
-3 drugs 
 
 
 
5 (11%) 
19 (42%) 
16 (36%) 
5 (11%) 
 
 
 
1 (14%) 
1 (14%) 
4 (58%) 
1 (14%) 
 
 
 
0.81 
0.33 
0.18 
0.81 
*Some patients on medications more than one 
 
Predictive factors of PAF patients with cerebral WML lesion  
Age was the only factor that was associated with brain WML in the univariate 
analyses. Disease duration, a reversed nocturnal BP circadian rhythm and supine HT were 
included in the multivariate analysis. The results showed that increasing age was associated 
with a 28% increased risk of having cerebral WML in patients with PAF (OR 1.28; CI 1.04-
1.58). There was no association with disease duration, reversed nocturnal BP rhythm and 
supine hypertension and the occurrence of WML in this group of patients (Table 7.5). 
Table 6.5. Predictive factors of ischemic small vessel lesions in cerebral white matter 
in the PAF WML group. 
 Odds ratio (OR) 95% Confidence Interval P-value 
Age 1.28 1.04-1.58 0.02 
Supine Hypertension 2.85 0.25-31.92 0.39 
Reversed nocturnal 
circadian rhythm 
1.40 0.17-11.80 0.76 
Disease duration 1.00 0.88-1.14 0.95 
 
Relationships between autonomic function parameters and disease duration  
All autonomic function parameters, including supine, HUT BP and BP changes during 
HUT, were not correlated with disease duration (all p>0.05), except the HUT change in 
plasma NA (∆ NA change; p<0.01). After controlling for age, gender, the presence of supine 
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HT and ∆ SBP change on HUT, there was still a significant correlation between ∆ NA HUT 
change and disease duration (p=0.01; see Table 6.6). 
Table 6.6. Multiple regression analysis of the correlation between the changes in 
plasma noradrenaline (NA) during HUT (pg/ml) and disease duration in PAF patients. 
Variable Parameter estimate Standard error P-value 
Plasma NA change -1.28 0.50 0.01 
Age  0.02 0.41 0.96 
Gender -8.90 5.87 0.14 
Supine Hypertension 5.06 7.64 0.51 
∆ SBP change on HUT -0.01 0.11 0.95 
 
 
Figure 6.4. Scatterplot showing the correlation between HUT ∆ Plasma NA change (Y 
axis) and disease duration (X axis; R=-0.34, p=0.01) in patients with PAF. 
 
Supine Hypertension (SHT) and associated factors 
There was no correlation between SHT and age, gender, disease duration, plasma 
NA and the number of anti-hypotensive medications (all p>0.05). Nevertheless, the change 
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in SBP (∆ SBP) during HUT was strongly associated with the presence of SHT in the 
univariate regression model (p<0.01). A change of SBP equal to or greater than 80 mmHg 
during HUT meant an 11.64 odds ratio of having SHT compared to a SBP fall less than 80 
mmHg after taking into account age, gender, disease duration (OR=11.64; CI 2.82-48.02, 
p<0.01; see Table 6.7). 
Table 6.7. Predictive factors of supine hypertension in patients with PAF. 
 Odds ratio (OR) 95% Confidence Interval P-value 
∆ SBP change on HUT 
   > 80 mmHg 
   < 80 mmHg 
 
11.64 
1 
 
2.82-48.02 
 
<0.01 
Age 
   > 68 years 
   < 68 years 
 
0.99 
1 
 
0.28-3.48 
 
0.99 
Gender 
   Female 
   Male 
 
2.91 
1 
  
0.73-11.7 
 
0.13 
Disease duration 
   > 12 years 
   < 12 years 
 
1.03 
1 
 
0.95-1.11 
 
0.49 
 
6.4 Discussion 
The aim of this study was to further examine the clinical characteristics of PAF by 
assessing the frequency of initial and presenting autonomic symptoms in confirmed PAF 
patients, as well as examine the intracranial imaging results and evaluate what factors (if 
any) are associated with ischemic small vessel lesions in cerebral white matter (WML) in this 
group of patients. The main findings were that orthostatic symptoms (e.g. dizziness and 
lightheadedness) are universal initial symptoms in PAF and presyncopal symptoms were 
more commonly reported in females. In addition, up to 60% of patients reported sudomotor 
symptoms in their first consultation. The results also indicated that erectile dysfunction (ED) 
was prevalent in males with almost half reporting it as an initial symptom and up to 70% at 
the first hospital visit. Non-specific symptoms, such as fatigue and chest pain were 
experienced in approximately 20% of the present study’s cohort.  
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The study also showed that supine hypertension was commonly observed and 
strongly associated with orthostatic hypotension (OH). Plasma noradrenaline (NA) was 
usually less than 200 pg/ml whilst supine and the plasma NA change during HUT was also 
less than 100 pg/ml. Additionally, more than half of PAF patients also revealed a 
pathological reversed BP circadian rhythm and brain MRI studies revealed white matter 
lesions (WML) were typical presenting in more than 80% of patients. 
The results of the current study are consistent with a previous study that reported 
presyncopal symptoms and syncope as the most common symptoms in PAF patients at the 
out-patient clinic or as in-patients (Mathias et al., 1999). “Coat-hanger” ache was also 
frequently reported in the present study with a similar figure to that previous study (Mathias 
et al., 1999). However, the presenting symptoms of chest pain and fatigue were less 
common in the current study, which could be due to a lower accuracy of records as often 
seen in retrospective data analyses. Other possible explanations are that non-specific 
symptoms (e.g. chest pain and fatigue) were less likely to be voluntarily reported from the 
patients without questioning from the clinicians. Similarly, anhidrosis and hypohidrosis were 
uncommon as an initial symptom in contrast to the reported symptoms at the first 
consultation. Nevertheless, abnormal sweating may have an insidious onset and may be 
less likely to be detected and/or reported by patients without a direct question. Urinary 
symptoms were less commonly reported as an initial symptom but these become more 
prominent during the disease progression, e.g., at the first consultation. This finding is in 
concordance with previous studies showing that urinary dysfunction seems to appear after 
orthostatic symptoms in PAF, which is contrary to patients with Multiple System Atrophy 
(Mabuchi et al., 2005). This difference in bladder progression may aid in differentiating 
between these two conditions. Interestingly, coat-hanger ache was more frequently reported 
in females compared to males in this study’s cohort. The cause of coat-hanger ache is 
thought to be due to a transient reduction in perfusion of muscles in the neck and shoulder 
areas during standing in patients with OH. Therefore, the higher prevalence of this symptom 
could be due to a relative small muscle mass in females compared to males. This may 
increase the chance of developing this symptom. Nonetheless, no study has investigated 
this hypothesis and this warrants further investigation.  
Not surprisingly, plasma NA was found to be lower with a smaller rise during HUT in 
the majority of the patients which is a typical finding in PAF (Goldstein et al., 2003a). These 
findings reflect the involvement of a post-ganglionic sympathetic lesion in PAF. This is in 
contrast to MSA patients, generally accepted as a pre-ganglionic autonomic disorder, who 
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tend to have a normal supine plasma NA level (Mathias et al., 2013a). On the other hand, 
Esler et al reported a nearly normal plasma NA levels in 4 patients with PAF but there was 
no information regarding the disease duration (Esler et al., 1980). The reason for this 
difference in plasma NA is unclear. Given that the patients in the present study had isolated 
autonomic failure without any additional neurological features for at least 3 years, they may 
have had a longer disease duration compared to those in the previous study. 
There was a significant association between the plasma NA HUT change (between 
supine and upright) and disease duration in PAF patients in the current study. There has 
been no study that has investigated this relationship and this is the first report of such a 
relationship in PAF. This finding suggests that the plasma NA HUT change may be lower as 
the disease progresses possibly reflecting a greater impairment of post-ganglionic 
sympathetic nerve activity. Furthermore, this finding also implies that the measurement of 
the plasma NA HUT change should be cautiously interpreted if such measurements are 
taken from PAF patients with short disease duration as the results could be relatively normal.    
Although the exact prevalence of SHT in PAF is unknown it was reported in more 
than 50% of patients with primary chronic autonomic failure (Shannon et al., 1997). The 
prevalence was higher in this cohort (70%), which could be due to a variety of factors, 
including, differences in patient cohorts, amount and frequency of medications and 
assessment protocols. Supine hypertension was also strongly associated with the degree of 
OH in patients with PAF in the current study, consistent with previous work (Goldstein et al., 
2003b) highlighting a link between the degree of autonomic failure and the severity of supine 
hypertension. The mechanism of supine hypertension in PAF remains unclear. Supine 
hypertension was not associated with disease duration, age or gender in the current study. 
In MSA, supine hypertension results from an inappropriate residual sympathetic tone but this 
finding is inconsistent in patients with PAF (Shannon et al., 2000). Other suggested 
mechanisms of supine hypertension include the movement of intra- and extra-vascular fluid 
from the peripheral to the central vascular compartment, impaired baroreflexes and 
supersensitivity to circulating catecholamines or to pressor agents (Iodice et al., 2011). 
Regardless of the pathophysiology, supine hypertension has a significant impact on OH 
treatment by limiting the use of pressor medications.  
Previous studies suggested that PAF patients are at higher risk of end-organ damage 
due to their cardiovascular autonomic dysfunction. Garland et al found a declined renal 
function in patients with PAF (Garland et al., 2009). Serum creatinine was significantly higher 
with a lower estimated glomerular filtration rate in PAF patients with supine hypertension 
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(SHT) compared with those without SHT. These findings are similar to a report of 
hypertensive cardiac ventricular hypertrophy in PAF (Vagaonescu et al., 2000). As BP 
fluctuations are universal in patients with PAF, the frequent cerebral WML among patients 
with PAF in this study may reflect an increase in the risk of stroke in this patient group. The 
risk factors that could be associated with WML in PAF patients in this cohort were 
investigated. Age was found to be the only predictive factor that was independently 
associated with WML in this study. Supine and HUT blood pressure, mean BP daytime and 
nighttime, a reversed circadian BP profile and supine hypertension were not associated with 
WML. Interestingly, there was also no difference in the risk of WML and the types and the 
number of pressor medications and cerebral WML in this study. Although there is no record 
of how many of the PAF patients developed symptomatic stroke, this finding supports the 
idea that the WML lesions in patients with PAF were less likely to be related to medications. 
Nonetheless, it is routine practice to monitor and re-evaluate autonomic function tests before 
adjusting/increasing medications.  
The WML findings in the current study are consistent with a previous study from 
Struhal et al. which showed an association between WML and age in patients with PAF. This 
study also found that the WML incidence was not increased in PAF in comparison with age-
matched control data from large prospective studies (de Leeuw et al., 2001; Launer, 2004). It 
is not clear whether individuals with PAF and WML have a higher risk of cerebrovascular 
diseases due to limited follow-up data. A recent study reported a small number of PAF 
patients who developed stroke (Struhal et al., 2013). Nevertheless, this finding needs further 
investigation by using a longitudinal design to follow-up how many patients actually develop 
symptomatic stroke to confirm this hypothesis. 
The limitations of this study are the retrospective design and the lack of detailed 
follow-up and also other metabolic profiles that could potentially increase a risk of 
cardiovascular disorders in patients with PAF. A long-term follow-up in these patients would 
provide more information regarding cardiovascular events in this patient group. 
In conclusion, this large cohort of PAF patients demonstrated that the most common 
initial symptoms in both male and females were of orthostatic intolerance, while erectile 
dysfunction was prevalent in males. Urinary symptoms, sweating abnormalities and 
gastrointestinal symptoms were more likely to gradually develop in the course of the 
disease. Cerebral WML were a very frequent finding in brain MRI imaging and age was an 
independent factor of these WM changes. Plasma NA was lower during supine with only a 
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minimal rise on HUT and longer disease duration of PAF was negatively correlated with the 
plasma NA HUT change. 
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7. Electrogastrography (EGG) in primary chronic autonomic failure 
7.1 Introduction  
Gastrointestinal (GI) symptoms can sometimes be prominent in autonomic disorders, 
such as PAF, MSA and PD. Abdominal pain, bloating and nausea/vomiting are commonly 
reported in MSA, as a result of delayed gastric emptying times (Thomaides et al., 2005). The 
gastrointestinal tract is controlled by extrinsic (sympathetic and parasympathetic) and 
intrinsic (enteric nervous system-ENS) pathways. These systems are vital for maintaining 
effective co-ordination of digestion. The extrinsic pathways, projecting from the dorsal motor 
nucleus of the vagus nerve has a crucial role in the initiation of gastric motility (Travagli et 
al., 2006). This is followed by peristaltic waves, which propel food contents towards the 
pylorus. These peristaltic waves are coordinated by gastric electrical activity, which is 
generated by the interstitial cells of Cajal (ICCs) on the greater curvature of the stomach 
(Sanders et al., 2006). The ICCs are considered gastric pacemaker cells because they 
generate rhythmic depolarization with the same frequency as slow waves of gastric 
myoelectrical activity (Camborova et al., 2003) and also relay signals between the ENS and 
the smooth muscle cells (Huizinga et al., 2004; Ward & Sanders, 2006). The frequency of 
gastric myoelectrical activity is approximately 3 cycles per minute in healthy subjects 
(Chang, 2005) and can be easily detected by cutaneous electrogastrography (EGG).  
A number of studies have used EGG in various gastric disorders, for instance 
diabetic gastropathy (Koch, 2001), functional dyspepsia (van der Voort et al., 2003) and 
recently in Parkinson’s disease and Multiple System Atrophy (Sakakibara et al., 2009). 
Gastric electrical dysrhythmia was detected in patients with PD (Lu et al., 2004) but not in 
MSA (Suzuki et al., 2005). Although no pathological studies of the involvement of ICC in 
autonomic failure disorders have previously been reported, there is evidence of alpha-
synuclein deposition in Auerbach’s and Meissner’s plexuses, which are closely linked to the 
ICC, in patients with PD (Braak et al., 2006b). Abnormal gastric slow waves in PD might 
reflect gastrointestinal involvement which is considered a potential early marker of the pre-
motor stage of PD and is consistent with a neuropathological study of Braak et al (Braak et 
al., 2003).  
PAF is characterized by orthostatic hypotension (OH) without other neurological 
features (Kaufmann, 1996). Symptoms of dysfunction of other autonomic domains, e.g., 
sexual and gastrointestinal function, are also common in PAF. Although there has been no 
study on the prevalence and pathophysiology of gastrointestinal (GI) symptoms in PAF, 
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these features (e.g. abdominal fullness, nausea/vomiting and constipation) are frequently 
reported among patients with PAF (see Chapter 6). GI dysfunction can even be a presenting 
feature in PAF patients (Yamanaka et al., 2006) (see Chapter 6). PAF and PD share a few 
common features, such as hyposmia, reduced cardiac MIBG reuptake and a presence of 
Lewy bodies, both in skin and the central nervous system (Hirayama et al., 1995; Ikemura et 
al., 2008; Silveira-Moriyama et al., 2009b; Shishido et al., 2010). These features raise a 
question of whether or not PAF is a limited form of PD without motor features (Kaufmann & 
Goldstein, 2010). Given these common features of PD and PAF and abnormal EGG findings 
previously reported in PD (Sakakibara et al., 2009), PAF may also have a similar pattern of 
EGG dysfunction as to patients with PD. Furthermore, MSA represents a pre-ganglionic 
autonomic disorder whilst PAF has mostly post-ganglionic autonomic pathology (Kaufmann 
et al., 2001). Comparing between these disorders would thus be an ideal model to evaluate 
autonomic disorders with different pathological lesions that present with similar clinical 
characteristics. To date, there have not been any studies investigating EGG activity in 
patients with PAF. The aim of this study was therefore to evaluate gastric myoelectrical 
activity (GMA) before and after standard liquid meal ingestion in PAF patients. It was 
hypothesized that PAF patients would have gastric dysrhythmia in line with the nature of 
post-ganglionic  autonomic pathology in this disorder, similar to PD. MSA patients were also 
examined in order to compare an autonomic disorder with a different lesion to PAF.  
 
7.2 Methods 
Participants  
Patients with PAF and MSA (with confirmed autonomic failure) were recruited. All 
patients fulfilled international consensus diagnostic criteria (as described in Chapter 3). Each 
participant was asked to refrain from eating for at least three hours before testing. All 
patients continued their current medications as usual. None of patients had history of 
dyspepsia, functional dyspepsia or gastrointestinal dysmotility disorders. Patients with a 
previous history of gastrointestinal surgery were excluded.  
Clinical history  
History and relevant information of all patients were recorded. These included, age, 
gender, duration of disease (time from diagnosis to testing date), medications and 
presenting symptoms. Patients were asked whether or not they had any following autonomic 
symptoms within the last 3 months including; upper gastrointestinal (UGI) symptoms 
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(nausea/vomiting, abdominal fullness), constipation, orthostatic intolerance symptoms 
(lightheadedness or dizziness when standing), bladder symptoms.  
Measurements and protocols 
 
Orthostatic BP and HR responses were assessed using a liquid meal challenge test 
with a 10-minute head-up tilt test (HUT) at 60° before and after the liquid meal. All 
participants rested for 15 minutes before undergoing a HUT challenge for up to 10 min. After 
returning to the supine position, participants rested for 15 minutes before a standard liquid 
meal was ingested through a straw whilst supine. The liquid meal consisted of 20g glucose 
and 60 g Complan® made up to 300 ml with full fat milk. All participants then rested for 45 
minutes before the orthostatic challenge was repeated. BP and HR were measured using 
upper arm sphygmomanometry (GE Medical Systems, Tampa, FL, USA). 
 
A four-channel cutaneous EGG device (Nipro EG; Nipro, Japan) was used to record 
gastric myoelectrical activity at a sampling rate of 1 Hz. Five surface electrodes were placed 
on 5 different sites on the abdomen as previously described (Sakakibara et al., 2009). EGG 
was recorded in the supine position during the period after the first and before the second 
HUT, which included 15-minute before (pre-prandial EGG recording) and 45-minute after 
meal ingestion (post-prandial EGG recording, Figure 7.1).  
 
Figure 7.1. Schematic showing the standard liquid meal protocol and  
EGG recording periods. 
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EGG analysis 
EGG data were analysed offline (EGS2 Ver 3.1 software, EG, Gram Co., Japan). 
Running spectral analysis was performed using Fast Fourier Transformation (FFT in the 
range 1.6 to 9.0 cycles per minute (cpm)). FFT was applied to consecutive 512-second data 
periods with a 392-second overlap. The dominant frequency (DF) was defined as the 
frequency at which the overall power spectrum showed peak power between 2.0 and 4.0 
cpm. The frequency ranges were also divided into 3 different types, including low frequency 
range (LFR; 1.6-2.0 cpm), normal frequency range (NFR; 2.0-4.0 cpm), and high frequency 
range (HFR; 4.0-9.0 cpm). LFR%, NFR% and HFR% were calculated from the ratios of LFR, 
NFR and HFR components of total power, respectively. The instability coefficient of dominant 
frequency (ICDF) is an indicator of the variability of the DF and was calculated as the ratio of 
the standard deviation and the mean of the EGG dominant frequencies. ICDF was calculated 
in 15-minute segments; pre- and post (30 min)-prandial periods. 
 
Statistical analyses  
Normally distributed data are presented as mean (± 1 SD), whereas median (inter-
quartile range) were used for non-normally distributed data. Independent t-tests or repeated 
measures ANOVA were used to compare BP and heart rate responses and the DF and ICDF 
responses between PAF and MSA patients before and after the liquid meal challenge. If 
there was a main effect of patient group or time, post hoc analyses were performed using 
Bonferroni corrections for multiple comparisons. All data were analysed using commercial 
available software (STATA 11.0; STATA Corporation, College station, Texas, USA). All tests 
were 2-sided and a p value of <0.05 was considered significant. 
 
7.3 Results 
23 patients (15 PAF and 8 MSA) were recruited. Patients with PAF were significantly 
older and had a longer disease duration compared with MSA (both p<0.01, see Table 6.1). 
Twenty seven percent (4/15) of the PAF patients had upper gastrointestinal (UGI) 
symptoms, including nausea and abdominal fullness, while these were reported in 38% (3/8) 
of patients with MSA. Constipation was common in both PAF and MSA (53% and 63%, 
respectively). All patients with PAF and MSA both had orthostatic hypotension and bladder 
symptoms (urinary frequency/urgency). Other demographic features are presented in Table 
7.1. 
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Table 7.1. Patient demographic data  
Variable PAF MSA 
Number 15 8 
% Female 67 63 
Age at testing, Mean (SD), yrs 69 (8)* 59 (6) 
Disease duration, Median      
(Interquartile range), yrs 
9 (6-11)* 4 (3-7) 
UGI symptoms 
Nausea 
Abdominal fullness 
Autonomic dysfunction 
Orthostatic intolerance symptoms 
Constipation 
Bladder symptoms 
 
2 (13%) 
2 (13%) 
 
15 (100%) 
8 (53%) 
15 (100%) 
 
2 (25%) 
1 (12.5%) 
 
8 (100%) 
5 (63%) 
8 (100%) 
*p<0.05 vs. MSA 
 
Cardiovascular responses to HUT 
 Supine blood pressure (BP) and heart rate (HR) were not significantly different 
between PAF and MSA patients. There were also no differences in HR and BP during head-
up tilting (HUT) between groups. All MSA and PAF patients had lower blood pressure during 
HUT (p<0.05) and fulfilled the criteria for OH (Kaufmann, 1996) but the degree of OH was 
not different between the two disorders (p>0.05). 
 After liquid meal ingestion, supine BP was significantly reduced compared with 
supine pre-prandial BP in both MSA and PAF patients (both p<0.05). There was no change 
in post-prandial HR however (p>0.05). BP was significantly lower during post-prandial HUT 
compared to pre-prandial HUT but there was no difference between MSA and PAF patients 
(both p<0.05). The post-prandial orthostatic BP change was not different in MSA compared 
to PAF (p>0.05; Table 7.2). 
 
 
169 
 
Table 7.2. Blood pressure and HR during supine, head-up tilting and orthostatic 
changes before and after liquid meal ingestion in MSA and PAF patients.   
Variable PAF (n=15) MSA (n=8) 
Pre-prandial   
  Supine SBP 153+29 145+21 
  Supine DBP 87+18 84+13 
  Supine HR 63+10 65+11 
  Tilt SBP  80+22$ 94+25$ 
  Tilt DBP 52+11$ 60+14$ 
  Tilt HR 71+16$ 73+16$ 
  Orthostatic ∆SBP  -73+31 -51+28 
  Orthostatic ∆DBP -36+18 -24+20 
  Orthostatic ∆HR 9+19 9+8 
Post-prandial   
   Supine SBP 120+35# 128+21# 
   Supine DBP 69+15# 68+15# 
   Supine HR 70+11 72+10 
   Tilt SBP  66+17$# 75+23$# 
   Tilt DBP 43+9$#* 53+10$# 
   Tilt HR 77+14$ 79+13$ 
   Orthostatic ∆SBP  -54+31 -53+17 
   Orthostatic ∆DBP -26+15 -15+12 
   Orthostatic ∆HR 7+13 7+6 
Values are mean+SD 
*p<0.05 vs. MSA, $p<0.05 vs. corresponding Supine value, #p<0.05 vs. corresponding 
pre-prandial value 
 
EGG responses 
Baseline (Pre-prandial) 
There was no significant difference in pre-prandial DF between groups (p>0.05). ICDF was 
significantly higher in PAF compared to MSA during baseline (p<0.05). 
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Post-prandial 
Post-prandial DF was significantly higher after meal ingestion in both PAF and MSA groups 
(p<0.01). There was no difference in the change in DF between groups (p>0.05). ICDF was 
significantly higher post-prandial (p<0.05) and was still significantly higher in PAF compared 
to MSA (p<0.05). The change in ICDF post-prandial was not different between groups 
(>0.05). The LFR%, NFR% and HFR% were not different between pre- and post-prandial 
conditions as well as between the two disorders (Table 7.3). 
Table 7.3. Mean (SD) Pre- and post-prandial and changes in Dominant frequency (DF), 
instability coefficient of dominant frequency (ICDF), low frequency range (LFR%), 
normal frequency range (NFR%), high frequency range (HFR%) in PAF and MSA 
patients. 
 
Variable PAF (N=15) MSA (N=9) 
DF (cpm)  
- Pre-prandial 
- Post-prandial  
- ∆ Pre-post prandial 
 
2.58+0.24 
  2.75+0.23** 
0.17+0.21 
 
2.61+0.32 
  2.77+0.31** 
0.16+0.34 
ICDF (%) 
- Pre-prandial 
- Post-prandial 
- ∆ Pre-post prandial 
 
12.84+4.23$ 
14.98+3.90*$ 
2.14+3.66 
 
6.09+2.39 
 7.82+1.57* 
1.73+2.89 
LFR% 
- Pre-prandial 
- Post-prandial  
- ∆ Pre-post prandial 
 
6.41+2.75 
5.84+3.49 
-0.56+3.73 
 
6.07+5.09 
5.00+3.56 
-1.07+5.56 
NFR% 
- Pre-prandial 
- Post-prandial  
- ∆ Pre-post prandial 
 
88.09+5.88 
90.57+4.75 
2.48+6.80 
 
89.06+4.30 
91.65+4.14 
2.58+5.43 
HFR% 
- Pre-prandial 
- Post-prandial  
- ∆ Pre-post prandial 
 
5.46+4.10 
3.59+1.52 
-1.88+4.43 
 
4.96+1.86 
3.44+1.12 
-1.53+2.30 
**p<0.01 vs. pre-prandial, *p<0.05 vs. pre-prandial, $p<0.05 vs. MSA 
 
7.4 Discussion 
The aim of this study was to evaluate gastric myoelectrical activity (GMA) before and 
after standard liquid meal ingestion in PAF patients. It was hypothesized that PAF patients 
would have gastric dysrhythmia in line with the nature of post-ganglionic  autonomic 
pathology in this disorder, similar to PD. MSA patients were also examined in order to 
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compare an autonomic disorder with a different lesion to PAF. The main findings were that 
PAF patients had gastric dysrhythmia as demonstrated by a significantly higher ICDF 
compared to MSA patients.  
Abnormal EGG findings were previously reported in patients with MSA and 
Parkinson’s disease (PD) but investigations have not been performed in PAF, an autonomic 
failure disorder with overlapping features with MSA and PD. Prior studies reported a low 
ICDF and normal post-prandial DF in MSA (Sakakibara et al., 2009). On the other hand, 
patients with PD had a high ICDF and a blunted increase in DF after meal ingestion 
compared with controls (Soykan et al., 1999). A subsequent study also demonstrated a 
reduction of the percentage of ‘normal’ gastric slow waves, as well as a lack of an increase 
in DF post-prandial, in PD compared with controls (Lu et al., 2004).  
Even though there has been no previous pathological study reporting the 
involvement of the ENS in patients with PAF, various clinical and pathological features in 
PAF, which are also common to PD patients, are suggestive of ENS dysfunction. Apart from 
parkinsonism, PAF and PD have several clinical features in common. These include 
hyposmia and various domains of autonomic dysfunction (e.g. OH, bladder dysfunction, 
sweating dysfunction, constipation) (Goldstein & Sewell, 2009; Mathias & Bannister, 2013). 
In addition, both PD and PAF also share abnormal pathological findings in the central 
nervous system (Lewy body deposition in the substantia nigra or locus ceruleus (Hague et 
al., 1997)) and in the periphery (Lewy bodies and neuritis in the dermis of a patient with PAF 
(Shishido et al., 2010)). These findings lead to the term “Lewy body synucleinopathies”, 
which include both PD, PAF and dementia with Lewy bodies (DLB) (Kaufmann & Goldstein, 
2010). Some experts proposed that these disorders may actually be the same entity but the 
site of Lewy body pathology will determine the clinical manifestation (Kaufmann & Goldstein, 
2010).  
 Given these common features between PD and PAF, gastric dysrhythmia, as 
evidenced by a high ICDF, during baseline and after the liquid meal ingestion in PAF 
patients in the present study may have resulted from an impaired gastric pacemaker in line 
with the finding of high ICDF in a patient with PD supporting the post-ganglionic autonomic 
pathology in these disorders (Arai et al., 2000). Nevertheless, there is no previous study 
specifically looking at the pathology of gastric pacemaker cells in PAF. Given similar 
gastrointestinal symptoms and ICDF findings in both disorders, gastric dysrhythmia in 
patients with PAF might reflect the involvement of these cells similar to that in PD patients.  
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Previous studies demonstrated a transient increase of DF after meal ingestion which 
returns to pre-meal levels in healthy controls while ICDF remains relatively unchanged 
(Sakakibara et al., 2009). Although an age-matched healthy control group as a comparison 
group was not used in the present study, the findings in MSA patients were consistent with 
previous studies in that DF was normal and ICDF was significantly lower in MSA (Suzuki et 
al., 2005; Sakakibara et al., 2009). ICDF is thought to reflect parasympathetic function (Muth 
et al., 1998). The decrease of ICDF in MSA may be caused by a reduced parasympathetic 
vagal outflow. Comparing with the same control data from these previous studies, the DF 
values were similar and the ICDF values were higher in the PAF patients in the present study 
(Sakakibara et al., 2009). Gastric dysrhythmia was previously reported in patients with 
functional dyspepsia (Lin et al., 1999). There was no difference in the number of 
gastrointestinal (GI) symptoms between MSA and PAF patients in the present study. In 
addition, the majority of participants did not report upper GI symptoms. This would indicate 
that the abnormal ICDF in PAF cannot entirely be explained by their underlying GI symptoms 
and that there might be a slight disproportion between the pathophysiology and 
symptomology of GI dysfunction in PAF. The present study also demonstrated that the 
orthostatic BP and HR changes were not different between MSA and PAF patients indicating 
that the abnormal ICDF findings in PAF were not due to differences in cardiovascular 
autonomic function.  
 
MSA patients can present with a variety of autonomic features, such as orthostatic 
hypotension, urinary frequency/urgency and gastrointestinal dysfunction, which are also 
evident in PAF. Overlapping autonomic features in MSA and PAF can sometimes make it 
difficult to differentiate PAF and MSA, particularly in early stages (Iodice et al., 2012). The 
difference between ICDF in MSA and PAF in our study warrants further evaluation of 
whether or not evaluating gastric slow wave activity in conjunction with a liquid meal 
challenge may be a potential non-invasive investigation in patients who present with 
autonomic failure. There is no consensus on the amount and/or variety of autonomic 
investigations in order to distinguish MSA and PAF, apart from assessing hemodynamic 
responses after clonidine infusion (Young et al., 2006). Vasodepressor effects of clonidine 
were reported to be more prominent in MSA patients in contrast to those in PAF which may 
reflect the difference in remaining function between these disorders. Some experts use a 
criterion of isolated autonomic failure without additional neurological features after years of 
follow-up to ensure the diagnosis of PAF (Young et al., 2006). Nevertheless, there are a few 
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reports of some patients with PAF who developed MSA features 5 years after the onset of 
autonomic failure (Iodice et al., 2012).   
In conclusion, a significantly higher ICDF in PAF patients indicates abnormal gastric 
myoelectric activity and gastric pacemaker function in PAF and supports the hypothesis of 
post-ganglionic impairment of PAF, similar to EGG findings and pathology in PD patients. In 
contrast, MSA patients appear to have normal or even lower ICDF. These findings also 
suggest that EGG may potentially be a non-invasive adjunct investigation to help 
differentiate patients with MSA from PAF. 
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Chapter 8 
8. Discussion and Future Directions 
8.1 Discussion 
The overall aim of this thesis was to compare and contrast various aspects of 
autonomic function, non-motor features and quality of life between the most common forms 
of primary chronic autonomic disorders, Multiple System Atrophy (MSA), Parkinson’s 
disease with and without autonomic failure (PD+AF and PD) and Pure Autonomic Failure 
(PAF). A variety of non-invasive autonomic and allied, as well as clinical, investigations were 
selected and used to compare disorders and examine how these aspects of autonomic 
disease contribute to quality of life in these different disorders and achieve the specific aims 
of the thesis.  
Patients with chronic autonomic disorders, namely MSA, PAF and PD+AF, share a 
fundamental feature, orthostatic hypotension (OH) as part of cardiovascular autonomic 
failure/dysfunction. Given that reason, the diagnosis in these conditions can sometimes be 
difficult if patients present with isolated autonomic failure without other neurological features. 
Both PD and MSA patients often present with autonomic failure and parkinsonian features, 
while patients with PAF commonly present with autonomic failure but can develop 
parkinsonian features in the later stage of disease after years of follow-up. These 
heterogeneous progressions can lead to difficulties in diagnosis of these disorders. It was 
not clear whether there were any measures that could be useful in aiding such a diagnosis. 
In fact, there were only a few studies comparing cardiovascular autonomic function between 
these disorders. 
In a series of studies in Chapters 4, cardiovascular autonomic function was examined 
using a variety of methods, including, traditional laboratory autonomic laboratory tests (e.g., 
head-up tilting and pressor tests), novel assessment of indices of cardiovascular autonomic 
function and 24 hr-ambulatory blood pressure monitoring, in MSA, PAF and PD patients 
(with and without autonomic failure). The first study (Chapter 4.1) systematically examined 
cardiovascular autonomic function in PD+AF, MSA and PAF patients who all met the criteria 
of OH. There was no difference in the degree of OH between MSA and PD+AF but it was 
more severe in PAF. This study confirmed previous studies reporting similar impairments in 
almost all cardiovascular autonomic function measures in these disorders, except the blood 
pressure recovery time (BRPT) and baroreflex sensitivity (BRS), derived from the Valsalva 
Manoeuvre (VM), which were the only 2 cardiovascular autonomic function indices that were 
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more severely impaired in MSA compared to PD+AF. This result suggests that BPRT and 
BRS could be additional autonomic markers to help distinguish MSA from PD (particularly in 
those with orthostatic hypotension). This study was also showed that cardiovascular 
autonomic function was also similar among MSA sub-types (e.g., the parkinsonian vs. the 
cerebellar sub-types), who have OH. It was also apparent that cardiovascular autonomic 
symptoms (such as dizziness or lightheadedness) were poorly correlated with the presence 
of OH, suggesting an absence of orthostatic symptoms in more than 20% of MSA patients 
with OH. This finding would support a referral for autonomic function tests in patients with 
suspected MSA, even without orthostatic symptoms.  
Apart from a trend of association between BPRT and disease duration in PD+AF 
patients, there was no clear relationship between disease duration and other cardiovascular 
autonomic function measures in MSA, PD+AF and PAF patients. These results indicated a 
diverse pattern of cardiovascular autonomic function progression in patients with chronic 
autonomic failure. Nevertheless, a previous study suggested a correlation between disease 
duration and cardiovascular autonomic dysfunction, as well as older age and medications in 
patients with PD (van Dijk et al., 1993) but these were not present in a group of patients with 
chronic autonomic failure in this thesis. 
When PD patients without autonomic failure were examined (Chapter 4.2), a 
significantly prolonged BPRT was also found in these PD patients without orthostatic 
hypotension, in comparison to age-matched controls. This finding suggests that subtle 
cardiovascular sympathetic dysfunction may occur in PD, even in asymptomatic patients 
without OH. This finding was supported by an abnormal BP response to the cold pressor test 
in PD patients without autonomic failure (Chapter 4.3). In agreement with the previous study 
of van Dijk et al., (1993) a significant relationship between PD disease duration and BPRT 
was also evident even after taking age and motor severity into account. This finding could be 
further investigated in prospective longitudinal studies of whether or not BPRT could be used 
as a cardiovascular autonomic function marker in patients with PD.  
Pressor tests, more conventional cardiovascular autonomic function tests that include 
isometric exercise, cold pressor and mental arithmetic manoeuvres, provide information on 
cardiovascular autonomic function, in particular sympathetic neural pathways, in patients 
with suspected or confirmed autonomic failure/dysfunction. Studies in this thesis (Chapter 
4.3) showed that the BP and HR responses to pressor stimuli are different among chronic 
autonomic disorders. With regards to isometric exercise, BP responses were significantly 
attenuated in PD+AF and MSA but not in PD, suggesting that the hemodynamic responses 
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to this manoeuvre are mainly dependent on the severity of autonomic dysfunction. These 
findings are in contrast to the BP and HR responses to cold pressor and mental arithmetic 
stimuli. During cold pressor stimuli, BP increased in all patient groups but less so than in 
controls. While the attenuated BP responses to CP were diminished in MSA and PD+AF as 
expected, a blunted increase in PD patients who do not have apparent autonomic 
dysfunction (as shown by no orthostatic hypotension) suggest that this test may not be 
sensitive enough to distinguish between varying severities of autonomic dysfunction. In 
response to mental arithmetic the BP responses were, as expected, diminished in MSA and 
PD+AF relative to healthy controls. Given that the BP changes during head-up tilting were 
similar between MSA and PD+AF, one would speculate that the hemodynamic responses to 
mental arithmetic would be similar in these patient groups. However, the BP response was 
significantly lower in MSA relative to PD+AF and thus might be a useful index for helping to 
distinguish between these conditions.  
24 hr-ABPM has been widely used in patients with hypertension but it is less well 
used in patients with chronic autonomic failure. It is known that BP is generally lower at 
night-time compared to daytime in healthy individuals. This normal circadian BP rhythm is 
also referred to as a “nocturnal BP rhythm” or “BP dipping”. Autonomic failure can affect this 
physiological response via a disruption of this pattern, either by an absent nocturnal BP fall 
(non-dipping) or even an increase in BP at night in compared to daytime (“reversed 
nocturnal BP”). In Chapter 4.4, circadian BP rhythms in MSA, PD with and without 
autonomic failure using 24 hr-ABPM were examined. The results confirmed that abnormal 
circadian BP rhythms (both non-dipping and reversed nocturnal BP) were common in all 
patient groups and most common in MSA patients with confirmed OH and PD+AF and then 
PD. These findings indicate that abnormal circadian BP rhythms are not specific features for 
a MSA vs. PD+AF diagnosis, but instead, are influenced by a patient’s autonomic function. 
The use of 24 hr-ABPM may provide an alternative assessment of OH in contrast to the 
traditional laboratory head-up tilting protocol. The efficacy of 24 hr-ABPM in detecting OH 
when used in conjunction with a diary in comparison to laboratory head-up tilting was 
examined and 24 hr-ABPM with a diary clearly showed a high sensitivity and specificity in 
detecting OH in patients with parkinsonism suggesting that 24 hr-ABPM might provide an 
alternative clinical assessment of OH in suspected autonomic failure patients.  
Impaired olfaction in PD has been increasingly studied in the last decade. It is partly 
due to growing evidence on the impact of non-motor symptoms on quality of life in patients 
with PD. Olfactory dysfunction is a well-known non-motor feature in PD. In contrast, the 
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evidence of olfactory dysfunction in MSA and PAF is inconsistent due to the rarity of these 
disorders. In chapter 5.1., this thesis confirmed mild olfactory dysfunction in MSA and 
markedly impaired olfaction in PD and PAF. The similar degree of impaired olfaction 
between PD and PAF lend support to the hypothesis that PAF may be a restricted form of a 
Lewy body disease. Furthermore, this study confirmed that the SS-16 olfactory function test 
is a useful tool to differentiate between PD and MSA, as well as between MSA and PAF with 
high sensitivity and specificity. The degree of impaired olfaction in PD was also correlated 
with motor severity; UPDRS part III, consistent with some previous studies. It was also 
demonstrated, for the first time, that olfactory dysfunction and motor severity (UMSARS part 
II) were also significantly correlated in patients with MSA. These results could potentially 
explain the discrepant findings between studies of olfactory function in patients with MSA.  
Quality of life is a crucial factor for patients with chronic autonomic disorders whose 
daily activities and physical and psychological health can be severely limited. In Chapter 5.2 
indices of quality of life (specific to each disorder), activities of daily life and depression were 
evaluated in chronic autonomic disorders (MSA, PD, PD+AF and PAF). All patients had 
significantly higher scores of depression relative to healthy controls and the level of 
depression was most severe in patients with MSA. In PD, there was a strong association 
between quality of life and several non-motor domains, including, depression, mood and 
behaviour, activities of daily life, reinforcing the link between quality of life and a number of 
non-motor features in PD. A limitation of this study must be noted. Only selected domains of 
non-motor symptoms, including HAM-D (depression), SE (ADL) and SCOPA-AUT 
(Autonomic), were assessed. There are a number of other non-motor symptoms of chronic 
autonomic disorders, for instance, cognitive dysfunction, fatigue, sleep disorders and pain 
that were not investigated. Alternative instruments, such as the Non-motor Symptoms Scale 
(NMSS) or additional specific questionnaires (e.g. fatigue severity scale) would have allowed 
a more extensive investigation of non-motor features of these disorders. 
In contrast to the findings in PD, there was no correlation between depression and 
quality of life in the MSA patients. Instead, and consistent with other findings in PD patients, 
quality of life was strongly associated with MSA patients’ physical function, global disability 
and activities of daily living but not with motor function. These results indicate a greater 
impact of activities of daily living on an MSA patient’s quality of life rather than the severity of 
their motor dysfunction. As there is no curative treatment in MSA, supportive care or 
interventions which aid a patient’s activities of daily living may be better strategies to improve 
quality of life in MSA.  
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With regards to PAF, for the first time, a mild degree of depression and lower quality 
of life compared to healthy controls was described. There was also an association between 
quality of life and activities of daily living in PAF. Comparing with SF-36 data from a previous 
study (Riazi et al., 2003), the quality of life scores in the PAF patients were, at least, 
impaired as much or even more than in patients with PD. These data suggest that although 
PAF patients do not have motor dysfunction, the restriction of activities of daily living and the 
level of depression were comparable to those with PD. As PAF patients have no other 
obvious neurological impairments, apart from orthostatic hypotension as well as disturbed 
autonomic function in other domains, their quality of life is therefore mainly contributed by a 
restriction to their daily living activities via episodes of autonomic dysfunction, e.g., OH. 
Despite the first patient with PAF being described almost a hundred years ago by 
Bradbury and Eggleston, there has been limited information regarding the presenting 
symptoms, clinical features and laboratory investigations in this disorder because of its low 
prevalence. In Chapter 6, a range of important initial and presenting symptoms alongside 
autonomic laboratory and brain imaging investigations in a large cohort of PAF patients were 
assessed.  Pre-syncopal and syncopal symptoms were the most common initial symptoms in 
the majority of PAF patients, whereas erectile dysfunction was also prevalent in almost a half 
of male patients. With regards to symptoms at the first consultation (e.g., after the period of 
initial symptoms), a greater range and frequency of symptoms were evident compared with 
the initial symptoms presentation. Pre-syncope, syncope and erectile dysfunction were again 
most prevalent. This was followed by hypohidrosis and “coat-hanger” pain in about 60% of 
patients. Bladder and bowel symptoms were reported in almost half of patients followed by 
non-specific symptoms such as fatigue or chest pain. These results indicate that when taking 
a clinical history from PAF patients it is vital to take history related to sudomotor, 
genitourinary, gastrointestinal and other non-specific symptoms, in addition to orthostatic 
symptoms such as dizziness or lightheadedness. Furthermore, bladder symptoms appear to 
develop as disease progresses in PAF. This is contrast to bladder symptoms in MSA, which 
are often present before orthostatic symptoms (Mabuchi et al., 2005). With regards to the 
laboratory investigations, 75% of patients had supine hypertension with a reversed circadian 
BP rhythm in more than 60%. A low level of supine plasma NA concentration (less than 200 
pg/ml) with a small rise during HUT was found in more than 90% of patients. Furthermore, 
longer disease duration was significantly associated with lower plasma NA HUT changes 
possibly reflecting greater impairments in sympathetic neural function as the disease 
progresses. 
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Paraventricular white matter lesions (WML) in brain MRI were a typical feature in 
PAF patients, with a prevalence of more than 80%, which might be similar to aged matched 
healthy individuals. Increasing age was identified as an independent risk factor that can 
predict cerebral white matter lesions in PAF, the number and type of anti-hypotensive 
medications were not associated with an increased risk of WML. The causes of WML in PAF 
remain unclear but wide fluctuations of BP in PAF may be a potential explanation. Further 
studies are needed to determine whether WML actually increase the future risk of stroke in 
PAF.  
Gastrointestinal (GI) symptoms are a common non-motor feature in PD and are also 
prevalent in MSA and PAF. GI dysfunction in PAF has been relatively under-researched 
however. The majority of GI investigations is relatively invasive and involves sophisticated 
laboratory procedures. Cutaneous electrogastrography (EGG) is a non-invasive method of 
recording gastric myoelectrical activity (GMA). To date there has been no study that has 
evaluated GMA in patients with PAF. In Chapter 7, EGG was used to record GMA before 
and after a standard liquid meal challenge test in PAF and MSA patients. Abnormal EGG 
patterns, indicating gastric dysrhythmia, were evident in PAF, but not in MSA. As both MSA 
and PAF had similar degrees of OH, these EGG differences appear to be independent from 
cardiovascular autonomic dysfunction. The difference in EGG findings between these two 
disorders may also help define the GI pathophysiology based on their differing lesion sites 
(pre- vs. post-ganglionic, respectively). The exact mechanism of gastric dysrhythmia in PAF 
is uncertain. It might reflect a balance of gastric pacemaker cells (Interstitial cells of Cajal; 
ICC) and vagal output from the brainstem. As patients with PAF have no pathological 
abnormalities in the brainstem, the presence of gastric dysrhythmia may be caused by the 
involvement of the ICC as part of post-ganglionic autonomic denervation, similar to that 
which occurs in patients with PD who also have impaired EGG profiles (Sakakibara et al., 
2009). Furthermore, abnormal EGG findings in both PAF and PD are in line with the 
proposed hypothesis that PAF is part of a restricted “Lewy body disorders 
spectrum”(Kaufmann & Goldstein, 2010). Future studies focusing on gastrointestinal 
pathological involvement in PAF may grant further insight of why the majority of PAF patients 
do not develop symptoms of Parkinson’s disease. This study also supports the use of EGG 
in conjunction with a liquid meal challenge as a non-invasive test to differentiate between 
PAF and MSA. Nevertheless, larger studies are needed to confirm whether or not this can 
be used in a clinical setting.    
 
181 
 
8.2 Future Directions 
Although there has been a significant progress in the understanding of autonomic 
function and non-motor symptoms in patients with primary chronic autonomic failure, the 
number of studies specifically investigating these disorders is still relatively few as they are 
hampered by several limitations and there are several questions that need to be further 
addressed in future studies. 
Firstly, the progression of cardiovascular autonomic function in chronic autonomic 
failure patients has not been adequately studied in the past. Most studies, including those in 
this thesis, used a cross-sectional design study to assess cardiovascular function in 
association with disease duration. Only a few prior studies conducted in a longitudinal 
approach.  Further investigations using novel autonomic function assessment techniques, 
such as BRPT or BRS, in these patients with a prospective study design would close a 
knowledge gap in this area. As autonomic dysfunction seems more prevalent with age, 
medications and disease duration, follow-up studies will be able to overcome these problems 
and may be able to identify the associated factors that increase the risk of developing 
autonomic dysfunction in patients with PD. This approach also offers a better opportunity to 
determine why cardiovascular autonomic function can variably progress and also determine 
the prognostic factors among patients with MSA. As shown from the findings that autonomic 
failure affects quality of life in patients with PAF, future studies in these patients as well as in 
those with other forms of autonomic failure should not only measure their autonomic function 
(e.g. BP or HR) but also include their quality of life at the same time. This will provide a real 
benefit toward the patients particularly when conducting an interventional trial, such as drug 
treatments.  
Most cardiovascular autonomic function tests rely on individual co-operation. Some 
tests require participants engaging in complicated tasks, such as the Valsalva manoeuvre. 
Other tests, for example isometric handgrip exercise, involve an individual’s ability to 
adequately perform a task to a reasonable level in order to interpret the results with 
confidence. Patients with a certain degree of cognitive dysfunction or those with movement 
difficulties may not be able to complete these tests adequately. The accuracy of these tests 
cannot therefore thoroughly be evaluated in these patient groups as a result. A poor 
correlation between orthostatic symptoms and autonomic dysfunction is another limitation, 
which is often encountered during testing. This example was clearly shown in the present 
studies that a reasonable number of patients had OH without any symptoms during HUT. 
This highlights an important autonomic laboratory investigation as part of the diagnostic 
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pathway. Development of new techniques in autonomic function testing, which require less 
co-operation from patients is also needed. The use of non-invasive tests, such as EGG or 
novel cardiovascular autonomic measures, may help to improve the diagnostic accuracy and 
facilitate a diagnosis in patients with autonomic dysfunction at earlier stages before the 
development of autonomic failure.  
With regards to patients with PAF, a prospective design would provide more accurate 
outcomes in determining the risk of end-organ damage. Considering the findings of WML in 
PAF on brain MRI, it is tempting to explore whether a significant fluctuation of BP in PAF 
patients would actually increase the risk of stroke or damage to other organs, such as renal 
failure, myocardial infarction. In addition, the similarities in a variety of clinical features and 
investigation findings between PAF and PD offers a great opportunity to examine why 
patients with PAF have a much lower prevalence of cognitive dysfunction and parkinsonism. 
As PAF is a rare autonomic disorder with a favourable life expectancy, a multi-centre 
longitudinal study would give better answers to these questions.  
In conclusion, all current works in this thesis provide further insight regarding 
cardiovascular autonomic function and other non-motor symptoms, as well as quality of life, 
in patients with primary chronic autonomic disorders. Additionally, some pathophysiological 
differences between disorders described in the studies, could help facilitate an earlier 
diagnosis, improve diagnostic accuracy and help prognostication of these disorders. These 
findings may also supply important information for developing future interventional studies, 
for instance drug or other therapeutic trials, on patients with primary chronic autonomic 
disorders.  
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Parkinson’s Disease Questionnaire (PDQ-39)  
Please tick one box for each question 
Due to having Parkinson’s disease, how often during the last month have you....  
   
 
Never Occasionally Sometimes Often 
 
Always 
 
 
1. Had difficulty doing the leisure 
activities which you would like to do? 
 
2. Had difficulty looking after your 
home, e.g. DIY, housework, cooking? 
 
3. Had difficulty carrying bags of 
shopping? 
 
4. Had problems walking half a mile? 
 
5. Had problems walking 100 yards? 
 
6. Had problems getting around the 
house as easily as you would like? 
 
7. Had difficulty getting around in 
public? 
 
8. Needed someone else to 
accompany you when you went out? 
 
9. Felt frightened or worried about 
falling over in public? 
 
10. Been confined to the house more 
than you would like? 
 
11 Had difficulty washing 
yourself? 
 
12 Had difficulty dressing 
yourself? 
 
13 Had problems doing up 
your shoe laces? 
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Please check that you have ticked one box for each question before going on to the next page 
 
212 
 
Please tick one box for each question 
Due to having Parkinson’s disease, how often during the last month have you....  
 
Never Occasionally Sometimes Often 
 
Always 
 
 
14. Had problems writing clearly? 
 
15. Had difficulty cutting up your 
food? 
 
16. Had difficulty holding a drink 
without spilling it? 
 
17. Felt depressed? 
 
18. Felt isolated and lonely? 
 
19. Felt weepy or tearful? 
 
20. Felt angry or bitter? 
 
21. Felt anxious? 
 
22. Felt worried about your future? 
 
23. Felt you had to conceal your 
Parkinson's from people? 
 
24. Avoided situations which 
involve eating or drinking 
in public? 
 
25.Felt embarrassed in public 
due to having Parkinson's 
Disease? 
 
26. Felt worried by other 
people's reaction to you? 
 
27. Had problems with your close 
personal relationships? 
 
28. Lacked support in the ways you 
need from your spouse or partner? 
If you do not have a spouse or 
partner tick here  
 
29. Lacked support in the 
ways you need from your 
family or close friends? 
 
 
 
 
 
 
 
 
 
 
 
 
 
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Please check that you have ticked one box for each question before going on to the next page 
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Please tick one box for each question 
Due to having Parkinson’s disease, how often during the last month have you....  
 
Never Occasionally Sometimes Often 
 
Always 
 
 
30 Unexpectedly fallen asleep during 
the day? 
 
31 Had problems with your 
concentration, e.g. when reading or 
watching TV? 
 
32 Felt your memory was bad? 
 
33 Had distressing dreams or 
hallucinations? 
 
34 Had difficulty with your speech? 
 
35 Felt unable to communicate with 
people properly? 
 
36 Felt ignored by people? 
 
37 Had painful muscle cramps or 
spasms? 
 
38 Had aches and pains in your joints 
or body? 
 
39 Felt unpleasantly hot or cold? 
 
 
 
 
 
 
 
 
 
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 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
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 
 
 
Please check that you have ticked one box for each question 
 
 
Thank you for completing the PDQ-39 questionnaire 
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MSA-QoL Questionnaire 
Having a health problem can affect a person’s quality of life in many different ways. In order to understand how 
your illness affects your life, we are interested which, if any, of the following problems you have experienced.      
We would also like to know how problematic each has been for you.  
Please note that this list includes many problems that you may never experience. 
In the last 4 weeks have you No 
Problem 
Slight 
Problem 
Moderate 
Problem 
Marked 
Problem 
Extreme 
Problem 
 Not 
appl. 
1. Had difficulty moving?        
2. Had difficulty walking?        
3. Had problems with your balance?        
4. Had difficulty standing up without support?        
5. Had difficulty speaking?        
6. Had difficulty swallowing food?        
7. Had too much saliva or drooling?        
8. Had difficulty with handwriting?        
9. Had difficulty feeding yourself?        
10. Had difficulty drinking fluids?        
11. Had difficulty dressing yourself?        
12. Needed help to go to the toilet?        
13. Had to stop doing things that you liked to 
do, e.g. your hobbies? 
       
14. Had difficulty doing things around the 
house, e.g. housework? 
       
15. Experienced bladder problems?        
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16. Experienced problems with constipation?        
In the last 4 weeks have you No 
Problem 
Slight 
Problem 
Moderate 
Problem 
Marked 
Problem 
Extreme 
Problem 
 Not 
appl. 
17. Experienced dizziness when standing up?        
18. Suffered from cold hands or feet?        
19. Experienced pain in your neck or shoulders?        
20. Experienced pain elsewhere, e.g. in your 
legs or your back? 
       
21. Had difficulty getting comfortable during 
the night? 
       
22. Had difficulty breathing during the night?        
23. Been feeling tired very quickly (without 
exerting yourself)? 
       
24. Experienced lack of energy?        
25. Experienced slowness of thinking?        
26. Had difficulty with your concentration, e.g. 
reading or watching TV? 
       
27. Felt frustrated?        
28. Felt depressed?        
29. Experienced a loss of motivation?        
30. Been feeling incapable?        
31. Worried about the future?        
32. Worried about your family?        
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33. Felt on your own or isolated?        
34. Experienced loss of confidence when 
interacting with others?  
       
35. Felt that your role in your family or among 
friends has changed? 
       
36. Experienced difficulty seeing your friends?        
 
In the last 4 weeks have you 
No 
Problem 
Slight 
Problem 
Moderate 
Problem 
Marked 
Problem 
Extreme 
Problem 
 Not 
appl. 
37. Had to give up social activities, e.g. going 
out for a meal, participating in events? 
       
38. Had difficulty talking to friends about your 
illness? 
       
39. Been embarrassed to talk to people?        
40. Felt that life has become boring?        
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Short Form Health Survey (SF-36) 
This survey asks for your views about your health.  This information will help keep track of 
how you feel and how well you are able to do your usual activities. 
 
Please answer these questions by “check-marking” your choice. Please select only 
one choice for each item. 
 
1- In general, would you say your health is: 
  1. Excellent   2. Very good   3. Good   4. Fair   5. Poor 
2- Compared to ONE YEAR AGO, how would you rate your health in general NOW? 
  1. MUCH BETTER than one year ago. 
  2. Somewhat BETTER now than one year ago. 
  3. About the SAME as one year ago. 
  4. Somewhat WORSE now than one year ago. 
  5. MUCH WORSE now than one year ago. 
3- The following items are about activities you might do during a typical day.  Does your 
health now limit you in these activities? If so, how much? 
Activities 1. Yes, 
Limited A 
Lot 
2.  Yes, 
Limited  
A Little 
3.  No,  
Not Limited 
At All 
a) Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous 
sports? 
  1. Yes, 
limited a lot 
  2. Yes, 
limited a little 
  3. No, not 
limited at all 
b) Moderate activities, such as moving a 
table, pushing a vacuum cleaner, bowling, or 
playing golf? 
  1. Yes, 
limited a lot 
  2. Yes, 
limited a little 
  3. No, not 
limited at all 
c) Lifting or carrying groceries?   1. Yes, 
limited a lot 
  2. Yes, 
limited a little 
  3. No, not 
limited at all 
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d) Climbing several flights of stairs?   1. Yes, 
limited a lot 
  2. Yes, 
limited a little 
  3. No, not 
limited at all 
e) Climbing one flight of stairs?   1. Yes, 
limited a lot 
  2. Yes, 
limited a little 
  3. No, not 
limited at all 
f) Bending, kneeing or stooping?   1. Yes, 
limited a lot 
  2. Yes, 
limited a little 
  3. No, not 
limited at all 
g) Walking more than a mile?   1. Yes, 
limited a lot 
  2. Yes, 
limited a little 
  3. No, not 
limited at all 
h) Walking several blocks?   1. Yes, 
limited a lot 
  2. Yes, 
limited a little 
  3. No, not 
limited at all 
i) Walking one block?   1. Yes, 
limited a lot 
  2. Yes, 
limited a little 
  3. No, not 
limited at all 
j) Bathing or dressing yourself?   1. Yes, 
limited a lot 
  2. Yes, 
limited a little 
  3. No, not 
limited at all 
 
4- During the past 4 weeks, have you had any of the following problems with your work or 
other regular activities as a result of your physical health? 
 Yes No 
a) Cut down on the amount of time you spent on work or 
other activities? 
  1. yes   2. No 
b) Accomplished less than you would like?   1. yes   2. No 
c) Were limited in the kind of work or other activities?   1. yes   2. No 
d) Had difficulty performing the work or other activities 
(for example it took extra effort)? 
  1. yes   2. No 
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5. During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)? 
 Yes No 
a) Cut down on the amount of time you spent on work or 
other activities? 
  1. yes   2. No 
b) Accomplished less than you would like?   1. yes   2. No 
c) Didn’t do work or other activities as carefully as usual?   1. yes   2. No 
 
6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbors, or groups? 
  1. Not at all   2. Slightly   3. Moderately       4. Severe       5. Very severe 
7. How much bodily pain have you had during the past 4 weeks? 
  1. None     2. Very mild       3. Mild       4. Moderate      5. Severe       6. Very severe 
8. During the past 4 weeks, how much did pain interfere with your normal work (including 
both work outside the home and housework)? 
  1. Not at all   2. A little bit   3. Moderately       4. Quite a bit       5. Extremely 
 
 
 
 
 
 
 
220 
 
9. These questions are about how you feel and how things have been with you during the 
past 4 weeks.  For each question, please give the one answer that comes closest to the way 
you have been feeling.  How much of the time during the past 4 week … 
 
1. All of 
the time 
2. Most 
of the 
time 
3. A good 
bit of the 
time 
4. Some 
of the 
time 
5. A little 
of the 
time 
6. None 
of the 
time 
a) Did you feel full of pep?   1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of 
the time 
  6. 
None of 
the time 
b) Have you been a very 
nervous person? 
  1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of 
the time 
  6. 
None of 
the time 
c) Have you felt so down in 
the dumps that nothing could 
cheer you up?  
  1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of 
the time 
  6. 
None of 
the time 
d) Have you felt calm and 
peaceful? 
  1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of 
the time 
  6. 
None of 
the time 
e) Did you have a lot of 
energy? 
  1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of 
the time 
  6. 
None of 
the time 
f) Have you felt downhearted 
and blue? 
  1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of 
the time 
  6. 
None of 
the time 
g) Do you feel worn out?   1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of 
the time 
  6. 
None of 
the time 
h) Have you been a happy 
person? 
  1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of 
the time 
  6. 
None of 
the time 
i) Did you feel tired?   1. All 
of the 
time 
  2. 
Most of 
the time 
  3. A 
good bit of 
the time 
  4. 
Some of 
the time 
  5. A 
little of 
the time 
  6. 
None of 
the time 
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10. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friends, relatives, etc.)? 
  1. All of the time 
  2. Most of the time. 
  3. Some of the time 
  4. A little of the time. 
  5. None of the time. 
 
         
 
11. How TRUE or FALSE is each of the following statements for you? 
 1. 
Definitely 
true 
2. 
Mostly 
true 
3. Don’t 
know 
4. 
Mostly 
false 
5. 
Definitely 
false 
a) I seem to get sick a little 
easier than other people? 
  1.  
Definitely 
true 
  2. 
Mostly 
true 
  3.  
Don’t 
know  
  4.  
Mostly 
false 
  5.  
Definitely 
false 
b) I am as healthy as anybody I 
know? 
  1.  
Definitely 
true 
  2. 
Mostly 
true 
  3.  
Don’t 
know  
  4.  
Mostly 
false 
  5.  
Definitely 
false 
c) I expect my health to get 
worse? 
  1.  
Definitely 
true 
  2. 
Mostly 
true 
  3.  
Don’t 
know  
  4.  
Mostly 
false 
  5.  
Definitely 
false 
d) My health is excellent?   1.  
Definitely 
true 
  2. 
Mostly 
true 
  3.  
Don’t 
know  
  4.  
Mostly 
false 
  5.  
Definitely 
false 
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Hamilton Rating Scale for Depression (HDRS or HAM-D) 
PLEASE COMPLETE THE SCALE BASED ON A STRUCTURED INTERVIEW 
Instructions: for each item select the one “cue” which best characterizes the patient. Be sure to 
record the answers in the appropriate spaces (positions 0 through 4). 
 
1 DEPRESSED MOOD (sadness, 
hopeless, helpless, worthless) 
0 |__| Absent. 
1 |__| These feeling states indicated only 
on questioning. 
2 |__| These feeling states spontaneously 
reported verbally. 
3 |__| Communicates feeling states non-
verbally, i.e. through facial expression, 
posture, voice and tendency to weep. 
4 |__| Patient reports virtually only these 
feeling states in his/her spontaneous 
verbal and non-verbal communication. 
 
2 FEELINGS OF GUILT 
0 |__| Absent. 
1 |__| Self reproach, feels he/she has let 
people down. 
2 |__| Ideas of guilt or rumination over 
past errors or sinful deeds. 
3 |__| Present illness is a punishment. 
Delusions of guilt. 
4 |__| Hears accusatory or denunciatory 
voices and/or experiences threatening 
visual hallucinations. 
 
3 SUICIDE 
0 |__| Absent. 
1 |__| Feels life is not worth living. 
2 |__| Wishes he/she were dead or any 
thoughts of possible death to self. 
3 |__| Ideas or gestures of suicide. 
4 |__| Attempts at suicide (any serious 
attempt rate 4). 
4 INSOMNIA: EARLY IN THE NIGHT 
0 |__| No difficulty falling asleep. 
1 |__| Complains of occasional difficulty 
falling asleep, i.e. more than half an hour. 
2 |__| Complains of nightly difficulty falling 
asleep. 
5 INSOMNIA: MIDDLE OF THE NIGHT 
0 |__| No difficulty. 
1 |__| Patient complains of being restless 
and disturbed during the night. 
2 |__| Waking during the night – any 
getting out of bed rates 2 (except for 
purposes of voiding). 
 
6 INSOMNIA: EARLY HOURS OF THE 
MORNING 
0 |__| No difficulty. 
1 |__| Waking in early hours of the 
morning but goes back to sleep. 
2 |__| Unable to fall asleep again if he/she 
gets out of bed. 
7 WORK AND ACTIVITIES 
0 |__| No difficulty. 
1 |__| Thoughts and feelings of incapacity, 
fatigue or weakness related to activities, 
work or hobbies. 
2 |__| Loss of interest in activity, hobbies 
or work – either directly reported by the 
patient or indirect in listlessness,indecision 
and vacillation (feels he/she has to push 
self to work or activities). 
3 |__| Decrease in actual time spent in 
activities or decrease in productivity.  
Rate 3 if the patient does not spend at 
least three hours a day in activities (job  
or hobbies) excluding routine chores. 
4 |__| Stopped working because of 
present illness. Rate 4 if patient engages 
in no activities except routine chores, or if 
patient fails to perform routine chores 
unassisted. 
 
8 RETARDATION (slowness of thought 
and speech, impaired ability to 
concentrate, decreased motor activity) 
0 |__| Normal speech and thought. 
1 |__| Slight retardation during the 
interview. 
2 |__| Obvious retardation during the 
interview. 
3 |__| Interview difficult. 
4 |__| Complete stupor. 
 
9 AGITATION 
0 |__| None. 
1 |__| Fidgetiness. 
2 |__| Playing with hands, hair, etc. 
3 |__| Moving about, can’t sit still. 
4 |__| Hand wringing, nail biting, hair-
pulling, biting of lips. 
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10 ANXIETY PSYCHIC 
0 |__| No difficulty. 
1 |__| Subjective tension and irritability. 
2 |__| Worrying about minor matters. 
3 |__| Apprehensive attitude apparent in 
face or speech. 
4 |__| Fears expressed without 
questioning. 
11 ANXIETY SOMATIC (physiological 
concomitants of anxiety) such as: 
gastro-intestinal – dry mouth, wind, 
indigestion, diarrhea, cramps, belching 
cardio-vascular – palpitations, headaches 
respiratory – hyperventilation, sighing 
urinary frequency 
sweating 
0 |__| Absent. 
1 |__| Mild. 
2 |__| Moderate. 
3 |__| Severe. 
4 |__| Incapacitating. 
12 SOMATIC SYMPTOMS GASTRO-
INTESTINAL 
0 |__| None. 
1 |__| Loss of appetite but eating without 
staff encouragement. Heavy feelings in 
abdomen. 
2 |__| Difficulty eating without staff urging. 
Requests or requires laxatives or 
medication for bowels or 
medication for gastro-intestinal symptoms. 
 
 
13 GENERAL SOMATIC SYMPTOMS 
0 |__| None. 
1 |__| Heaviness in limbs, back or head. 
Backaches, headaches, muscle aches. 
Loss of energy and fatigability. 
2 |__| Any clear-cut symptom rates 2. 
 
 
14 GENITAL SYMPTOMS (symptoms 
such as loss of libido, menstrual 
disturbances) 
0 |__| Absent. 
1 |__| Mild. 
2 |__| Severe. 
 
 
 
 
 
 
15 HYPOCHONDRIASIS 
0 |__| Not present. 
1 |__| Self-absorption (bodily). 
2 |__| Preoccupation with health. 
3 |__| Frequent complaints, requests for 
help, etc. 
4 |__| Hypochondriacal delusions. 
 
16 LOSS OF WEIGHT (RATE EITHER a 
OR b) 
a) According to the patient: 
0 |__| No weight loss.  
1 |__| Probable weight loss associated 
with present illness. 
2 |__| Definite (according to patient) 
weight loss. 
3 |__| Not assessed. 
b) According to weekly measurements: 
0 |__| Less than 1 lb weight loss in week. 
1 |__| Greater than 1 lb weight loss in 
week.  
2 |__| Greater than 2 lb weight loss in 
week. 
3 |__| Not assessed. 
 
17 INSIGHT 
0 |__| Acknowledges being depressed and 
ill. 
1 |__| Acknowledges illness but attributes 
cause to bad food, climate, overwork, 
virus, need for rest, etc. 
2 |__| Denies being ill at all. 
 
 
Total score: |__|__| 
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SCOPA-AUT 
 
By means of this questionnaire, we would like to find out to what extent in the past month 
you have had problems with various bodily functions, such as difficulty passing urine, or 
excessive sweating. Answer the questions by placing a cross in the box which best reflects 
your situation. If you wish to change an answer, fill in the ‘wrong’ box and place a cross in 
the correct one. If you have used medication in the past month in relation to one or more of 
the problems mentioned, then the question refers to how you were while taking this 
medication. You can note the use of medication on the last page. 
 
1. In the past month, have you had difficulty swallowing or have you choked? 
 
 
 
never sometimes regularly often 
 
2. In the past month, has saliva dribbled out of your mouth? 
 
 
 
never sometimes regularly often 
 
3. In the past month, has food ever become stuck in your throath? 
 
 
 
never sometimes regularly often 
 
4. In the past month, did you ever have the feeling during a meal that you were full very 
quickly? 
 
 
 
never sometimes regularly often 
 
 
5. Constipation is a blockage of the bowel, a condition in which someone has a bowel 
movement twice a week or less. 
In the past month, have you had problems with constipation? 
 
 
 
never sometimes regularly often 
 
 
6. In the past month, did you have to strain hard to pass stools? 
 
 
 
never   sometimes      regularly           often 
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 7. In the past month, have you had involuntary loss of stools? 
 
 
 
never sometimes regularly often 
 
Questions 8 to 13 deal with problems with passing urine. If you use a catheter you can 
indicate this by placing a cross in the box “use cathether”. 
 
8. In the past month, have you had difficulty retaining urine? 
 
 
 
never sometimes regularly often use 
catheter 
9. In the past month, have you had involuntary loss of urine? 
 
 
never sometimes regularly often use 
catheter 
   
10. In the past month, have you had the feeling that after passing urine your bladder was 
not completely empty? 
 
 
never sometimes regularly often use 
catheter 
 
11. In the past month, has the stream of urine been weak? 
 
 
 
never sometimes regularly often use 
catheter 
 
12. In the past month, have you had to pass urine again within 2 hours of the previous 
time? 
 
 
 
never sometimes regularly often use 
catheter 
 
 
13. In the past month, have you had to pass urine at night? 
 
 
 
 
never                 sometimes           regularly        often     use  
                   catheter  
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             14. In the past month, when standing up have you had the feeling of either becoming 
lightheaded, or no longer being able to see properly, or no longer being able to think 
clearly? 
 
 
 
never sometimes regularly often 
 
 
15. In the past month, did you become light-headed after standing for some time? 
 
 
 
never sometimes regularly often 
 
16. Have you fainted in the past 6 months? 
 
 
 
never sometimes regularly 
 
 
17. In the past month, have you ever perspired excessively during the day? 
often 
 
 
 
never sometimes regularly often 
 
18. In the past month, have you ever perspired excessively during the night? 
 
 
 
never sometimes regularly often 
 
 
19. In the past month, have your eyes ever been over-sensitive to bright light? 
 
 
 
never sometimes regularly often 
 
20. In the past month, how often have you had trouble tolerating cold? 
 
 
 
never sometimes regularly often 
 
21. In the past month, how often have you had trouble tolerating heat? 
 
 
 
             Never            sometimes     regularly           often 
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The following questions are about sexuality. Although we are aware that sexuality is a highly 
intimate subject, we would still like you to answer these questions. For the questions on 
sexual activity, consider every form of sexual contact with a partner or masturbation (self- 
gratification). An extra response option has been added to these questions. Here you can 
indicate that the situation described has not been applicable to you in the past month, for 
example because you have not been sexually active. Questions 22 and 23 are intended 
specifically for men, 24 and 25 for women. 
 
The following 3 questions are only for men 
 
22. In the past month, have you been impotent (unable to have or maintain an erection)? 
 
 
never sometimes regularly often not 
applicable 
 
23. In the past month, how often have you been unable to ejaculate? 
 
 
 
never sometimes regularly often not 
applicable 
 
23a.  In the past month, have you taken medication for an erection disorder? (If so, which 
medication?) 
 
 
 
no yes:    
 
Proceed with question 26 
 
 
 
The following 2 questions are only for women 
 
24. In the past month, was your vagina too dry during sexual activity? 
 
 
 
never sometimes regularly often not 
applicable 
 
25. In the past month, have you had difficulty reaching an orgasm? 
 
 
 
 
never sometimes regularly often not 
applicable 
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The following questions are for everyone 
 
The questions below are about the use of medication for which you may have or have not 
needed a doctor’s prescription. If you use medication, also give the name of the substance. 
 
26.In the past month, have you used medication for: 
 
a. constipation? 
 
d. urinary problems? 
 
 
no yes:    
 
no yes:    
 
e. blood pressure? 
 
 
no yes:    
 
f. other symptoms 
(not symptoms related to no yes:    
Parkinson’s disease) 
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